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Abstract 
This thesis investigates the prevalence and pathophysiology of gastrointestinal 
involvement in systemic sclerosis (SSc). The primary pathologies within the 
gastrointestinal tract affect the mucosa, vasculature, smooth muscle and enteric 
nervous system. The aim of this thesis was to conduct experiments to assess these 
pathologies within a well-characterised SSc patient cohort. 
Introduction: A review of the current understanding of the pathophysiology of 
gastrointestinal disease in systemic sclerosis.  
Prevalence of GI symptoms: A prospective questionnaire study of 400 patients in 
order to assess gut disease burden and review of patient disease characteristics. 
Anorectal involvement: Extensive anorectal physiological assessment of 
symptomatic and asymptomatic systemic sclerosis patients compared with 
incontinent controls in order to assess aspects of neuropathy and myopathy.  
Nutritional effect as an assessment of mucosal involvement: Nutritional assessment 
of patients with and without gastrointestinal symptoms through anthropometric 
assessment, indirect calorimetry and bioelectrical impedance. 
The pathophysiology of gastrointestinal involvement in systemic sclerosis was 
further investigated in an established mouse model of scleroderma. This transgenic 
mouse model expresses a kinase deficient type II TGFβ receptor (TβRIIΔk) in 
fibroblasts and the mice develop skin fibrosis as well as pulmonary fibrosis and a 
structural vasculopathy. Gastrointestinal tissue from these mice was examined 
histologically and the contractile activity of gut tissue was examined in vitro. 
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CHAPTER 1: 
PATHOPHYSIOLOGY OF GASTROINTESTINAL INVOLVEMENT IN 
SYSTEMIC SCLEROSIS 
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1.1. Introduction 
Systemic sclerosis (SSc) is a chronic autoimmune disorder of unknown aetiology. 
The prevalence of SSc in UK is 8 per 100,000 of population although this varies in 
different studies (1-3). It is 3-5 times more common in women than in men, the 
peak age of onset is 30-50 years and it is twice more common in afro-caribbeans 
than in caucasians. Systemic sclerosis is characterised by proliferative vascular 
lesions and fibrosis of the skin and multiple internal organs, such as lungs, kidneys, 
heart and the gastrointestinal tract (GIT). There are 2 main SSc subsets, diffuse 
cutaneous or limited cutaneous based on the extent of skin involvement. Skin 
thickening above the elbows or knees is classified as diffuse cutaneous SSc and skin 
tightness limited to areas distal to elbows or knees is classified as limited 
cutaneous, the face can be affected in both subsets. The importance of this 
classification is that these 2 subsets have differing natural histories, organ 
involvement, prognoses and autoantibody associations (4).  
After the skin the GIT is the most commonly affected organ in SSc. GIT involvement 
is reported in up to 90% of SSc patients in both diffuse and limited cutaneous 
forms. It can occur at any stage of the disease and can be slowly or rapidly 
progressive. Severe GI involvement occurs in about 8% of patients and is associated 
with increased mortality (5). Like with other severe organ involvement it is more 
likely to develop early – in the first 3 years – in the course of the disease (5), but 
involvement of any part of the GIT can occur at any stage. 
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1.2. Microvascular changes in SSc 
One of the prominent early clinicopathological features of SSc is involvement of the 
vasculature. In the periphery this manifests as Raynaud’s phenomenon, cutaneous 
and mucosal telangiectasia and nailbed capillary abnormalities. Telangiectasias 
found anywhere along the GI tract from the oral cavity to the rectum are the most 
common cause of blood loss which occurs in SSc with a frequency of 15% (6). 
Gastric antral vascular ectasia (GAVE) is a specific vascular abnormality seen in the 
gastric antrum and is associated with SSc (7). It is characterised by large, 
longitudinal, convoluted vessels in the gastric antrum converging towards the 
pylorus. These are highly prone to bleeding but often easily amenable to 
endoscopic treatment with laser therapy and argon plasma coagulation. Other than 
bleeding and probably more important, in the viscera involvement of the 
vasculature can lead to pathologies such as renal disease and pulmonary arterial 
hypertension (8;9).  
Vascular change is thought to not only represent a common pathological 
manifestation but also to be the initiating event in the pathogenesis of GI 
involvement in SSc. Vascular abnormalities mainly affect small arteries, they are 
characterised by endothelial cell swelling and myointimal proliferation resulting in 
narrowing of the lumen and disruption of the internal elastic lamina (10). The 
consequence of this is recurrent episodes of vasoconstriction and tissue ischaemia. 
Vascular changes have been demonstrated along different parts of the 
gastrointestinal tract. For example reduced blood flow, determined endoscopicaly 
by laser Doppler or endoscopic oxygen electrode sensors has been found in the 
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stomach and duodenum in SSc patients (11;12). Rectal biopsies from patients with 
SSc show enteric vessels with thickened basal lamina, hypertrophied endothelial 
cells and partially obliterated lumen (13). Not only is a vascular event thought to be 
the initiating factor in the pathogenesis of GI manifestations in SSc but the vascular 
insufficiency and ischaemia has a perpetuating effect on smooth muscle atrophy 
and intestinal secretory and absorptive function.  
Microvascular dysfunction and features such as Raynaud’s phenomenon may also 
be secondary to a dysfunction in the autonomic control of microcirculation (14). 
Autonomic dysfunction is common in SSc and is characterized by marked 
adrenaline-mediated sympathetic overactivity and instability and impaired 
parasympathetic activity. This has been demonstrated in a number of studies in SSc 
patients mainly by means of conventional autonomic tests such as measurement of 
heart rate variability and cardiorespiratory reflex tests (15-17). Dysautonomia may 
contribute to intestinal ischaemia by inducing vasoconstriction as demonstrated by 
decreased superior mesenteric arterial blood flow (18). A number of studies have 
investigated the association between autonomic dysfunction and gastrointestinal 
impairment. Dessein et al showed that clonidine, an α2 adrenergic agonist, 
increased lower oesophageal sphincter pressure in patients with oesophageal 
symptoms and adrenaline-mediated sympathetic overactivity suggesting a potential 
role of autonomic dysregulation on oesophageal dysfunction (19). Iovino et al 
showed a positive correlation between gastric compliance and autonomic nerve 
function (20). In contrast di Ciaula et al did not find any association between 
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autonomic neuropathy and dyspepsia, gastric and gallbladder motility and intestinal 
transit (21). 
 
1.3. Smooth muscle changes in SSc 
The pathological effect of SSc in the GI tract is not confined to the vasculature. 
Several studies have demonstrated oesophageal, intestinal and colonic dysmotility 
in patients with SSc. The pathophysiology of this is similar throughout the GI tract; 
the mucosa is largely uninvolved, with the structure and function of epithelial cells 
and villi usually being normal. Findings are histologically localised to the submucosa 
and muscular layer. There is inflammatory cell infiltration in the lamina propria and 
collagen deposition in the submucosa. In the muscularis propria there is fibrosis and 
atrophy of the smooth muscle, the circular layer being more markedly affected that 
the longitudinal (22). Atrophy is usually patchy, but as the disease progresses 
becomes more extensive and often associated with marked fibrosis. There is also 
progressive collagen deposition and fibrosis of the serosa contributing to the 
attenuated motility and reduced distensibility of the viscera. 
In ultrastructural studies of the muscle coat wide areas of marked focal fibrosis, 
characterised by collagen and elastic fibre depositions, are seen surrounding 
smooth muscle cells. Intercellular spaces are widened and gap junctions between 
smooth muscle cells are decreased which may account for impaired smooth muscle 
cell contraction and reduced transmission of peristalsis (23). Enteric neurons and 
satellite cells have been shown to be structurally normal except for cytoplasmic 
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vacuolisation but the surrounding axon terminals have a pale axoplasm with 
decreased number of vesicles and dense bodies and without cytoskeletal elements 
(13). Furthermore, abundant elastic and collagen fibres envelope nerve endings, 
separating them from smooth muscle cells and there are signs of degeneration of 
unmyelinated fibres.  
The most accepted theory regarding the pathophysiology of GI dysmotility in SSc is 
that it is a progressive process with initial neural dysfunction followed by smooth 
muscle atrophy and eventually muscle fibrosis. The initial neural dysfunction has 
been hypothesised to be secondary to arteriolar changes in the vasa nervorum 
although an alternative explanation is direct nerve fibre compression by collagen 
deposits. A number of autoantibodies are found in patients with SSc but their 
involvement in the pathophysiology is still unknown. Certain autoantibodies are 
associated with specific organ involvement and disease characteristics. There is 
increasing evidence that autoantibodies in SSc play a pathogenic role (24). 
Antimyenteric neuronal antibodies have been found in SSc and may contribute in 
the process either as an initiating or concomitant event (25). This is supported by 
the finding that IgG from patients with SSc when injected in immunosuppressed 
rats induced alteration in intestinal myoelectic activity (26). This was further 
supported by the findings of Goldblatt et al of antibodies found in the serum of SSc 
patients inhibiting muscarinic receptor-mediated enteric cholinergic 
neurotransmission (27). In their study the patients that demonstrated those 
antibodies also reported more severe gastrointestinal symptoms. Singh et al 
showed that IgGs isolated from SSc patients (but not from normal volunteers) 
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attenuate muscarinic receptor activation by bethanechol in isolated smooth muscle 
cells of the rat internal anal sphincter (28). These antibodies are not yet checked 
routinely in SSc patients, nor have been tested in large patient cohorts. 
During the neuropathic phase there is dysmotility but the muscle is still responsive 
to methacholine and symptoms tend to respond to prokinetic agents. Cisapride a 
known gastrointestinal prokinetic agent mediates its effects by the release of 
acetylcholine in the myenteric plexus. It has been shown to increase oesophageal 
and gastric transit (29), enhance gastric fundal contractions (30) and increase 
colonic transit (31) in patients with SSc. Chronic neural dysfunction perpetuates 
smooth muscle atrophy with gut muscle being less contractile but still responsive. 
Patients are more likely to become symptomatic at this point and treatment with 
prokinetics may still be partially successful. With disease progression fibrosis is 
superimposed on smooth muscle atrophy, rendering the muscle unresponsive to 
methacholine and patients no longer respond to prokinetics (32).  
GI involvement in SSc manifests as a spectrum of disorders of mainly motility and 
transit time with specific abnormalities observed in the different parts of the GI 
tract. An interesting aspect of this spectrum is that the clinical manifestations can 
be progressive but the progression can be slow or rapid and can occur at any age. 
By understanding the disease process and pathophysiology further it may be 
possible to arrest this disease progression at an early stage and before significant 
symptoms develop. 
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1.4. Neuropathy 
Oesophagus 
Oesophageal dysmotility is the most common GI manifestation in SSc, being 
present in 80-90% of patients. Normal oesophageal function is characterised by 
tonic lower oesophageal sphincter (LOS) pressure being higher than gastric 
pressure, thus preventing significant gastro-oesophageal reflux. In a normal 
swallow, the oesophageal body contracts in a peristaltic manner and the 
contraction is propagated towards the stomach at a rate of 3-5 cm/sec. The LOS 
relaxes at the start of the peristaltic wave to allow the bolus to empty into the 
stomach. Peristalsis is the net result of the coordinated relaxation and contraction 
mediated by the inhibitory and excitatory myenteric plexus neurons along the 
length of the oesophagus. The excitatory neurons release acetylcholine while the 
inhibitory neurons release nitric oxide (NO) and vasoactive intestinal polypeptide 
(VIP) resulting in oesophageal and LOS contractions and relaxations, respectively. 
Defective excitatory innervation may partly explain low amplitude or ineffective 
oesophageal peristaltic contraction (33). Typical findings in SSc are a decrease in the 
amplitude and spread of the oesophageal body contractions in the distal two thirds 
(smooth muscle portion) of the oesophagus associated with reduced LOS pressure 
which relaxes variably to accommodate the bolus. With progression, the amplitude 
of contractions and LOS pressure decrease further and there is often lack of 
peristalsis and impaired coordination between the LOS and distal oesophagus. 
These abnormalities result in prolonged oesophageal transit time and delayed 
oesophageal emptying causing dysphagia. Furthermore the reduced LOS pressure 
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predisposes to gastro-oesophageal reflux. The dysmotility exacerbates the resulting 
reflux symptoms since there is impaired acid clearance.  
Autonomic dysfunction, with high circulating adrenaline levels, has been shown to 
correlate with decreased distal oesophageal contraction amplitude and with 
reduced LOS pressure suggesting some causality of dysautonomia and dysphagia. In 
one study treatment with clonidine improved the autonomic dysfunction and also 
improved both oesophageal symptoms and oesophageal physiology in some 
patients (19).  
Stomach 
The stomach has been reported to be involved in at least 50% of patients with SSc. 
Normal antral and duodenal manometry in the fasting state is characterised by the 
migrating myoelectrical complex (MMC) which is a cyclical pattern of contractile 
activity which repeats at intervals of 1.5-2 hours and follows 3 cyclical phases. 
Phase I of the MMC lasts 5-20 minutes and is characterised by absence of 
contractions. Phase II lasts 10-40 minutes and consists of intermittent contractions 
on a background of slow waves. Phase III lasts 3-6 minutes and consists of bursts of 
regular rhythmic contractions at the same rate as the slow waves. This sequence of 
peristaltic activity progresses through the intestines in a regular cycle during fasting 
state and its purpose, in conjunction with an increase in gastric, biliary and 
pancreatic secretions, is to clear remnants of digestion and prevent excessive 
bacterial colonisation in the stomach and small intestine. Initiation of the MMC is 
thought to be partially controlled by motilin in response to vagal stimulation and 
propagation is coordinated by the enteric nervous system. Eating induces a marked 
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increase in contractile activity in the lower body and antrum, with strong peristaltic 
waves that increase in amplitude as they propagate towards the pylorus. This 
serves in grinding the food into chyme and forcing it through the pyloric canal into 
the small intestine. In patients with SSc the MMC in the fasting state occurs less 
frequently, is of low amplitude or even absent (34) and there is evidence of gastric 
dysrrhythmia (35). In the fed state there is again decreased frequency and 
amplitude of antral contractions. This type of abnormality is also observed in 
patients with diabetic neuropathy, supporting the hypothesis of gut dysfunction 
relating to a neuropathic process in SSc patients. The result is delayed gastric 
emptying and often exacerbation of gastro-oesophageal reflux. Autonomic 
dysfunction in the stomach causes impaired gastric accommodation and 
compliance. Increased proximal stomach compliance has also been shown in 
diabetic patients with autonomic neuropathy (36). In a study of SSc patients, those 
with higher scores of autonomic dysfunction showed greater impairment of gastric 
compliance compared with patients with normal autonomic scores (20).  This 
abnormality can delay gastric emptying and induce more dyspeptic symptoms and 
bloating.  
Small intestine 
The motility pattern in the normal small intestine is similar to the stomach. Fasting 
small bowel motility follows the 3 cyclical phases of the MMC as described above. 
After a meal the contents of the small intestine are slowly transported distally 
through irregular vigorous contractions initiated at the small intestine. As in the 
stomach, small intestinal motility is abnormal in SSc, with a neuropathic pattern 
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early in the disease. In the fasting state the MMC is often absent and there are 
uncoordinated contractions, whereas in the post-prandial state there are reduced 
contractions and there is diminished response to distension of the duodenum 
resulting in slow intestinal transit and intestinal dilatation (37).  The hypomotility, 
poor intestinal clearance and also reduced gastric acid secondary to acid 
suppressant therapy can lead to small intestinal bacterial overgrowth and 
consequent malabsorption of many substances such as carbohydrates, proteins, 
lipids and vitamins. Furthermore, alterations in the gut flora can affect the gut 
mucosa and its immune function as has been shown in other gastrointestinal 
disorders such as inflammatory bowel disease (38). 
Colon and anorectum 
The colon and the anorectum is the second (after the oesophagus) most commonly 
affected region of the GI tract in SSc. The motility of the normal colon is different to 
the small intestine with no cyclic pattern. It consists of either segmental or 
propagated (low amplitude or high amplitude) contractions. Segmental 
contractions, typically at a frequency of 3 cycles/minute, induce a slow aboral 
propulsion. Low amplitude propagated contractions occur about 50 times per day 
and function to transport fluid chyme and flatus through the colon, high amplitude 
propagated contractions occur only about 5 times per day and function to propel 
large volumes of colonic content. Post-prandially the motor activity rises sharply for 
30-60 minutes, this constitutes the gastrocolic response and is mediated by a 
cholinergic pathway, this is often absent in SSc, colonic motility is reduced and 
there is prolonged colonic transit (39;40).  
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Anorectal function is impaired in between 50 and 70% of patients with SSc (32). 
Colonic peristalsis delivers content episodically to the rectum where it is retained 
until a socially opportune time for defaecation. When faeces or air arrive at the 
rectum, the rectum is stretched; the IAS relaxes reflexively (rectoanal inhibitory 
reflex) and at the same time the EAS contracts voluntarily to maintain continence. 
The maintenance of faecal continence is dependent on complex voluntary and 
involuntary coordination between anal and colorectal activity. The IAS receives 
both an autonomic and enteric innervation that contributes to resting tonic anal 
canal pressure (41). Resting anal tone reflects primarily (80%) IAS function, with a 
minority contribution from the EAS (42).  Disordered anorectal function occurs 
frequently in SSc and is a major factor in the development of faecal incontinence. 
The rectoanal inhibitory reflex (RAIR) has been reported to be diminished or absent 
in approximately 50% of patients studied, and this occurs even in the early stages of 
SSc. Heyt et al assessed 35 patients with SSc and found an absent RAIR in 25 (43). In 
a study by Jaffin et al RAIR was absent in 8 out of 10 patients (44). This abnormality 
is thought to be secondary to a neural defect in the myenteric plexus possibly 
related to vascular ischaemia and fibrosis. Diminished or absent RAIR has been 
found to correlate to symptoms, especially faecal incontinence (43). More extensive 
anorectal dysfunction occurs in the later stages of the disease when smooth muscle 
atrophy and fibrosis become more prominent. Correlation between oesophageal 
dysmotility and anorectal abnormalities have been reported (45) but not 
consistently (46).  
 
28 
1.5. Myopathy  
Oesophagus 
Smooth muscle atrophy and collagen deposition are the pathological hallmarks 
found in SSc (47). Gut smooth muscle becomes weak and there is progressive 
muscle fibrosis ultimately resulting in complete lack of smooth muscle function. 
This can occur throughout the GI tract. In the oesophagus muscle atrophy and 
fibrosis affect the smooth muscle portion (distal two thirds) resulting in abnormal 
and often absent peristalsis. Myoelectrical studies of oesophageal smooth muscle 
show absent myoelectrical activity (48) and more frequent involvement of the 
circular compared to the longitudinal muscle (10). In late disease the LOS pressure 
is virtually absent meaning dysphagia may actually not be as prominent despite the 
deterioration in body contractions but the reflux symptoms may deteriorate. There 
is also shortening of the oesophagus which may contribute to the formation of 
hiatus hernia and this can exacerbate gastro-oesophageal reflux. Very late in the 
disease the oesophageal skeletal muscle (proximal third) and the upper 
oesophageal sphincter may also become involved which in combination with 
gastro-oesophageal reflux predisposes SSc patients to aspiration. 
Stomach and small intestine 
The stomach and the small intestine are similarly affected by smooth muscle 
atrophy and fibrosis. The MMC is absent and there is dramatic hypomotility. There 
is also no contractile response to a meal with only very few and low amplitude 
contractions (37). The response of the muscle to hormones such as gastrin and 
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secretin is also attenuated and may become absent (22). Pedersen et al and 
Gregersen et al in 2 studies investigating the mechanical properties of duodenal 
wall in SSc patients showed that the duodenum was stiffer and muscle function 
impaired (49;50). Zuber-Jerger et al in an endoscopic ultrasound study showed that 
involvement of the upper GI tract in patients with SSc leads to a thickening of the 
mucosa, submucosa and muscularis, secondary to accumulation of extracellular 
matrix in the oesophagus, stomach and duodenum (51). Apart from the effect on 
motility, collagen deposition also contributes to malabsorption as it may interfere 
with intestinal wall permeability. The weakness of the intestinal smooth muscle 
predisposes to the formation of multiple small bowel diverticulae which are 
characteristic in SSc and are one of the causes of small bowel bacterial overgrowth. 
Marie et al in their series of 8 SSc patients who underwent 24hr small bowel 
manometry initially and at 5 year follow-up demonstrated a high frequency (75%) 
of intestinal motor disturbance at initial evaluation and myogenic abnormalities at 
5-yr follow-up in all SSc patients (52). Their findings support the theory that 
neurogenic abnormalities precede myogenic disturbances in small-bowel of SSc 
patients.  
Colon and anorectum 
Colonic motility is further diminished in the late stages of SSc both in the fasting 
and the postprandial phase. In the absence of significant small bowel involvement 
and associated diarrhoea, the resulting slow transit leads to worsening constipation 
with often associated abdominal pain and bloating.  
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The anorectum is more often affected. There is already neural dysfunction as 
demonstrated by a diminished or absent RAIR. Smooth muscle atrophy and fibrosis 
affect the IAS (and less commonly the EAS). The sphincters become thin and 
atrophy can be demonstrated on anal ultrasound (53). In addition atrophy can be 
identified manometrically demonstrated by low resting pressure (IAS) but also low 
maximal squeeze pressure (EAS). Chiou et al studied 17 patients, 9 with faecal 
incontinence and 8 asymptomatic and found reduced resting pressure compared to 
controls and absent RAIR in 12 of the patients (54). Herrick et al found low resting 
and squeeze pressure in SSc patients with constipation compared to controls (55) 
and in another study of 6 patients with constipation resting pressures were 
decreased in all patients (40). Another study of 8 patients with faecal incontinence, 
four of them with prolapse, showed low resting pressure in all patients and 
especially those with prolapse and also reduced squeeze pressure and reduced 
rectal capacity (56). The length of the fibrosed atrophic anal canal is shortened. All 
these factors contribute to the development of faecal incontinence. Interestingly 
manometric abnormalities have also been noted in asymptomatic SSc patients 
(43;44). Furthermore collagen deposition leads to reduced rectal capacity and 
compliance which in turn contributes to faecal urgency (56). Chronic constipation or 
diarrhoea, which can result from the abnormal colonic dysmotility described 
previously, as well as the observed neural dysfunction and reduced rectal 
compliance predispose patients with SSc to develop rectal prolapse. This can 
contribute further to reduced anal sphincter pressures and incontinence (56). 
Treatment of these symptoms should focus on reversing physiology (anti-
diarrhoeals, laxatives and biofeedback) or be more generic such as lifestyle advice 
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and diet alteration. Increasingly modalities applied to patients with idiopathic pelvic 
floor dysfunction and faecal incontinence are being offered to patients with 
systemic sclerosis (SNS, rectal prolapse surgery) (57). 
 
1.6. Summary 
GI tract involvement in SSc can occur with both limited and diffuse disease, at any 
time from diagnosis and at any age. It can range from minimal to extensive and 
cause a variety of symptoms from minimal heartburn to chronic pseudo-obstruction 
and malnutrition. Although there are valid theories, as described above, on the 
pathogenesis of GI involvement, there are still many questions. If the initial event is 
immunological, is GI involvement associated with certain disease subtype or 
autoantibodies, same way as pulmonary arterial hypertension? Is a vascular event 
and resulting ischaemia the main causative factor leading to all subsequent 
abnormalities? Is there a true progression from the neuropathic to the myopathic 
stage or do they occur independently? Are there any predictive factors for severe 
GI involvement or rapid disease progression? Treatment of GI involvement is so far 
largely symptomatic with no pharmacological or other agents known to arrest 
disease progression. Understanding the pathogenesis further may facilitate better 
treatment options and possibly preventative measures. 
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1.7. Thesis intention 
This chapter has reviewed the established data on aetiopathogenesis of gut 
involvement in SSc. The primary pathologies within the GI tract affect the mucosa 
and vasculature, the smooth muscle and the enteric nervous system (Figure 1). The 
aim of this thesis was to conduct experiments to assess these pathologies within a 
well-characterised SSc cohort. 
The first requirement was to characterise the gut symptom burden of the patients 
using the best available instruments. To that end I undertook a study of 402 
patients in the Royal Free cohort using the Scleroderma Gastrointestinal 1.0 
questionnaire (Chapter 2). 
To assess aspects of neuropathy in the gut is difficult owing to the complex 
interaction between enteric and extrinsic nervous systems. There is also the 
problem of access to gut nerves and the interpretation of the neurophysiology. I 
have conducted a study applying best available anorectal neurophysiological 
techniques in SSc patients, comparing symptomatic with asymptomatic individuals 
to establish pathophysiological implications (Chapter 3). 
In these same patients I chose to assess the contribution of anal sphincter 
myopathy. The anal sphincter is an obvious choice of study since it has both an 
involuntary (autonomically innervated) smooth muscle component and a somatic 
striated one (Chapter 3). 
Nutritional insufficiency is a significant co-morbidity in a sub-group of SSc patients. 
Whilst there may be contributory factors related to a generalised inflammatory 
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process, I hypothesised that gut infiltrative mucosal involvement would be a 
measurable contributor. So, in Chapter 4 I undertook definitive nutritional 
assessment by indirect calorimetry and bioelectrical impedance in symptomatic and 
non-symptomatic SSc individuals. Again the intention was to speculate on the 
pathophysiological contribution of these processes in SSc gut dysfunction. 
Finally, Chapter 5 reports on an animal model of SSc, the transgenic mouse strain 
TβRIIΔk-fib with fibroblast specific TGF-β signalling activation. This mouse strain 
replicates skin, vascular and some pulmonary aspects of SSc. Gut involvement in 
this model has not been previously studied. It is known that these mice develop 
skin fibrosis and systemic vasculopathy as well as lung fibrosis, and by assessing the 
intestinal tract by both structural and physiological means I intended to 
demonstrate aetiopathogenic processes that may be relevant to human SSc. 
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Figure 1.1: Schematic representation of the intestinal tract layers depicting the structures 
affected in systemic sclerosis. 
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CHAPTER 2: 
PREVALENCE OF GASTROINTESTINAL SYMPTOMS IN PATIENTS 
WITH SYSTEMIC SCLEROSIS. 
 
  
Publication generated from this chapter can be found in Appendix 9 
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2.1. Introduction 
As I have considered in the previous chapter, the gastrointestinal tract (GIT) is 
affected in approximately 90% of patients (22;58) and gut involvement is the 
leading cause of morbidity and the third most common cause of mortality in 
patients with SSc (5). Any part of the GIT can be affected leading to a wide range of 
symptoms from gastro-oesophageal reflux to faecal incontinence (54;59-61). In 
clinical practice, skin, cardiorespiratory and renal involvement remain the focus of 
clinical assessment, despite the frequency of GI symptoms. In view of the 
sometimes embarassing nature of GI symptoms or the perception that they are not 
as important as other symptoms, GI involvement is frequently under-assessed. 
Compounding on that is the fact that treatment for GI symptoms is largely based on 
symptomatic control and there is no evidence to date that immunosuppression 
helps with GI disease progression. Unfortunately symptom control is often 
inadequate resulting in a significant effect on health-related quality of life (62). 
Health related quality of life (HRQOL) instruments are often used to assess disease 
activity and symptom burden in chronic rheumatological disorders such as 
rheumatoid arthritis with the RAQoL (63) and SSc with HAQ-DI (64;65) and also GIT 
related disorders such as inflammatory bowel disease with the IBDQ (66;67). 
HRQOL instruments can be generic illness instruments measuring general health 
status such as SF-36 and EuroQoL or disease specific providing a more detailed 
assessment of the specific illness and its impact. Recently Khanna et al in the USA 
developed a disease-specific HRQOL instrument for patients with SSc to assess their 
GIT-related activity and severity, which can be used in clinical trials and day-to-day 
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care (68). The SSC-GIT 1.0 is a 52-item questionnaire that has 7 scales: 5 aspects of 
GI dysfunction encountered in SSc patients (namely reflux, distension, diarrhoea, 
constipation and pain) and two generic aspects (emotional well-being and social 
functioning). The instrument has been shown to have satisfactory reliability 
(Cronbach’s alpha 0.69-0.93 for the different scales, test-retest correlation 
coefficient ≥0.69) (68). This was the first questionnaire, specifically addressing GI 
symptoms in SSc. The patients self-rated their GI symptom severity as mild in 36%, 
moderate in 44% and severe in 20 %. The patients studied were not an unselected 
SSc patient group but patients with known GI involvement. 
The aim of the study in this chapter was to validate this questionnaire in a UK 
population of patients with SSc and to assess GIT-related disease activity in 
unselected patients attending the scleroderma outpatient clinic at Royal Free 
Hospital, a tertiary referral centre. 
 
2.2. Methods 
The SSC-GIT 1.0 questionnaire was used with permission from Dr D. Khanna 
(Appendix 1). This questionnaire assesses the frequency of 5 categories of 
symptoms: reflux, distension, diarrhoea, constipation, abdominal pain and the 
effect of symptoms on social functioning and emotional well-being. The 
questionnaire assesses the number of days (divided in 4 scales: 0 days, 1-2 days, 3-4 
days, 5-7 days) during the previous week that patients had specific symptoms, thus 
assessing frequency rather than severity of symptoms. In view of the wide range of 
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symptoms and the nature of the disease this is more relevant and preferable in 
assessing disease burden. Patients were advised to answer the questions and 
report on their symptoms whilst on their current medications, including those for GI 
symptoms such as acid suppressants, prokinetics, loperamide or laxatives. This 
allowed me to assess both the frequency of GI symptoms but also the symptom 
control achieved by standard treatment methods.  
The Royal Free Hospital Scleroderma Unit is a tertiary referral centre. 
Approximately 1200 SSc patients are under regular follow-up, the majority of 
patients usually seen every 6-12 months. A third of this patient cohort was 
estimated to be a representative sample and therefore I aimed to collect 400 
completed questionnaires. Patients were approached whilst attending for their 
outpatient appointment from December 2007 to June 2008. All patients attending 
the outpatient clinic were approached and encouraged to answer the questionnaire 
irrespective of whether they had a history of GI symptoms. Patients that did not 
speak English were excluded. Questionnaires were checked directly and if not filled 
in completely patients were encouraged to do so. Despite these efforts, some 
questionnaires were incomplete. Any questionnaires with less than 50% of 
questions answered, for any of the categories, were excluded. The questionnaires 
were scored as indicated in the original paper (68). Each item was rescaled to a 
range of 0 to 100, where 100 indicated better health. Scoring for the 4-item 
questions (comprising all except two questions) was as follows: 1=100, 2=66.6, 
3=33.3, 4=0. The two 2-item questions were scored as follows: 1=0, 2=100. For each 
category the average score was calculated. For each patient with a completed 
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questionnaire, the patients’ notes and/or the Royal Free Hospital Scleroderma 
patient database were reviewed to establish disease subtype, disease duration, 
presence of autoantibodies and evidence of pulmonary, cardiac or renal 
involvement. Pulmonary fibrosis was defined as predicted forced vital capacity 
(FVC) or carbon monoxide diffusing capacity (DLCO) of <55% or a 15% decline from 
baseline in FVC or DLCO, with fibrosis confirmed on high-resolution CT. Pulmonary 
arterial hypertension had to be confirmed by right heart catheterization with mean 
pulmonary arterial pressure of >25 mmHg and normal pulmonary capillary wedge 
pressure. Scleroderma renal crisis was defined as new-onset systemic hypertension 
>150/85 mmHg and a documented decrease in estimated glomerular filtration rate 
≥30%. Cardiac involvement was defined as haemodynamically significant cardiac 
arrhythmias, pericardial effusion or congestive heart failure requiring specific drug 
treatment. Any previous clinical record of gastrointestinal involvement, as patient 
symptoms or positive tests, was recorded. Drug history was also recorded, with 
special reference to immunosuppression or use of drugs for GI symptoms. 
Khanna et al in their study found that the SF-36 was not as good at discriminating GI 
symptom severity as the SSC-GIT 1.0. In order to assess if there is any correlation 
between the 2 questionnaires a small proportion of patients (approximately 10%) 
both with and without significant GI symptoms also filled in the SF-36 questionnaire 
(Appendix 2). Correlations between the total SF-36 score and total SSC-GIT 1.0 
score, SF-36 physical health score and total of the 5 symptom categories of the SSC-
GIT score and SF-36 mental health score and the category for emotional well being 
of the SSC-GIT 1.0 score were calculated.  
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Summary statistics were computed for each GIT scale.  Data were non-normally 
distributed so it is presented in medians and interquartile ranges, however to 
enable comparison with previous work in this area, means and standard deviations 
are also provided.  The proportion of patients scoring the maximum possible value 
for each scale (ceiling effect) and the lowest possible value for each scale (floor 
effect) was computed.  Matrices of pairwise correlation coefficients were computed 
to assess the associations between GI symptoms and to examine the associations 
between GI symptoms and: 1) presence of other internal organ involvement, 2) 
presence of autoantibodies, 3) previously documented gastrointestinal disease and 
reported symptoms. No adjustment was made for multiple testing since the 
analysis was exploratory. I investigated associations in all patients and then in 
patient subgroups although the power was limited for the subgroup analysis.  All 
statistical analyses were conducted using Stata 10 Intercooled (StataCorp LP, Texas, 
USA) statistical software. 
 
2.3. Results 
430 questionnaires were collected and analysed at a later date. Twenty-eight (6.5%) 
questionnaires had less than 50% of questions in one or more of the categories 
answered and were therefore excluded from the analysis.  402 completed 
questionnaires were the total included in the analysis. All the patients’ notes and/or 
Scleroderma database were reviewed and demographics, disease characteristics 
and other internal organ involvement were recorded. The patients’ demographics 
and disease characteristics are shown in table 2.1. Thirty nine per cent of patients 
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were on immunosuppressants (mycophenolate mofetil 16%, methotrexate 12%, 
azathioprine 8%) and 72% were on medications for GI symptoms. 
The majority of patients were female (88.8%) with a mean age of 55 years and 
median disease duration of 10 years (range 1-52 years). 69% of the patients that 
completed the questionnaire had limited cutaneous (lcSSc) SSc and 30% diffuse 
cutaneous (dcSSc) SSc. There were 2 patients with autoimmune Raynaud’s and 1 
patient with scleroderma sine scleroderma. Patients with overlap syndromes were 
categorised according to the SSc disease subtype. The disease subtype and 
autoantibody profile reflected the overall Royal Free patient cohort (69).      
The SSC-GIT 1.0 questionnaires were scored as described above. The findings are 
summarised in table 2.2. Overall there was a high prevalence of GI symptoms. 
Eighty-five percent of patients reported reflux symptoms and 87% reported 
distension at least 1-2 days per week, whereas 50% and 47% of patients reported 
diarrhoea and constipation, respectively, 1-2 days per week. Figure 2.1 depicts the 
percentage of patients reporting symptoms for each frequency category. Ninety-
seven percent of patients reported symptoms at least once a week, and 15% 
reported daily symptoms; only 3% of patients reported no symptoms. 72% of 
patients were taking medication for GI symptoms, predominantly acid suppressants 
(71%), prokinetics (13%) and laxatives (4%). Despite this, 94% reported upper and 
79% lower GI symptoms. The use of medication did not prevent the occurrence of 
symptoms. In fact, the patients on acid suppressants or prokinetics (AS/P) reported 
more frequent reflux and distension symptoms than the patients that were not on 
acid suppressants or prokinetics (reflux score: AS/P: 70.36 ± 1.47 vs no AS/P: 83.49 
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± 1.67; distension score: AS/P: 66.39 ± 1.44 vs no AS/P: 76.42 ± 1.93; p<0.001). 157 
patients (39%) were on immunosuppressants: mycophenolate mofetil (16%), 
methotrexate (12%), azathioprine (8%), cyclosporine (2%), other (1%); there was no 
difference in GI symptoms with immunosuppressant use.  
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Table 2.1: Patient demographics and disease characteristics 
Age (mean + sd) 55.4 + 12.1 
Sex - Female/Male (%) 357/45 (88.8/11.2) 
Disease duration - median (range)  10 years (1-52 years) 
Disease subtype – lcSSc/dcSSc (%) 277/122 (68.9/30.3) 
Internal organ involvement 
Cardiac 
Pulmonary 
Renal 
Gastrointestinal 
n (%) 
25 (6%) 
168 (42%) 
24 (6%) 
345 (86%) 
Autoantibodies  
ANA  
ACA 
SCL-70  
U3-RNP 
RNAP  
U1-RNP 
other                          
n (%) 
382 (95%) 
128 (31.8%) 
88 (21.9%) 
13 (3.2%) 
32 (8%) 
21 (5.2%) 
45 (11.2%) 
 
Abbreviations: lcSSc - limited cutaneous systemic sclerosis, dcSSc – diffuse 
cutaneous systemic sclerosis, ACA – anti-centromere antibody, Scl-70 – anti- 
topoisomerase antibody, RNAP – anti-RNA polymerase 
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Table 2.2: Descriptive statistics of SSC-GIT 1.0 questionnaire scores 
SSC-GIT 1.0 
scales 
Sample 
size 
No. 
of 
Items 
Median 
score  
(IQ range) 
Mean 
score 
±SD 
Min 
score 
Max 
score 
Floor  
effect 
% 
Ceiling 
effect 
% 
Reflux 402 9 81.5  
(59.3-92.6) 
73.99 ± 
23.92 
7.4 100 0 14.9 
Distension 402 6 72.2  
(50-88.9) 
69.16 ± 
23.84 
5.6 100 0 13.2 
Diarrhoea 402 3 88.9  
(44.4-100) 
75.17 ± 
30.39 
0 100 1.5 49.8 
Constipation 401 3 100  
(55.5-100) 
76.63 ± 
29.95 
0 100 2.7 53.2 
Abdominal 
Pain 
401 2 100  
(66.7-100) 
80.59 ± 
26.68 
0 100 3.5 51 
Social 
functioning  
401 20 96.7  
(85-100) 
89.73 ± 
15.69 
12 100 0 42.3 
Emotional 
well-being 
401 9 88.9  
(57.4-100) 
76.19 ± 
30.64 
0 100 1 43.8 
 
Figure 2.1: Percentage of patients for each symptom and frequency category. 
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The mean scores +/- standard deviation (possible score 0-100) ranged from 69.16 ± 
23.84 for distension to 89.73 ± 15.69 for social functioning (Table 2.2). I found that 
distension and reflux were the categories with the lowest scores, meaning that 
patients complain of these symptoms most frequently. All 7 scales showed a ceiling 
effect (percentage of patients that reported no symptoms for that scale thus 
scoring 100 [highest score] for the scale). This ranged from 13.2% and 14.9% for 
distension and reflux scales respectively to 53.2% for the constipation scale. The 
lower ceiling effect on the reflux and distension scales reflects the higher 
prevalence of these symptoms but also the fact that there were more questions in 
these domains than in the diarrhoea and constipation domains. Only 3 of the 7 
scales showed a floor effect (percentage of patients having the lowest score [0] for 
a category) which was small, ranging from 1.5% for diarrhoea to 3.5% for abdominal 
pain. 
There was a high correlation between most symptom categories (table 2.3). The 
highest was between reflux and distension (r=0.89). There was no significant 
correlation between diarrhoea and constipation. The effect on emotional well being 
was significant, with an average score of 76.2, and was associated with low scores 
in all other symptom categories.  The strongest correlation was with reflux (r=0.47) 
with distension being second (r=0.46) and diarrhoea third (r=0.41) whereas the 
weakest one was constipation (r=0.18). There was also significant correlation 
between all symptom categories and the effect on social life (r=0.23 to 0.63). The 
correlation between reflux and effect on social life was the greatest (r=0.63) with 
emotional well being being second (r=0.58). 
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Forty-four patients, 24 with and 20 without significant GI symptoms completed the 
SF-36 questionnaire. There was a positive correlation between the total SF-36 score 
and the total SSC-GIT 1.0 score (r=0.41). There was also a positive correlation 
between the physical health SF-36 score and the total of the 5 symptom categories 
score (reflux, distension, diarrhoea, constipation and abdominal pain) (r=0.48). 
There was significant correlation between the social function scores of SF-36 and 
SSC-GIT 1.0 (r=0.42) and between the SF-36 mental health score and the score of 
emotional well-being category of the SSC-GIT 1.0 (r=0.29; p=0.55) but the latter did 
not reach statistical significance (figure 2.2).  
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Table 2.3: Correlation matrix of all SSC-GIT 1.0 scores  
(r=Pearson correlation coefficient):  
 Reflux Distension Diarrhoea Const
n
 Abdo pain Emotional Social 
Reflux r=1.0000  
 
     
Distension r=0.8913 
p<0.0001 
r=1.0000 
 
     
Diarrhoea r=0.3539 
p<0.0001 
r=0.3675 
p<0.0001 
r=1.0000 
 
    
Const
n
 r=0.3529 
p<0.0001 
r=0.3340 
p<0.0001 
r=-0.470 
p=0.3479 
r=1.0000 
 
   
Abdo pain r=0.5018 
p<0.0001 
r=0.4857 
p<0.0001 
r=0.2729 
p<0.0001 
r=0.4261 
p<0.0001 
r=1.0000 
 
  
Emotional r=0.4716 
p<0.0001 
r=0.4612 
p<0.0001 
r=0.4118 
p<0.0001 
r=0.1767 
p=0.0004 
r=0.4007 
p<0.0001 
r=1.0000 
 
 
Social r=0.6312 
p<0.0001 
r=0.4329 
p<0.0001 
r=0.4781 
p<0.0001 
r=0.2341 
p<0.0001 
r=0.4789 
p<0.0001 
r=0.5772 
p<0.0001 
r=1.0000 
 
  
 
Table 2.4: Correlation table of SSC-GIT 1.0 scores and internal organ involvement 
(r= Pearson correlation coefficient). 
 
 
 
 
 
 
 
 
 
 
  
 Pulmonary 
fibrosis 
Pulmonary 
hypertension 
Cardiac 
involvement 
Reflux  
(all SSC-GIT scores) 
r=0.0132 
p=0.7919 
r=-0.0501 
p=0.3161 
r=-0.0325 
p=0.5163 
Diarrhoea  
(all SSC-GIT scores) 
r=0.1347 
p=0.0068 
r=-0.0522 
p=0.2965 
r=0.0635 
p=0.2036 
Constipation  
(all SSC-GIT scores) 
r=-0.0960 
p=0.0547 
r=0.0181 
p=0.7184 
r=0.0175 
p=0.7274 
Severe diarrhoea 
(SSC-GIT score <66.6) 
r=0.0766 
p=0.2184 
r=-0.0086 
p=0.8907 
r=0.0461 
p=0.4591 
Severe reflux  
(SSC-GIT score <66.6) 
r=0.1026 
p=0.2212 
r=-0.0529 
p=0.5291 
r=-0.0601 
p=0.3365 
Severe constipation 
(SSC-GIT score <66.6) 
r=0.0277 
p=0.6509 
r=-0.0714 
p=0.2434 
r=0.0073 
p=0.9052 
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Figure 2.2: Correlation between SF 36 scores and SSC-GIT 1.0 scores in 44 patients 
with and without GI symptoms. A) SF-36 total score and SSC-GIT 1.0 total score, 
B) SF-36 Physical health score and SSC-GIT 1.0 total symptom score, C) SF-36 mental 
health score and SSC-GIT 1.0 emotional score, D) SF-36 social functioning score and 
SSC-GIT 1.0 social score. 
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There was little evidence of any difference in symptom scores in any of the 
categories between dcSSc and lcSSc. With regards to autoantibody profile, U3RNP 
antibodies were associated with more frequent diarrhoea symptoms (p=0.015). 
There was a trend towards less frequent reflux symptoms in PM-SCL positive 
patients, but this was not statistically significant. There was no significant 
association with U1RNP and GI symptoms or any other significant association 
between autoantibody profile and GI symptoms.  
I looked for an association between GI symptoms and the presence of other 
internal organ involvement (table 2.4). We found an association between diarrhoea 
scores and pulmonary fibrosis (r=0.135, p=0.0068), in that patients with pulmonary 
fibrosis were less likely to have diarrhoea. In contrast there was a negative 
correlation between constipation scores and pulmonary fibrosis although this did 
not reach statistical significance (r=0.096, p=0.0547). Specifically we did not find 
significant association between cardiac disease and GI symptoms, although case 
reports have suggested that diarrhoea and malabsorption can exacerbate cardiac 
complications, most likely secondary to electrolyte imbalances. Investigating 
whether more frequent GI symptoms were associated with other internal organ 
involvement, the groups were split in two groups according to scores, those with 
score less than 66.6 and those with scores more or equal to 66.6. The former group 
identifying patients with more frequent symptoms, equivalent according to the 
questionnaire to symptoms equal to or more than 3-4 days/week as an average for 
the category, suggestive of more severe GI involvement. No associations were 
found between either of the two severity groups and evidence of other internal 
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organ involvement. Interestingly although it has been previously suggested that 
severe gastro-oesophageal reflux may contribute to pulmonary fibrosis (70;71), 
such an association was not evident from our data (r=0.1). Patients with pulmonary 
fibrosis were more frequently taking acid suppressants than patients without 
pulmonary fibrosis (78% vs 66%; p=0.01) but no association was found between 
frequency of reflux symptoms and documented pulmonary fibrosis or pulmonary 
hypertension.  
In order to assess whether the questionnaire scores reflected previously 
documented gastrointestinal disease and reported symptoms, patients’ notes were 
reviewed and any gastrointestinal diagnosis or report of symptoms noted, for 
example gastro-oesophageal reflux, distension, endoscopic findings such as GAVE, 
small intestinal bacterial overgrowth, diarrhoea, constipation, anorectal symptoms 
(prolapse or faecal incontinence). Patients with documented gut involvement had 
overall significantly higher respective questionnaire scores for all the questionnaire 
categories (reflux, distension, diarrhoea, constipation) than those patients without 
previously documented gut involvement. There was no available documentation on 
the severity of GI involvement and therefore we could not correlate this to 
questionnaire scores. Unfortunately GI investigations results were often not 
available as tests were frequently done at patients’ local hospitals. It was not 
possible therefore to correlate symptoms with objective measures of GI 
involvement.  
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2.4. Discussion 
The development of SSC-GIT 1.0 by Khanna et al provided the first HRQOL 
instrument to capture GIT involvement in patients with SSc (68). HRQOL 
questionnaires are widely used both in clinical practise and as research tools both in 
rheumatological and gastrointestinal diseases. For example the inflammatory bowel 
disease questionnaire (IBDQ) is a 32-item questionnaire that assesses bowel 
function, general systemic health and social and emotional impact. It has been 
validated cross-culturally and is a regularly used tool in clinical studies. It has been 
shown to be responsive to changes in bowel function and detect differences in 
severity of disease activity (72-74). The SSC-GIT 1.0 assesses a variety of GI 
symptoms and the effect on social and emotional functioning in a similar way. In 
contrast though to inflammatory bowel disease for which there are objective 
markers, both laboratory and endoscopic, indicative of disease activity, gut 
involvement in SSc is often difficult to assess.  
In developing this questionnaire Khanna et al assessed 88 SSc patients with GI 
involvement. In his patient cohort the questionnaires answered by the patients 
indicated a variety of GI problems. I have confirmed a similar burden of disease in a 
UK patient cohort to that reported in the USA population that the questionnaire 
was developed in. The high frequency of GI involvement in SSc is well documented 
and it has a major impact on the quality of life.  A number of studies have 
demonstrated GI involvement of both the upper and lower GI tract based on 
endoscopic findings or physiological studies as well as reported symptoms 
(56;61;75).  This questionnaire is designed to provide information not only about 
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symptoms but also about the psychological impact and the effect on the patients’ 
social life. The questionnaire analysis showed that patients often reported both 
upper and lower GI symptoms although upper GI symptoms such as reflux 
symptoms and dysphagia occur more frequently. There is a significant effect of gut 
symptoms to patients’ emotional and social well-being.   
The SSC-GIT 1.0 has seven scales: reflux, distension, diarrhoea, constipation, pain, 
emotional well-being, and social functioning. Khanna et al had joined the reflux and 
indigestion scales in one bigger category as they found a strong correlation 
between the 2 categories (68). The 2 categories were kept separate in the current 
analysis in order to distinguish between reflux symptoms and distension as this is 
indicative of gastroparesis and small bowel involvement. There was though a high 
correlation between those 2 categories as reported previously. All seven scales 
showed some ceiling effect, ranging from 13-15% in reflux and indigestion to 50-
53% in diarrhoea, constipation and abdominal pain. The higher ceiling effect in the 
latter three symptoms may be explained by the lower prevalence of lower GI 
symptoms. Furthermore, less items in the questionnaire were dedicated to those 
symptoms (three for diarrhoea, three for constipation and two for pain). Khanna et 
al found much lower ceiling effect in the reflux/indigestion scale than was found in 
our patient cohort. This is most likely secondary to the much large number of 
patients but more importantly secondary to the fact that asymptomatic patients 
were included in the 400 patients studied. Overall the mean questionnaire scores 
documented were comparable although a bit higher than those published by 
Khanna et al (68). Higher scores reflect lower symptom burden and this may well be 
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again a reflection of the larger sample size, including patients with no GI symptoms. 
Additionally a large percentage of patients were on regular medication for their GI 
symptoms.  
General GI involvement has not been associated previously with a specific disease 
subtype (76), unlike other internal organ pathology such as pulmonary 
hypertension or renal crisis that are associated with lcSSc and dcSSc respectively. 
Nishimagi et al  investigated 302 patients with SSc and found that in patients with 
early severe GI involvement, defined as malabsorption, pseudo-obstruction or need 
for hyper-alimentation, the ratio of dcSSc to lcSSc was higher than in patients 
without severe GI involvement (77). They also found that these patients were less 
likely to suffer from interstitial lung disease.  In that study the presence of anti-
centromere (ACA) or SCL-70 antibodies was less frequent in patients with severe GI 
involvement and there was a higher frequency of anti-U3RNP, anti-U1RNP and 
other anti-nucleolar antibodies (77). However, Steen investigating features 
associated with specific autoantibodies found that subjective gastrointestinal 
involvement occurred in more than 80% of patients without association with 
specific disease subtype or autoantibodies, but severe GI involvement was 
significantly greater in patients with anti-U3RNP and also Th/To and anti-U1RNP (5). 
In my study no association was found between general GI involvement and disease 
subtype or specific autoantibodies. This was though a study based on subjective 
symptoms and not proven GI involvement. The symptom category of this 
questionnaire most likely to indicate severe GI involvement is diarrhoea as it is 
often secondary to small intestinal involvement and bacterial overgrowth. A higher 
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incidence of more severe diarrhoea symptoms was found in patients with anti-
U3RNP antibodies, but not so with anti-U1RNP. The frequency of other 
autoantibodies such as anti-KU, Th/To was too small for any meaningful 
associations.  
Regarding association between the gastrointestinal tract and other organ 
involvement, previous studies have shown that there may be a causative link 
between gastro-oesophageal reflux and pulmonary fibrosis (70). Anecdotal 
evidence suggests a link between cardiac involvement and GIT involvement, 
possibly secondary to electrolyte disturbances often associated with diarrhoea and 
malabsorption.  In this study there was an inverse relationship between symptoms 
of diarrhoea and pulmonary fibrosis. It may be that treatment for pulmonary 
fibrosis has some protective effects against intestinal involvement although review 
of patients’ medications did not reveal any association between specific 
medications or immunosuppression and GI symptoms. Patients with pulmonary 
fibrosis were, as expected, more frequently on immunosuppressants but 
interestingly there was no difference in the frequency of diarrhoeal symptoms with 
immunosuppressant use. There was no evidence of more severe reflux symptoms in 
patients with pulmonary fibrosis. An explanation for this may be that reflux 
symptoms often do not represent severity of oesophageal disease, for example 
patients with Barrett’s oesophagus often have less severe symptoms (78). Another 
explanation is that patients with pulmonary fibrosis have had their reflux symptoms 
treated more aggressively as suggested by the fact that these patients were more 
frequently on acid suppressants. This could indicate more severe or more frequent 
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symptoms but it could also indicate that physicians are more likely to prescribe / 
encourage use of PPI in patients with documented pulmonary fibrosis. It would be 
worth assessing in future studies oesophageal involvement in specific patient 
groups with pulmonary fibrosis, for example patients with dcSSc who are SCL-70 
negative and in whom epithelial injury is more strongly implicated or patients with 
lcSSc, ACA positive. Furthermore it is worth exploring specific autoantibody and 
disease subtype association with site-specific gut involvement, rather than overall 
gut involvement.  
One of the major limitations of using a subjective symptom questionnaire is that 
this may not accurately depict actual disease activity and severity. Previous studies 
have shown that asymptomatic patients did have abnormal oesophageal motility 
when investigated (79), so disease activity may actually have been underestimated 
using subjective measures. Furthermore patients were often on drugs such as 
proton pump inhibitors, prokinetics and laxatives as treatment for their 
gastrointestinal symptoms. On the other hand, GI symptoms may occur irrespective 
to actual SSc gut involvement, as for example bloating is often a symptom of 
irritable bowel syndrome, a condition occurring in up to 20% of the Western 
population, especially women (80). Additionally some of the drugs used commonly 
in SSc patients can have significant gastrointestinal side effects such as 
mycophenolate, bisphosphonates, opiates, antibiotics.  
One of the main drawbacks of this questionnaire is that it is using symptom 
frequency only and not severity to assess symptom burden, unlike other quality of 
life questionnaires. In view of the multi-organ gastrointestinal involvement and the 
56 
variety of symptoms, the frequency of these symptoms is likely to be indicative of 
symptom burden. Furthermore, Khanna et al showed that the SSC-GIT 1.0 scales 
were able to discriminate the self-rated severity of GI symptoms and found a 
significant association between this questionnaire and other quality of life 
questionnaires (68) such as the SF-36 and health assessment questionnaire (SHAQ) 
(81). This association was confirmed in my study as there was positive correlation 
between the SSC-GIT 1.0 scores and related SF-36 dimensions. In some instances, 
for example SF-36 mental health score and the emotional effect category of the 
SSC-GIT 1.0 questionnaire, the correlation was lower than it would be expected. 
This could be explained by the fact that the SF-36 assesses general health and well 
being whereas the SSC-GIT 1.0 assesses specifically GI symptoms. In SSc, a disease 
that affects multiple organs, general health and well-being is likely to be affected by 
a variety of factors and therefore it is not surprising that the correlation between 
the 2 questionnaires is not greater than was shown. The fact that there is significant 
correlation between the SF-36 and SSc-GIT 1.0 supports further the importance and 
significant effect of GI involvement in SSc. 
Another limitation of this questionnaire is that there are symptoms that are not 
explored adequately, in general lower GI symptoms compared to upper GI 
symptoms are less assessed, specifically for example constipation and faecal 
incontinence (43;44). The importance of bowel function in quality of life is 
demonstrated in neurological disorders such as spinal cord injury and multiple 
sclerosis. The neurogenic bowel dysfunction score was devised to assess colorectal 
and anal dysfunction in spinal cord injury patients and has been used in other 
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neurological disorders (82-84). Nonetheless, with a disease that can affect the 
whole of the GIT, there must be a balance between assessing adequately all 
different symptoms and avoiding a questionnaire that is too long, too time-
consuming and therefore less practical for use on a regular basis in order to 
monitor disease progression. In fact the 52-item SSC-GIT 1.0 questionnaire was felt 
to be too long and a shorter version of this questionnaire has now been developed 
(85). Ideally the use of objective measures or tests to assess GI involvement should 
be used but these tests are often invasive and although more accurate in 
diagnosing GI involvement in SSc they are probably less useful in assessing disease 
progression. Whilst treatment for GI involvement remains symptomatic a dedicated 
GI questionnaire gives an accurate assessment of symptom burden and can be used 
to assess this at different times and be used as a guide to adjust treatment. 
In summary, patients with SSc have an extremely high burden of both upper and 
lower gut symptoms. There is no strong association of gut symptoms with other 
organ involvement or disease profile. The degree of symptoms demonstrated is 
more than would be expected from the symptoms documented in the clinical notes 
suggesting that patients usually under-report these symptoms. This is regrettable 
since many of the symptoms may be amenable to treatment and therefore routine 
assessment of GI symptoms is recommended. 
Having established gut disease burden in patients with SSc and in order to 
investigate the pathophysiology of gut disease in SSc I examined the anorectum, an 
area of the gut easily accessible and which allows assessment of the main 
pathologies recognised in systemic sclerosis.  
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CHAPTER 3: 
ANORECTAL PHYSIOLOGY AND ENDOANAL ULTRASOUND 
IMAGING IN SYSTEMIC SCLEROSIS PATIENTS 
 
  
Publications generated from this chapter can be found in Appendix 9 
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3.1. Introduction 
The exact pathophysiology of GIT involvement is not known but it is related to both 
neurogenic and myogenic abnormalities (37;58). Physiologically the typical resulting 
abnormality is dysmotility such as low amplitude contraction in the distal 
oesophagus and decreased or absent migrating motor complexes in the intestine 
(37;60;86). Anatomical changes such as intestinal dilatation usually occur as the 
disease progresses and are thought to relate to severe dysmotility. Histologically 
the main changes seen in the GIT are patchy atrophy of the muscularis propria and 
varying degrees of fibrosis as the disease progresses (47). The smooth muscle 
atrophy seen is thought to be secondary to vascular ischaemia and neural plexus 
dysfunction (10;13). Reduced blood flow has been demonstrated in the stomach 
and duodenum (11;12).  
In health faecal continence is maintained by the co-ordinated function of the pelvic 
floor, the rectum and the anal sphincters. The smooth muscle internal anal 
sphincter (IAS) is primarily responsible for the anal resting tone, contributing about 
85% of the anal resting pressure. The striated external anal sphincter (EAS) 
contributes a small part towards the resting anal pressure but is primarily 
responsible for the voluntary contraction of the anal sphincter (42). Disruption or 
weakness of the IAS typically leads to passive faecal incontinence, whereas that of 
the EAS leads to urge faecal incontinence (87;88). The IAS being a smooth muscle is 
more likely to be affected in SSc (53) and it has been suggested that the changes 
are similar to those seen in the lower oesophageal sphincter. 
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A number of observational studies have investigated anorectal problems in SSc. The 
anorectum is affected in 50-70% of patients with SSc with more than 20% of 
patients developing faecal incontinence (32;89). The underlying mechanisms have 
not been systematically addressed though, and are still unclear, although there is 
evidence of smooth muscle atrophy and fibrosis but also of neural dysfunction. 
Most studies have shown a reduced resting anal pressure but a normal maximal 
squeeze pressure and an absent or impaired rectoanal inhibitory reflex (RAIR) 
(40;44;54;56). Apart from a strong correlation between an absent RAIR and faecal 
incontinence (43), the other physiological measurements have not been shown to 
correlate with symptoms. Imaging of the anal sphincters suggests that the IAS is 
thinned and hyperechoic on ultrasound in the majority of patients with SSc and 
faecal incontinence (43;90;91), although some patients may have a thickened 
hypoechoic sphincter (90). Even less is known about patients with SSc and no faecal 
incontinence. If the pattern is similar to that seen in oesophageal involvement, we 
would expect to see structural and functional changes even in the absence of 
symptoms (79). 
The aim of this study was to undertake a comprehensive analysis of anorectal 
function, including neurophysiological and sonographic assessment, of patients 
with SSc with and without faecal incontinence in order to understand further the 
pathophysiology of anorectal dysfunction in these patients. 
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3.2. Methods 
3.2.1. Patients 
The study environment was a tertiary referral gastrointestinal physiology unit in 
collaboration with a tertiary referral scleroderma unit. Forty four patients with 
systemic sclerosis, 24 with anorectal symptoms and 20 patients without anorectal 
symptoms were recruited to the study. Patients were recruited whilst attending the 
Rheumatology outpatients department at Royal Free Hospital. Consecutive patients 
were approached to take part in the study. 30 patients with history of faecal 
incontinence were approached and 24 agreed to take part, whereas 42 patients 
with no known history or complaints of anorectal symptoms were approached and 
20 consented to take part in the study. Patients were recruited over a period of 12 
months. Twenty age and sex matched patients referred to our tertiary GI physiology 
unit, over approximately the same period of time, for investigations of faecal 
incontinence were used as incontinent controls. Patients with diabetes mellitus and 
patients with neurological disorders were excluded. All patients gave informed 
consent to participate in the study, which was approved by the National Hospital 
for Neurology and Neurosurgery & Institute of Neurology Joint research ethics 
committee. 
 
3.2.2. Symptom assessment 
Anorectal symptoms were assessed by history taking and review of notes. Faecal 
incontinence was assessed using the Wexner incontinence score (a validated 5-item 
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self-completed instrument with a score of 0 representing no incontinence and a 
score of 20 representing total incontinence) (92) (Appendix 5). Constipation was 
assessed using the Wexner constipation score (an 8-item self-completed instrument 
with a score of 0 representing no symptoms and maximum score of 32 representing 
severe constipation) (93) (Appendix 4). 
Systemic sclerosis patients were asked to complete the following questionnaires on 
the day of their assessments:   
1. Scleroderma GI tract 1.0 questionnaire: A 52 item self-completed instrument that 
provides a profile for GI symptoms in 5 broad categories and their effect on social 
and emotional well-being (68) (Appendix 1). 
2. SF-36 general health questionnaire: a multi-purpose, short-form health survey 
with 36 questions that yields an 8-scale profile of functional health and well-being 
scores (94) (Appendix 2).  
3. EuroQol: a 6-item self-completed instrument that provides a simple descriptive 
profile for health status by asking if the patient has no problems, some problems or 
significant problems in domains of: mobility, self care, usual activities, 
pain/discomfort, anxiety/depression (scoring 1,2 or 3 respectively) (95) (Appendix 
3). 
SSc patients’ notes were reviewed for data on SSc subtype, disease duration and 
other internal organ involvement. The cause of faecal incontinence in incontinent 
controls was established on review of their notes and investigations. 
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3.2.3. Anorectal manometry 
No bowel preparation was given prior to testing. An 8 channel radial water-
perfused manometry system with a perfusion rate of 0.6 ml/minute (MMS, 
Enschede, Netherlands) was utilised. A latex-free balloon with 500mls capacity was 
attached at the end of the manometry catheters (External Diameter 3.9mm) 
(Ardmore Healthcare Limited, Amersham, UK). With the subject in the left lateral 
position, the station pull-through technique (catheter inserted to 5 cm and pulled 
back in 0.5 cm steps) was employed to assess anal canal length, anal resting 
pressure and anal squeeze pressure.  Resting tone was determined as the highest 
average (of the 8-channel measurements) pressure at rest. The voluntary 
contraction squeeze pressure was determined as the highest pressure attained on 3 
consecutive tries. The normal ranges quoted are the ones that are used at the GI 
physiology Unit at University College Hospital. 
 
3.2.4. Rectoanal inhibitory reflex (RAIR) 
Rapid distension of the rectum elicits an intrinsic reflex that produces relaxation of 
the IAS. The RAIR was elicited by rapid inflation and deflation of the latex balloon at 
the end of the anal manometry catheter using 50ml of air. The parameters of the 
RAIR analysed were as shown in figure 3.1. The RAIR was accepted to be present if 
the amplitude reduction was at least 25% of resting anal pressure. The process was 
repeated 3 times and the greatest response was used for the measurements. The 
RAIR was considered absent if the amplitude reduction was less than 25% of the 
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resting pressure in all 3 attempts. The point at which anal pressure returned to ⅔ of 
its original resting value was deemed to be the end of the reflex (96). The excitation 
latency was measured as being the time taken from maximal stimulation to when 
the anal pressure returned to its resting level. The beginning of the recovery time 
was when the amplitude reached its nadir. The total duration of the reflex was 
measured from the point of maximal stimulation to the point at which the 
amplitude returned to ⅔ of the original resting pressure (96).  
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Figure 3.1: RAIR parameters analysed.  
The point of maximal stimulation was the start-point of the RAIR. The end-point 
was when the anal pressure had recovered to ⅔ of the original resting pressure; this 
was the reflex duration. Amplitude reduction was measured from resting pressure 
to lowest point of the RAIR. Percentage amplitude reduction was calculated with 
resting pressure being set at 100%. Time taken for the pressure to return to resting 
from maximal stimulation was termed the excitation latency. Recovery time began 
as soon as the RAIR reached maximal relaxation. 
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3.2.5. Anorectal sensory measurements  
A bipolar electrode catheter (Galtec, Isle of Skye, Scotland, UK) was placed in the 
anal canal first and then the rectum to measure the anal and rectal sensitivities 
respectively. For determination of anal sensitivity electrical stimulation was applied 
at 5 Hz with a pulse width of 0.1 msec; the current was then incrementally 
increased to 20mA until the patient reported a change in sensation. In the rectum, 
electrical stimulation was applied at 10 Hz with a pulse width of 0.5 msec and 
increased to 50 mA until the patient reported a change in sensation. 
 
3.2.6. Rectal Compliance 
A mechanical barostat, insufflating air at 30ml/sec (Distender II, G & J Electronics, 
Ontario, Canada) was used for pressure-volume measurements. A 20cm x 15cm 
pillow shaped, polyethylene, over-sized, non-compliant bag (maximum volume 
600ml) tied to ridges 10cm apart to a dual lumen silicon catheter was utilised to 
measure compliance (Mui Scientific Inc., Ontario, Canada). The catheter was placed 
directly into the rectum at least 5 cm from the anal verge. The minimal distending 
pressure (MDP) was determined by inflation at 1mmHg increments. The pressure 
was maintained for 15 seconds at each step. During each distension the subject was 
asked to breathe deeply to see if there were any pressure variations with 
respiration. If variations with respiration were not seen by 10mmHg, the MDP was 
set at 10mmHg. The basal operating pressure (BOP) was set at MDP + 2mmHg. By 
using the BOP as a baseline, the conditioning distension sequence was performed; 
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sequential 4mmHg staircase distensions were attained up to 20mmHg. Each step 
was maintained for 15s. Once the conditioning distension was completed, the index 
distension was performed; sequential 4mmHg stepwise distensions were attained 
up to a maximum of BOP + 40mmHg. Each distension step was maintained for 1 
minute. The mean volume of air within the bag during the last 10s of each 
distension was calculated. This volume was then plotted against the pressure to 
produce a pressure-volume (P-V) curve. Compliance was measured as the gradient 
of the steep linear aspect of the curve (figure 3.2). 
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Figure 3.2: Examples of typical pressure/volume compliance curves. The 
corresponding mean volume of air within the bag during the last 10s of each 
distension (increasing pressure) was calculated (crosses) and plotted against the 
pressure to produce a pressure-volume (P-V) curve (dotted line). Compliance was 
measured as the gradient of the steep linear aspect of the curve (continuous line). 
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3.2.7. Laser Doppler Rectal Mucosal Blood Flow 
Mucosal blood flow can be detected by Laser Doppler flowmetry (97).  Studies in 
SSc patients suggest that the primary pathological lesion results from changes in 
the microvasculature producing a reduction in blood flow. Furthermore, rectal 
mucosal blood flow has been shown to be a measure of gut-specific autonomic 
innervation and altered by changes in that (98). A DRT4 laser Doppler flowmeter 
(Moor Instruments, Devon, UK) was used, this produces a low intensity beam 
almost exclusively of monochromatic coherent 780 nm light generated by a near 
infrared laser diode source and delivered by a fibreoptic probe. With patients in the 
same position the probe was placed against the mucosa 10 cm above the lower 
limit of the anal margin. A recording was taken for 20 seconds after a stable 
recording was obtained. Three recordings of blood flow were made at 120° 
circumferentially, and the mean of these was taken as the mucosal flux. 
 
3.2.8. Endoanal ultrasound 
Endoanal ultrasound was performed to assess the integrity of anal sphincters and 
possible presence of sphincter infiltration and atrophy. A conventional Hitachi EUB 
8500 ultrasound machine was used with an EUP R54AW-19 endoanal probe 
covered with a lubricated condom inserted into the anus with the patient in the 
prone position. Conventional anal endosonography was performed according to a 
standard technique (99). Images of the anal sphincters were taken at proximal, mid, 
and distal canal levels. Images were acquired by a trained radiographer and 
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assessed independently by two experts. Where there was no agreement, a 
consensus was reached after discussion. The anal sphincter complex was examined 
and the integrity and atrophy of the internal and external sphincters were 
described as follows, and scored 1-3 for analysis purposes (100): 
Integrity: Focal thinning: thinning in muscle thickness, but fibres in continuity. 
Defect/scar: discontinuity of muscle fibres with or without replacement by lower 
echogenicity scar tissue. Integrity score: 1=intact, 2=focal thinning, 3=defect/scar. 
Atrophy: Mild internal sphincter atrophy: abnormal increased echogenicity and/or 
measurement 1.5-2mm. Severe internal sphincter atrophy: measurement <1.5mm. 
Mild external/puborectalis atrophy: muscle structure visible but abnormal high 
echogenicity suggestive of fatty replacement. Severe external/puborectalis atrophy: 
muscle structure very poorly or not defined suggestive of marked fatty 
replacement. Atrophy score: 1=normal, 2=mild atrophy, 3=severe atrophy. 
The IAS was measured at the level of greater thickness at the 3, 6, 9 and 12 o’clock 
positions and the average thickness was calculated. 
 
3.2.9. Correlation between physiological and structural parameters and symptoms 
In order to establish which parameters most clearly contribute to symptoms the 
correlation coefficient between Wexner scores and physiology parameters and 
endoanal ultrasound findings in both the SSc patients and the incontinent controls 
was calculated. 
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3.2.10. Statistics 
Statistical analysis was performed using GraphPad Prism 4 (California, USA). Data 
were expressed as mean (with 95% confidence intervals) or median (range), 
depending on whether the recorded values assumed a normal “Gaussian” 
distribution. A Kolmovgorov-Smirnov test was carried out to determine if data 
followed a normal distribution. Normally distributed values were compared 
between the three groups via one-way ANOVA, and for values not normally 
distributed the Kruskal-Wallis test was used. Bonferroni and Dunn’s multiple 
comparison corrections were made respectively. For comparisons between the 2 
SSc patient groups the Mann-Whitney test was used. The chi-squared test was used 
to compare proportions between groups. Pearson correlation was used to calculate 
correlation between Wexner incontinence and constipation scores and 
physiological parameters and Spearman correlation to calculate correlation 
between Wexner incontinence scores and structural parameters. Statistical 
significance was declared for p values ≤ 0.05.  
 
3.3. Results 
3.3.1. Patients 
Forty four patients with SSc were studied. Twenty four patients reported faecal 
incontinence (symptomatic), of these patients 15 reported diarrhoea and 10 
reported constipation, with one patient reporting both symptoms, a pattern 
commonly seen in systemic sclerosis. Twenty patients had no faecal incontinence 
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(asymptomatic), of these, 2 reported diarrhoea and 3 reported constipation. The 
mean disease duration was 11.8 (8.1-15.4) years in the symptomatic group and 8 
(5.1-11.0) years in the asymptomatic group (p=NS). Twenty of 24 (83%) 
symptomatic patients and 13 of 20 (65%) asymptomatic patients had limited 
cutaneous SSc respectively (chi-squared 1.96, p=0.16). Sex and age matched 
patients with incontinence but no SSc were used as controls, matched to the 
symptomatic SSc group. The cause for incontinence in the control group was 
obstetric injury resulting in anal sphincter defects in 9 (45%) patients, obstetric 
injury but without demonstrable anal sphincter defect in 4 (20%) patients, 
neurological in 1 (5%) patient and idiopathic/functional pelvic disorder in 6 (30%) 
patients. There was no significant difference in parity between the two groups with 
incontinence but the asymptomatic SSc group had lower median parity. Table 3.1 
summarises the demographics of the three patient groups. Wexner incontinence 
scores were higher in the incontinent control (IC) and symptomatic (Sx) groups 
compared to the asymptomatic (ASx) group. Although many patients reported both 
urge and passive faecal incontinence, urge incontinence was more common in the 
incontinent control group (IC) (16/20 IC patients vs 12/24 SSc Sx patients). SSc 
patients more commonly reported passive incontinence or soiling (20/24 patients). 
The Sx SSc patients also had higher constipation scores compared to the ASx 
patients. The GI questionnaire, EuroQol and SF-36 scores of the SSc patients are 
summarised in table 3.2. 
 
  
73 
Table 3.1: Demographic characteristics of the three patient groups. 
 Asymptomatic SSc 
Mean (95% CI) 
Symptomatic SSc 
Mean (95% CI) 
Incontinent 
Controls 
Mean (95% CI) 
Age 57.5 (53.3-61.7) 59.2 (55.4-63) 54.2 (47.9-60.4) 
F/M ratio 20 / 0 20 / 4 20 / 0 
Parity (median- IQR) 1 (0-2) 2 (1-2) 2 (2-3.5) * 
Disease duration  8.0 (5.1-11.0) 11.8 (8.1-15.4) N/A 
lcSSc/dcSSc 13 / 7 20 / 4 N/A 
Autoantibodies  
-ACA 
-SCL-70 
N (%) 
8 (40) 
2 (10) 
N (%) 
17 (71) 
3 (13) 
N/A 
Internal organ 
involvement 
-Pulmonary 
-Cardiac 
-Renal 
-Oesophageal 
N (%) 
 
5 (25) 
1 (5) 
2 (10) 
14 (70) 
N (%) 
 
10 (42) 
2 (8) 
2 (8) 
23 (96) 
N/A 
Wexner Incontinence  
(median- IQR) 
2 (0.5-3.5) 10 (8-16) * 14 (11.5-16) * 
Wexner Constipation 
(median- IQR) 
3 (1.5-6) 10 (6-14) * N/A 
 * p<0.05 compared to ASx 
Abbreviations: lcSSc - limited cutaneous systemic sclerosis; dcSSc - diffuse 
cutaneous systemic sclerosis; CI - confidence interval, IQR – interquartile range 
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Table 3.2: Questionnaire scores in systemic sclerosis patients. 
 Asymptomatic SSc 
Median (IQ range) 
Symptomatic SSc 
Median (IQ range) 
SF-36 
-Total score 
-Physical Health score 
-Mental Health score 
 
62.43 (54.45-77.84) 
60.4 (42.8-75.1) 
65.15 (53.95-70.9) 
 
54.01 (39.74-73.57) 
50.8 (27-68.5) 
62.35 (35.63-72.95) 
Euroqol (EQ-5D) 
-Mobility 
-Self-care 
-Usual activities 
-Pain/Discomfort 
-Anxiety/Depression 
-VAS score 
 
1 (1-2) 
1 (1-1.5) 
1 (1-2) 
1.5 (1-2) 
1 (1-2) 
80 (60-80) 
 
1 (1-2) 
1 (1-2) 
2 (1-2) 
2 (2-2) 
2 (1-2) 
62 (53-80) 
SSC-GIT 1.0 
-Reflux 
-Distension 
-Diarrhoea 
-Constipation 
-Abdominal pain 
- Social  
-Emotional 
 
92.6 (81.5-96.5) 
83.3 (72.2-94.35) 
100 (77.75-100) 
100 (77.7-100) 
100 (83.3-100) 
100 (100-100) 
100 (94.45-100) 
 
55.6 (42.55-77.75) * 
50 (36.1-63.85) * 
61.1 (27.75-100) * 
66.65 (22.2-100) * 
66.7 (50-100) * 
81.7 (65-95) * 
55.6 (31.45-77.75) * 
* p<0.05; Comparisons made using the Mann-Whitney test 
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3.3.2. Anorectal physiology measurements 
The resting pressure was below the normal range (60-160 cmH2O) in both the Sx 
and the IC group and was lowest in the IC group (IC: 42.2 [33-57.4] vs ASx: 63.8 
[53.7-73.9]; p<0.05 vs Sx: 50.8 [40.7-61]; p>0.05) (Figure 3.3A). The squeeze 
pressure was lower in the IC group compared to both the ASx and Sx groups (IC: 
46.95 [30-63.9]) vs ASx: 104.6 [81-128.3] vs Sx: 121.4 [101.3-141.6]; p<0.05) and 
below the normal range (50-180 cmH2O) (Figure 3.3B). There was no significant 
difference in the mean squeeze pressure between the ASx and Sx groups. There 
was no significant difference in rectal compliance or rectal mucosal blood flow in 
the 3 groups. 
Anal electrosensation threshold was highest in the Sx patients (Sx: 10.4 [8.8-11.4] vs 
ASx: 6.7 [5.7-7.7] vs IC: 8.5 [6.5-10.4]) (Figure 3.4A), the difference was statistically 
significant in comparison to ASx group, p<0.05. Although the anal sensory threshold 
was also higher in the IC patients compared to the ASx patients (p>0.05) this was 
still within the normal range (2.0-9.4) whereas this was not the case for the Sx 
patients. Rectal electrosensation thresholds were similar in the 3 groups (Figure 
3.4B). The anorectal physiology results are summarised in Table 3.3. 
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Figure 3.3: Resting and squeeze pressure in the 3 groups.  
(A) The resting pressure was lowest in the IC group 42.2 (33-57.4) vs Sx: 50.8 (40.7-
61) vs ASx: 63.8 (53.7-73.9). (B) Squeeze pressure was significantly lower in the IC 
group (46.95 (30-63.9)) compared to the Sx (121.4 (101.3-141.6)) and ASx (104.6 
(81-128.3)) groups. Results given as mean +/- standard deviation. 
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Figure 3.4: Anal sensory threshold and rectal sensory threshold in the 3 groups.  
(A) Anal sensory threshold was higher in the Sx (10.4 (8.8-11.4)) compared to the 
ASx group (6.7 (5.7-7.7)) and IC group (8.5 (6.5-10.4)). (B) Rectal sensory thresholds 
were not significantly different in the 3 groups. Results given as mean +/- standard 
deviation. 
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Table 3.3: Anorectal physiology measurements in symptomatic and asymptomatic 
SSc patients and incontinent controls. 
 Normal 
range 
Asymptomatic 
SSc 
Mean (95% CI) 
Symptomatic 
SSc 
Mean (95% CI) 
Incontinent 
Controls 
Mean (95% CI) 
Resting pressure 
(cmH2O) 
60-160 63.8  
(53.7-73.9) 
50.8  
(40.7-61) * 
42.2  
(33-57.4) 
Squeeze pressure 
(cmH2O) 
50-180 104.6  
(81-128.3)# 
121.4  
(101.3-141.6)# 
46.95  
(30-63.9)  
Rectal compliance 
(ml/mmHg) 
11-15 10.9  
(9.1-12.7) 
10.6  
(8.8-12.5) 
11.9  
(10.2-13.7)  
RMBF  
(flux units) 
90-250 158.4  
(134.3-182.5) 
150.1  
(123.6-176.6) 
136  
(89.8-182.1)  
Anal sensory 
threshold (mA) 
2.0-9.4 6.7  
(5.7-7.7) 
10.4  
(8.8-11.4) * 
8.5  
(6.5-10.4) 
Rectal sensory 
threshold (mA) 
7.0-36.0 19.7  
(15.5-24) 
24.4  
(20.4-28.4) 
23.1  
(20.1-26.1) 
* p<0.05 compared to ASx; # p<0.05 compared to IC 
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3.3.3. Rectoanal inhibitory reflex (RAIR) measurements 
Eleven of 24 (46%) Sx SSc patients compared to only 2 of 20 (10%) ASx SSc patients 
and 1 of 20 (5%) IC demonstrated an absent RAIR, chi-squared 13.04, p<0.01. The 
total duration of the reflex was also longer in the Sx patients (Sx: 19.2 [13.7-24.6] vs 
ASx: 13 [11.2-14.9] vs IC: 13 [10.6-15.4] secs; p=0.001) (Figure 3.5A). The latency of 
the reflex was longer in the Sx patients compared to ASx and IC (Sx: 2.4 [1.5-3.2] vs 
ASx: 1.4 [1-1.9] vs IC: 1.3 [1.1-1.6] secs; p=0.006) (Figure 3.5B). There was a trend of 
lower amplitude (Sx: 42% [32.5-51.5] vs ASx: 57% [46.7-67.5] vs IC: 53.2% [45.7-
60.7]; p=0.69) and longer recovery (Sx: 11.6 [7-16] vs ASx: 7.3 [5.6-9.1] vs IC: 7.6 
[5.5-9.7] secs, p=0.055) of the reflex in the Sx patients compared to the ASx and IC 
but these differences were not statistically significant. 
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Figure 3.5: RAIR parameters in the 3 groups, (A) duration of RAIR and (B) latency. Sx 
group had longer total RAIR duration (Sx: 19.2 (13.7-24.6), ASx: 13 (11.2-14.9), IC: 
13 (10.6-15.4)) and latency (Sx: 2.4 (1.5-3.2), ASx: 1.4 (1-1.9), IC: 1.3 (1.1-1.6)) 
compared to the other 2 groups. 
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This significant difference in the presence of RAIR between Sx and ASx SSc patients 
was investigated further in order to establish the association with faecal 
incontinence and any other factors that may be contributing to this by comparing 
patients with present RAIR with those with absent RAIR. The patients with absent 
RAIR had higher Wexner incontinence scores than those with present RAIR (10.3 
[6.9-13.8] vs 6 [3.9-8]; p=0.023). Disease characteristics and the rest of the 
physiology parameters were compared in those patients. There was no difference 
between disease duration in the patients with and without elicited RAIR. There was 
no significant difference in other physiological parameters between the SSc patients 
that had a demonstrable RAIR and those patients that did not. Specifically the 
resting pressure between the SSc patients with present and absent RAIR was not 
significantly different (present 58.81 [51.1-66.6] vs absent 51.77 [3.1-69.4]). 
Nonetheless there was a difference in IAS atrophy scores between the 2 groups, the 
patients with absent RAIR having higher IAS atrophy score (median IAS-A: present 
RAIR: 2 [1-2] vs absent RAIR: 2 [2-3]; p=0.045). Despite the lower resting pressure in 
IC group only 1 patient had an absent RAIR.  
 
3.3.4. Endoanal ultrasound 
Anal sphincter atrophy and integrity scores are given as medians with interquartile 
range and shown in figure 3.6. EAS integrity scores: Sx: 1 [1-1], ASx: 1 [1-1], IC 1 [1-
2] (figure 3.6A), IAS integrity scores: Sx: 1 [1-2], ASx: 1 [1-1], IC: 1 [1-3], EAS atrophy 
scores were 1 [1-1] for all 3 groups and IAS atrophy scores: Sx: 2 [1.5-3], ASx: 2 [1-
2], IC: 1 [1-1] (figure 3.6B). IAS thickness: Sx: 1.85 [1.5-2.3], ASx: 1.8 [1.7-2.25], IC: 
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2.3 [2.05-2.85] (figure 3.6C). SSc patients had more atrophic IAS sphincter but 
largely intact IAS and EAS compared to incontinent controls. The age and sex 
matched incontinent controls were more likely to have EAS defects; they also had 
less IAS atrophy, evidenced by, most importantly, atrophy scores but also IAS 
thickness. Surprisingly there was no significant difference in atrophy scores or IAS 
thickness between the symptomatic and asymptomatic SSc patients. Examples of 
internal and external anal sphincter defect and IAS atrophy are shown in figure 3.7. 
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Figure 3.6: A) EAS integrity scores in asymptomatic (ASx), symptomatic (Sx) SSc 
patients and incontinent controls (IC); B) IAS atrophy scores in the 3 groups; C) IAS 
thickness in the 3 groups. (The horizontal line depicts the median, the rectangles 
the IQ range and the error bars the maximum and minimum values)
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Figure 3.7: Endoanal ultrasound images showing A) EAS and IAS defect (thick 
arrows), IAS (black arrows), EAS (white arrows) and B) IAS atrophy (white arrow). 
A) 
 
B)  
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3.3.5. Correlation between physiological and structural parameters and symptoms 
In the control group there was no significant correlation between Wexner 
incontinence score and anorectal physiology parameters. In the SSc patients there 
was a positive correlation with anal sensory threshold (r=0.5383, p=0.0002) (figure 
3.8A) and negative correlation with resting pressure (r=-0.3433, p=0.0225) (figure 
3.8B) and compliance (r=-0.3359, p=0.0258) (figure 3.8C). There was also a positive 
correlation of Wexner constipation score and anal sensory threshold (r=0.4286, 
p=0.0037) (table 3.4).  
There was no significant correlation between incontinence scores and atrophy and 
integrity scores or IAS thickness. In subgroup analysis, there was a positive 
correlation between Wexner incontinence score and IAS atrophy in the SSc patients 
(r=0.3768, p=0.0117). There was no correlation between IAS thickness or IAS 
atrophy scores and disease duration in SSc patients. There was no correlation 
between disease subtype or disease duration and Wexner incontinence scores.  
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Table 3.4: correlation table of Wexner incontinence and constipation scores and 
anorectal physiological parameters and Wexner incontinence scores and structural 
parameters in systemic sclerosis patients 
 Resting 
pressure 
Squeeze 
pressure 
Anal 
sensation 
Rectal 
sensation 
Rectal 
compliance 
Wexner 
incontinence 
score 
r=-0.3433 
p=0.0225 
r=-0.0038 
p=0.9807 
r=0.5383 
p=0.0002 
r=0.2922 
p=0.0543 
r=-0.3359 
p=0.0258 
Wexner 
constipation 
score 
r=-0.3489 
p=0.8221 
r=0.0931 
p=0.5476 
r=0.4286 
p=0.0037 
r=0.0722 
p=0.6416 
r=-0.2486 
p=0.1037 
(r= Pearson correlation) 
 
 IAS 
atrophy 
IAS 
integrity 
IAS 
thickness 
EAS 
atrophy 
EAS 
integrity 
Wexner 
incontinence 
score 
r=0.3768 
p=0.0117 
r=0.2235 
p=0.1448 
r=-0.1785 
p=0.2837 
r=0.3128 
p=0.0387 
r=-0.2982 
p=0.9603 
(r= Spearman correlation) 
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Figure 3.8: Correlation of Wexner incontinence score with anal sensory threshold 
(A), resting pressure (B) and rectal compliance (C). There is a positive correlation 
with anal sensory threshold and negative correlation with resting pressure and 
rectal compliance. 
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3.4. Discussion 
Continence is maintained through the coordinated function of the pelvic floor, the 
rectum and the anal sphincters. Injury to components of this system either sensory 
or motor can therefore impair it (101). Anorectal involvement is reported in 50-70% 
of patients with systemic sclerosis (89). Faecal incontinence is probably 
underreported in view of the stigmatising nature of the symptom and its social 
implications. In an anonymous questionnaire study, 24% of patients reported faecal 
soiling (102). As the anorectum is the second most commonly affected site of the GI 
tract, after the oesophagus, a number of small studies have investigated anorectal 
symptoms through physiologic measurements such as anorectal manometry, 
sensation and reflexes. Despite those studies the pathophysiology of faecal 
incontinence in SSc remains largely unknown. The key pathophysiological elements 
of SSc, vascular involvement, neuropathy, smooth muscle atrophy and fibrosis are 
all candidates and most likely may all contribute at some point in the disease 
process. By trying to establish the sequence of events, if there is one, it may 
become possible to prevent either the onset or at least the progression of 
symptoms. 
In this study of SSc patients with and without anorectal symptoms, SSc patients had 
higher mean resting pressure than the incontinent controls. This was the case for 
both Sx and ASx SSc patients although the mean resting pressure in Sx patients was 
lower (not statistically significant). A low mean resting pressure has been 
demonstrated in most studies to date (40;44;54;56) although 2 studies have found 
similar results to mine. Lock et al studied 26 patients, 3 with faecal incontinence, 
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and Heyt et al studied 35 patients, 13 incontinent. Both studies found that the 
mean resting pressure was within normal limits and not significantly different 
between patients with and without incontinence (43;46). In the latter study the 
mean resting pressure in SSc incontinent patients, although within normal limits, 
was lower than healthy controls. The patients’ anorectal symptoms in these studies 
were quite variable which may explain the variability in the measurements of mean 
resting pressure. The mean squeeze pressure in all SSc patients was normal and 
higher than incontinent controls. This is in keeping with previous studies and 
expected as SSc is known to affect mainly smooth muscle, in the anal sphincter 
complex this being the internal anal sphincter rather than the striated external anal 
sphincter. In contrast faecal incontinence in other patients is most commonly 
secondary to obstetric injury to the EAS (103).  
Despite the knowledge that the anal sphincters are affected in SSc there are only 
few studies which have assessed the anal sphincter structure. Engel et al were the 
first to report morphologic changes of the internal sphincter in SSc patients. They 
described two female patients with SSc and passive faecal incontinence with very 
thin, hyperechoeic internal anal sphincter (53). DeSouza et al in a MRI study of 18 
patients with SSc and 19 controls with and without incontinence showed that the 
SSc patients with incontinence had thinner internal anal sphincters than controls, 
but not SSc patients without incontinence (91) suggesting that incontinence is 
related to smooth muscle atrophy in this group. They further found reduced 
gadolinium enhancement of the IAS in all SSc patients suggesting an ischaemic 
origin of IAS atrophy. They did not find any significant difference in the external 
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anal sphincter thickness in SSc patients (91). Koh et al in their study of 11 SSc 
patients with incontinence showed that there appeared to be two distinct types of 
morphologic changes in the IAS. Patients had either very thinned, difficult to 
delineate and hyperechoic internal sphincters or, less commonly, a thickened, 
homogeneous and uniformly hypoechoic internal anal sphincter (90). 
In my study, SSc patients both those with faecal incontinence and the 
asymptomatic ones had thinned and atrophic IAS compared to the incontinent 
controls. In contrast the incontinent controls had more commonly evidence of 
external anal sphincter defects. I did not find any SSc patients with thickened IAS in 
our unselected sequential cohort of patients. Nonetheless the normal resting 
pressure often observed in SSc patients with faecal incontinence suggests that the 
mechanism for incontinence is more complex than purely structural or secondary to 
IAS dysfunction caused by smooth muscle atrophy and fibrosis. 
The gastrointestinal smooth muscle may be involved early in patients with SSc, 
before the onset of clinical symptoms. This is seen in the oesophagus where 
physiologic, mainly motility abnormalities are seen even in patients with no 
oesophageal symptoms (75;104;105). The oesophageal abnormalities in SSc are low 
basal LOS pressure resulting in loss of competence and also lack of peristalsis of the 
lower oesophageal body (79;106;107). These abnormalities were thought to be 
secondary to collagen deposition resulting in smooth muscle atrophy and fibrosis 
(108).  A more recent histological study of oesophageal tissue in SSc patients and 
controls found smooth muscle atrophy in 94% of SSc patients and only 5% of 
controls. The pathological findings seemed to be either secondary to loss of neural 
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function or a primary smooth muscle lesion (10). The IAS shares similarities with the 
lower oesophageal sphincter (LOS) in that they are both smooth muscle 
continuation of the circular muscle layer of the gut that maintains chronic tone. 
Engel et al showed thinning of the muscularis propria with fibrous replacement of 
both the circular and longitudinal layers of the smooth muscle (53). Although 
collagen deposition and smooth muscle atrophy are well recognised in GIT 
involvement in SSc, there is evidence that these abnormalities are preceded by 
vascular insufficiency and neural dysfunction (11;109).  
Vascular involvement, especially affecting the small vessels is common in SSc. 
Decreased oesophageal blood flow has been found in patients with Raynaud’s 
phenomenon and reduced gastric and duodenal blood flow has been demonstrated 
in SSc patients (11;12). In the anorectum deSouza et al showed that SSc patients 
with faecal incontinence had reduced gadolinium enhancement of the IAS (91). 
Histological studies of gastrointestinal mucosa show evidence of partially 
obliterated enteric vessels with hypertrophied endothelial cells and thickened basal 
lamina (13). In my study, through the use of laser Doppler probe the rectal mucosal 
blood flow was examined to assess for any obvious ischaemia. There was no 
demonstrable difference found in rectal mucosal blood flow between SSc patients, 
both symptomatic and asymptomatic, and incontinent controls. Although this 
finding is in contrast to the reduced gastrointestinal blood flow measured in the 
gastric antrum and duodenum by a similar technique there are a number of 
possible explanations for this disparity. Although the use of laser Doppler probe for 
measurement of blood flow in the rectal mucosa has been validated (97;98) there is 
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still some criticism of the method as there remains a risk of poor contact secondary 
to faeces. Nonetheless according to previous experience, if there is no adequate 
contact with the mucosa then no reading is obtained. On the other hand, other 
factors may also affect rectal mucosal blood flow. The rectal microcirculation is 
sensitive to menstrual cyclical changes (110). Although most patients in this study 
were post-menopausal women, I did not control for this in the remaining patients. 
Gastrointestinal mucosal blood flow is partly regulated by autonomic nerve supply 
(98). Autonomic dysfunction is well recognised in SSc, although not tested for in this 
study, and could therefore affect the findings.  
The pathogenesis of neuropathy may be caused by compression of nerve fibres by 
collagen deposits or secondary to arteriolar changes in the vasa nervorum. Another 
possible mechanism is autoantibody related. Autoantibodies are seen in more than 
97% of patients with SSc. Most of the SSc specific autoantibodies are associated 
with specific clinical characteristics. Although so far it is thought that 
autoantibodies are the result and not the cause of SSc, there is increasing amount 
of evidence pointing to a pathogenic role of some autoantibodies (24). With regards 
to neuropathy and gastrointestinal involvement, antibodies from SSc patient sera 
have been shown to specifically inhibit M3-muscarinic receptor–mediated enteric 
cholinergic neurotransmission (25-27). Furthermore Kawaguchi et al showed that 
anti-M3-muscarinic receptor (M3R) antibody frequently appeared in patients with 
SSc with severe GIT involvement, suggesting that M3R-mediated enteric cholinergic 
neurotransmission may provide a pathogenic mechanism for GIT dysmotility in SSc 
(111). With regards to anorectal dysfunction IgGs isolated from SSc patients 
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specifically interfered with the muscarinic receptor activation in smooth muscle 
cells of rat IAS (28). These autoantibodies are not routinely checked for as yet in SSc 
patients but if neuropathy is proven to be key to the development of GI / anorectal 
symptoms and M3 muscarinic receptor antibodies have a pathogenic role then 
there is a potential for new therapeutic agents. A neurogenic component in gut 
involvement in SSc is also supported by histological studies. Malandrini et al 
obtained deep rectal biopsies from 3 patients with SSc and showed structurally 
normal enteric neurons but abnormal axon terminals with axoplasm devoid of 
cytoskeletal elements suggestive of degeneration and depletion of 
neurotransmitters (13). This is supported by other studies that have shown 
depletion of the neuropeptides NY and YY in SSc (112).  
My results suggest that neuropathy plays a key role in the development of faecal 
incontinence in SSc. The RAIR reflects a reflex relaxation of the IAS in response to 
rectal distension. It is a local intramural reflex within the wall of the rectum and 
anal canal and thought to be independent of spinal cord involvement (101) but it 
can be influenced by higher centres. It is absent in all patients with Hirschprung’s 
disease where there is a congenital absence of ganglion cells in the rectum and 
colon (113). The RAIR facilitates an important sensory role requiring intact 
anorectal sensation, intact intramural nervous system and a coordinated sphincter 
response. The components of the reflex are: the latency period, the amplitude and 
the recovery time. The latency period reflects duration of neurological synaptic 
transmission, the amplitude reflects the muscular component and the recovery 
period reflects partly the neurological factors and partly the muscle tone. Impaired 
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RAIR secondary to neuropathy and correlation with faecal incontinence has been 
suggested in diabetic patients, specifically showing correlation between time to 
recovery and faecal incontinence scores (114). I demonstrated an absent RAIR in 
46% of SSc patients with incontinence. In contrast, RAIR was absent in only 10% of 
SSc patients without incontinence and only one of 20 incontinent controls. 
Incontinent SSc patients had longer latency period which would suggest underlying 
neuropathy rather than reduction in muscle tone secondary to atrophy. Previous 
studies have demonstrated absent RAIR in SSc in 12-71% of patients. Basilisco et al 
observed that RAIR was absent in 5/6 patients with constipation but only 1 of 8 
patients with normal bowel habit (40). Heyt et al showed a correlation between 
impaired RAIR and incontinence, 11 of 13 incontinent patients had absent or 
impaired RAIR whereas 14 of 22 continent patients had absent or impaired RAIR. 
The amplitude of the RAIR was lower in the incontinent patients (43). In their study 
the majority of patients reported at least one lower GI symptom which may explain 
why they found an impaired RAIR in a higher percentage of their continent patients, 
whereas in my study the asymptomatic patients had no or minimal lower GI 
symptoms. The lower amplitude noted in the incontinent patients may reflect 
either neuropathy or lower muscle tone. It is most likely that neuropathy plays a 
role in the development of other symptoms such as diarrhoea, constipation or 
evacuation difficulty and not just incontinence. Further evidence of neuropathy in 
incontinent SSc patients is demonstrated in my study by impaired anal sensation. 
Sensory testing by mucosal electrosensitivity is an indirect way of measuring the 
innervation of the anorectum. Roe et al have shown that patients with idiopathic 
faecal incontinence had sensory deficit as demonstrated by reduced anal sensory 
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threshold (115). In my study SSc patients with incontinence had higher anal sensory 
threshold than SSc patients without anorectal symptoms. Although the anal sensory 
threshold was also high in the incontinent controls this was within the normal 
range. Sensory information from the anal canal is carried by the somatic pudendal 
nerves whereas the pelvic visceral nerves are the main sensory pathways from the 
rectum. The anal canal is believed to have a greater variety of afferent nerve 
endings than the rectum (116;117) and this could explain the fact that anal sensory 
threshold and not rectal sensory threshold was affected. 
These findings further support the hypothesis that anorectal symptoms and 
especially faecal incontinence in SSc patients is not exclusively secondary to smooth 
muscle atrophy. I did find evidence of IAS atrophy but this was seen in both the 
symptomatic and asymptomatic patients and there was not associated significant 
impairment of the resting tone. In contrast there were distinct neuropathic 
abnormalities in the symptomatic SSc patients not seen in the asymptomatic 
patients or in the incontinent controls.  
The enteric nervous system consists mainly of the myenteric and submucosal plexi 
although other plexi have also been identified.  The enteric plexi control a lot of the 
coordinated activity of the gastrointestinal tract in the absence of extrinsic 
innervation although a number of sympathetic and parasympathetic fibres 
terminate in the enteric plexi. Axons of plexus neurons innervate smooth muscle 
cells in the muscularis mucosae and muscularis externa as well as gland cells and 
exocrine and endocrine cells. Interneurons in the plexi connect afferent sensory 
fibres with efferent neurons to smooth muscle cells. Furthermore afferent fibres 
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from mechanoreceptors and chemoreceptors in the mucosa and gut wall synapse 
at the plexi thus allowing local reflex activity such as the RAIR.  Neuropathy in SSc is 
multifactorial and is most likely affecting the enteric plexi. This would explain the 
findings of anal sensory neuropathy as well as the absent RAIR as both of these 
processes would depend on intact enteric plexi. The potential pathogenic role of 
autoantibodies to muscarinic receptors may still be due to effect on 
parasympathetic fibres in the intramural plexi. Studies to investigate these 
mechanisms further are likely to shed more light both in the pathogenesis of 
gastrointestinal involvement in SSc and the effect of treatments. With regards to 
management of anorectal symptoms it is possible that sacral neuromodulation may 
be more successful than other therapies and it may be worth considering treating 
early minimally symptomatic or even asymptomatic patients if anorectal physiology 
abnormalities are present. 
In conclusion I have demonstrated a possible neuropathogenic mechanism 
underlying faecal incontinence in SSc, as suggested by the impaired RAIR and anal 
sensation. It may be that structural changes occur early in all SSc patients, but the 
development of faecal incontinence occurs with disease progression in some 
patients as neuropathy develops. This specific question will be addressed in further 
studies. Although the oesophagus and the anorectum are the most commonly 
affected areas of the GI tract, involvement of the rest of the GI tract often occurs 
but as it is less easily accessible, it is more difficult to study and assess. I 
hypothesised that not only neuropathy and myopathy but also an infiltrative 
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process earlier in the disease process may have an effect on absorption and 
therefore an effect on nutrition.  
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CHAPTER 4: 
THE EFFECT OF GASTROINTESTINAL INVOLVEMENT ON 
NUTRITION – NUTRITIONAL ASSESSMENT IN SYSTEMIC 
SCLEROSIS 
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4.1. Introduction 
Approximately 8% of patients with diffuse cutaneous SSc develop severe GI 
involvement described by Steen and Medsger as malabsorption syndrome, 
repeated episodes of intestinal pseudo-obstruction, or severe GI problems which 
require hyperalimentation (5). The mortality rate secondary to severe GI 
involvement has been reported to be 6-12% (118) and therefore early identification 
and prevention would be highly desirable. 
SSc can affect any part of the GI tract and therefore the availability of nutrients is 
affected both by intake and absorption. Patients often have microstomia and 
xerostomia which makes the actual act of eating more difficult. Atrophic gingivae 
and papillae cause loss of taste and are associated with reduced oral intake. 
Oesophageal dysmotility and acid reflux cause dysphagia especially of coarser food, 
fruit and vegetables. Delayed gastric emptying and small intestinal dysmotility can 
cause bloating and patients often complain that they cannot have a normal size 
meal. Furthermore subjective intolerance of foodstuffs is common, and patients 
often follow a largely restricted diet.  
Impairment of small bowel motility results in intestinal symptoms such as nausea, 
vomiting, bloating, distension, anorexia, abdominal pain, or even an overt 
malabsorption syndrome. The small intestinal hypomotility may provoke luminal 
dilatation and clinical pseudo-obstruction.  Histological data and muscle mechanics 
data support the hypothesis that this is the result of abnormal collagen deposition 
as is seen in the oesophagus (50). Small intestinal bacterial overgrowth (SIBO) 
occurs because of impaired motility and intestinal stasis but also intestinal 
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diverticulae or sacculation (119). Malabsorption may be caused by SIBO, impaired 
blood supply but also decreased intestinal permeability secondary to intestinal 
mucosal fibrosis. The latter can cause malabsorption of fat and bile salts (59). This 
can accelerate transit and lead to steatorrhoea which can be exacerbated, although 
much less commonly by pancreatic insufficiency secondary to reduced pancreatic 
secretions (120). Involvement of the small intestine is a specifically difficult problem 
that can ultimately lead to intestinal failure. 
Simple measures such as small but more frequent meals and artificial saliva or 
simple water can be effective, nevertheless patients often remain symptomatic. 
Medications such as proton pump inhibitors (PPI) and prokinetics may improve 
gastro-oesophageal reflux and delayed gastric emptying but when a patient is 
unable to maintain their nutritional status artificial feeding may be necessary. Oral 
nutritional supplements are the least invasive form of artificial feeding and the first 
line of management to boost calorific intake if tolerated by the patient. Nasogastric 
or percutaneous endoscopic gastrostomy (PEG) or jejunostomy feeding can be tried 
especially when intake is the main problem (118). In a small number of patients 
parenteral nutrition (PN) needs to be considered, most commonly when enteral 
feeding is not tolerated or adequate (59). However it can be associated with 
significant risks and complications such as central venous catheter infections, 
occlusions and fractures of lines, venous thromboses as well as complications of the 
PN itself such as hepatic disease.  
Malnutrition has been defined as “a state of nutrition in which a deficiency, excess 
or imbalance of energy, protein, and other nutrients causes measurable adverse 
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effects on tissue/body form (body shape, size, composition) and function and 
clinical outcome” (121). 
There have not been many studies looking at nutrition in patients with SSc but it is 
clear that both oral intake and absorption of nutrients can be affected by GI 
involvement (122). There are few studies that have looked into nutritional 
assessment in patients with SSc. One study comparing 30 patients with SSc versus 
matched healthy controls showed that although the intake of energy and nutrient 
distribution was not significantly different, there was lower intake of dietary fibre. 
Anthropometric assessment revealed lower arm muscle circumference and in 2 
patients there was subnormal triceps skinfold thickness. 43% of patients were 
found to have fat malabsorption. There was no deficiency of trace elements apart 
from selenium which was lower in SSc patients. Overall this study showed that 
although the oral intake of nutrients is not different in SSc patients with significant 
gastrointestinal involvement there is decreased nutrient absorption and possibly 
selective nutrient loss leading to malnutrition (123). A recent multicentre study by 
the Canadian Scleroderma Research group showed that of 586 patients with SSc in 
the study screened using the malnutrition universal screening tool (MUST), 10.4% 
were at moderate risk and 17.4% at high risk of malnutrition (124). Overall it is 
recommended that patients with SSc should be screened regularly for malnutrition 
and that a multidisciplinary approach should be taken when there is such evidence 
(125). At the other end of the spectrum, there are a few case series that have 
looked at the outcome of SSc patients needing PN. A recently published 
retrospective review over a 13-year period described 8 patients with SSc requiring 
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PN. The median duration of PN was 40 months and overall there was a lower rate 
of line infections compared to other PN patients. 3 patients died, none of causes 
related to the PN. Hand function was a major factor for failure of the patients to 
manage the PN regime independently (126). Overall PN can be successfully used 
long-term for patients with SSc that are unable to maintain their nutritional status 
because of severe GI involvement. Nonetheless nutritional assessment and early 
treatment or supplementation may delay the need for PN and the morbidity 
associated with malnutrition.                                                                                                                                     
The aim of this study was to perform detailed anthropometric and calorimetric 
assessments and hence establish any evidence of clinical or subclinical malnutrition 
and what features may be associated with that in SSc patients. As there have been 
no trials of bioelectrical impedance and indirect calorimetry with large numbers of 
SSc patients this was an exploratory study looking at the SSc patient cohort with 
and without GI symptoms previously studied.  
 
4.2. Methods 
Nutritional assessment incorporated conventional anthropometric measurements, 
indirect measurement of energy expenditure (indirect calorimetry) and indirect 
measurement of body composition (bioelectrical impedance).  The MUST screening 
tool data was also collected for comparability with other subject/patient groups.  
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4.2.1. Patients 
Patients attending the rheumatology outpatient department at Royal Free hospital  
were approached and invited to participate in the study. Verbal and written details 
about the study were provided and patients were contacted approximately 3-7 
days later. Written consent was obtained when patients attended for the study day. 
Forty three patients with SSc were studied. 23 patients had at least moderate GI 
symptoms and 20 were either asymptomatic or had only mild GI symptoms on 
direct questioning and past medical history. All measurements were taken on one 
study day.  
 
4.2.2. Questionnaires 
Patients were asked to complete the following questionnaires on the day of their 
assessments.   
1. Scleroderma GI tract 1.0 questionnaire: A 52 item self-completed instrument 
that provides a profile for GI symptoms and their effect on social and emotional 
well-being. The questions cover 7 broad categories: reflux, distension, diarrhea, 
constipation, abdominal pain, effect on social functioning and emotional well being 
(Appendix 1) (68).  
2. SF-36 general health questionnaire: a multi-purpose, short-form health survey 
with 36 questions that yields an 8-scale profile of functional health and well-being 
scores (94) (Appendix 2). 
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3. EuroQol: a 6-item self-completed instrument that provides a simple descriptive 
profile for health status by asking if the patient has no problems, some problems or 
significant problems in the following domains: mobility, self care, usual activities, 
pain/discomfort, anxiety/depression (95;127) (Appendix 3). 
 
4.2.3. Anthropometric assessments 
1. Height, weight, body mass index (BMI) 
Height was recorded to the nearest 0.5 cm. Weight was recorded to the nearest 0.5 
kg. BMI was calculated using height and weight (weight (kg)/height2 (m)). 
2. Mid-arm circumference/area (MAC) 
The patient was asked to bend the non-dominant arm at the elbow at a right angle 
with the palm up. The measurement was taken at the posterior surface of the arm. 
The mid-point between the acromial process of the scapula and the olecranon 
process of the elbow was measured and marked. The patient was then asked to 
stand with the non-dominant arm hanging loosely by the side. The circumference 
was measured at the previously marked mid-point with a tape tightened snugly 
(128). 
3. Triceps skinfold thickness (TSF) 
Measurement of this was taken on the upper non-dominant arm posterior surface. 
The patient was asked to stand with the non-dominant arm hanging loosely by the 
side. A vertical pinch of skin and subcutaneous fat was grasped between thumb and 
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forefinger, 1 cm above the midpoint mark. The skinfold was gently pulled away 
from underlying muscle tissue. The skinfold calliper (Gaiam Ltd, UK) jaws were 
placed over the skinfold at midpoint while maintaining grasp of the skinfold and a 
reading was taken to the nearest mm 2-3 seconds after applying the calliper. Three 
readings were taken and averaged. 
The mid arm muscle circumference (MAMC) was calculated using the MAC and TSF 
measurements by the formula: MAMC = MAC - 3.14 x TSF (128). 
4. Forearm muscle strength (handgrip test) 
Muscle strength was assessed by recording the maximal voluntary contraction of 
the non-dominant arm using a handgrip dynamometer (DynEx1, MD Systems, Ohio, 
USA) with the subject standing and the hand held by the side. Three readings were 
taken and averaged. 
For all the above measurements the values were compared to sex and age 
reference values (129) and are presented as percentiles of these values. 
 
4.2.4. Malnutrition Universal Screening Tool (MUST) 
This tool has been developed by the Malnutrition Advisory Group of BAPEN. It is 
called the 'Malnutrition Universal Screening Tool' ('MUST') to indicate that it can be 
applied to all types of adult patients in all care settings. It is a valid, reliable, and 
easy to use tool which can be applied to all adult patients (121). 
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Using the MUST, patients are scored to establish the malnutrition risk based on BMI 
(BMI >20 = 0, 18.5-20 = 1, <18.5 = 2), unplanned weight loss in last 3-6 months (<5% 
= 0, 5-10% = 1, >10% = 2), presence of acute illness and likely no oral intake for >5 
days = 2. A total score of 0 suggests low risk, score of 1 medium risk and score of 2 
or more high risk of malnutrition.  
 
4.2.5. Indirect calorimetry (non-invasive measurement of resting energy 
requirements) 
Indirect calorimetry measures energy expenditure (EE) by calculating the patient’s 
metabolic rate through measurements of oxygen consumption (VO2) and carbon 
dioxide production (VCO2). It is based on the premise that gas volumes and 
concentrations exchanged at the mouth reflect cellular metabolic activity. By 
measuring the difference between inspired and expired levels of O2 and CO2, 
determinants of VO2 and VCO2 can be obtained. These values can then be 
converted to a resting energy expenditure (REE) (130). The respiratory quotient (the 
VCO2:VO2 ratio) varies from 0.67 (ketone body metabolism) in the fasting state, to a 
maximum of 1.3 (lipogenesis derived from glucose). And usually lies between 0.8 
and 1.0 the former reflecting a fat rich diet and the latter a carbohydrate rich diet in 
health. The resting energy expenditure comprises 60-80% of the total daily energy 
expenditure with the rest made up of the specific dynamic action of nutrients and 
physical activity energy expenditure. The effect of disease on energy metabolism 
has been mostly investigated by studies on REE. 
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Patients were asked to fast for 4 hours prior to the assessment (except water) and 
asked to rest in a supine position for 10 minutes before the study. A canopy, 
connected via a pipe to the calorimeter (VMax Series 2130 System, Sensor Medics 
Corp, CA, USA) was placed over the patient’s head (appendix 8.1) and 
measurements of inspired and expired levels of O2 and CO2 were taken in a quiet 
thermoneutral environment for 15-20 minutes provided that a steady state 
(defined as a period of five minutes in which variations of VO2 and VCO2 are <10%) 
was reached. Signals from the calorimeter were transmitted to a PC for online 
display and subsequent storage to hard disk. A dedicated software program (Viasys) 
was used for online monitoring and analysis purposes. REE was calculated by 
averaging measurements during steady state (minimum of 10 minutes). This was 
then given as a percentage of the basal metabolic rate (BMR) calculated based on 
sex, age, height and weight. The BMR based on predictive equations is an 
estimation of the basal metabolic rate of a healthy individual. The REE as calculated 
by indirect calorimetry data is a more accurate measure of the actual metabolic 
rate. The comparison with the predicted value allows an assessment on whether 
that individual is hyper or hypo-metabolic. 
 
4.2.6. Bioelectrical Impedance 
Bioelectrical impedance (BIA) is an indirect method for assessment of body 
composition (fat/muscle/water). The principle behind it is that living organisms 
consist of intra and extra-cellular fluids that behave as electrical conductors and cell 
membranes that act as electrical condensers (figure 4.1). Bioelectrical resistance is 
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the pure opposition of a biological conductor to the flow of an alternating current 
whereas reactance is the resistive effect due to capacitance produced by tissue 
interfaces and cell membranes.  
Body impedance (Z) is defined as the opposition of a conductor to the flow of an 
alternating current, and consists of two components: resistance (R) and reactance 
(Xc). Resistance (R) is the major opposition of the conductor and at usual low 
frequency (50 kHz), the extra-cellular part of non-adipose tissue works as a resistor. 
Reactance is an additional opposition or the storage of an electrical charge by a 
condenser for a short period of time; the lipid component of the membranes of the 
body cell mass (BCM) behave as capacitors and reduce the flow of intracellular ions. 
In practice, impedance is the amount of dropped voltage when a small constant 
current with a fixed frequency passes between electrodes spanning the body. Lean 
tissue, which is rich in water and electrolytes, has minimal impedance and 
fat/adipose tissue has maximum impedance. Lean body mass and fat mass (FM) can 
therefore be calculated from the difference in conductivity. Capacitance, or the 
storage of electric charge by a condenser, causes the current to lag behind the 
voltage, creating phase shift. This shift is quantified as the phase angle. Phase angle 
has been shown to play an important role as a morbidity and mortality marker in 
several clinical conditions such as HIV, lung cancer, pancreatic and colorectal cancer 
(131). 
Each patient was asked to avoid caffeine containing drinks and alcohol for 24 hour 
prior to testing and to fast (except water) for 4 hours prior to testing. Patients 
rested flat for 5-10 minutes prior to testing. Two electrode pads were placed on the 
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dorsum of right hand (over the wrist and at the mid-point between the 2nd and 3rd 
metacarpals) and 2 on the dorsum of the right foot (over the ankle joint and at the 
mid-point between the 2nd and 3rd metatarsals) (figure 4.2). The area was cleaned 
with alcohol wipe prior to placement of the electrodes. The patient was then asked 
to lie flat and completely relaxed and remain still while the data was being 
processed. The data was collected using a hand-held monitor (Maltron Bioscan; 
Maltron Int ltd, Essex, UK). The measurements calculated were resistance, 
reactance, impedance, phase angle, fat mass, fat free mass, total body water, 
extracellular water, intracellular water, body cell mass.  
 
4.2.7. Statistics 
Statistical analysis was performed using GraphPad Prism 4. Data were expressed as 
mean (with 95% confidence intervals) or median (interquartile range), depending 
on whether the recorded values assumed a normal “Gaussian” distribution. A 
Kolmovgorov-Smirnov test was carried out to determine if data followed a normal 
distribution. Paired t test was used to compare the indirect calorimetry and 
bioelectrical impedance measurements in the 2 groups and the non-parametric 
Mann-Whitney test was used for comparison of anthropometric assessment values 
between the 2 groups. The chi-squared test was used to compare proportions 
between groups. Statistical significance was declared for p values ≤ 0.05.  
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Figure 4.1: Schematic representation of body composition compartments. (FFM=fat 
free mass) 
 
       
Abbreviations: FFM – fat free mass 
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Figure 4.2: Placement of electrodes in hand and wrist and foot and ankle for 
tetrapolar bioelectrical impedance (132). 
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4.3. Results 
4.3.1. Patients 
Forty-three patients, 23 with moderate to severe GI symptoms and 20 patients with 
no or mild GI symptoms were studied. Forty patients were female, mean age 57.3 
years and mean disease duration 10.3 years. 11 patients had lcSSc and 32 dcSSc. 
The demographic characteristics of the 2 patient groups are shown in Table 4.1. 
There was no significant difference in age, sex, disease subtype or disease duration 
between the 2 patient groups. One asymptomatic patient did not undergo indirect 
calorimetry due the patient’s time constraints and 5 symptomatic and 4 
asymptomatic patients did not have impedance measurements due to equipment 
failure.  
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Table 4.1: Demographic characteristics of symptomatic and asymptomatic patients. 
 Symptomatic (n=23) Asymptomatic (n=20) p value 
Age  
(mean & 95% CI) 
56.6  (52.5-60.7) 58.2  (56.5-65.8) 0.58 
Disease duration 
(mean & 95% CI) 
11.3  (8-14.7) 9.1  (5.4-12.8) 0.35 
Female : Male 20/3 20/0 0.24 
LcSSc:DcSSc 19/4 13/7 0.29 
Autoantibodies  
-ACA 
-SCL-70 
n (%) 
16 (70) 
3 (13) 
n (%) 
9 (45) 
2 (10) 
 
0.13 
1.0 
Internal organ 
involvement 
-Pulmonary 
-Cardiac 
-Renal 
n (%) 
 
7 (30) 
5 (22) 
2 (9) 
n (%) 
 
5 (25) 
1 (5) 
1 (5) 
 
 
0.75 
0.19 
1.0 
  
Abbreviations: 95% CI – 95% confidence interval, ACA – anti-centromere antibody, Scl-70 – 
anti-topoisomerase antibody.
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4.3.2. Questionnaire scores 
The SSC-GIT 1.0 scores for the 2 patient groups can be seen in figure 4.3 and table 
4.2. The scores were statistically significantly lower in the symptomatic group for all 
categories. SF-36 and EuroQol scores can be seen in table 4.2. The SF-36 total score 
was not different between the 2 groups (Sx: 53.27 [35.67-73.27] vs ASx: 63.93 
[53.47-77.84]) and neither was the mental health score (Sx: 61.70 [29.40-72.50] vs 
ASx: 65.15 [53.95-70.62]). The physical health score was lower in the symptomatic 
group (Sx: 48.20 [25.20-61.60] vs ASx: 61.70 [44.40-75.10]; p<0.03). A higher 
percentage of patients in the symptomatic group reported at least some problems 
for each of the EuroQol domains (figure 4.4). 
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 Figure 4.3: SSC-GIT 1.0 scores for symptomatic and asymptomatic patients.  
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Figure 4.4: Percentage of patients that indicated at least some problems (scores 1 
or 2) in the domains of the EuroQol questionnaire. 
 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
Mobility Self-care Usual activities Pain/Discomfort Anxiety/Depression 
%
 o
f 
p
a
ti
e
n
ts
 r
e
p
o
rt
in
g
 p
ro
b
le
m
s
 
Symptomatic 
Asymptomatic 
116 
Table 4.2: Questionnaire scores in systemic sclerosis patients. 
 Symptomatic SSc 
Median (IQ range) 
Asymptomatic SSc 
Median (IQ range) 
SF-36 
-Total score 
-Physical Health score 
-Mental Health score 
 
53.27 (35.67-73.27) 
48.2 (29.4-72.5) * 
61.7 (29.4-72.5) 
 
63.93 (53.47-77.84) 
61.7 (44.4-75.1) 
65.15 (53.95-70.62) 
Euroqol (EQ-5D) 
-Mobility 
-Self-care 
-Usual activities 
-Pain/Discomfort 
-Anxiety/Depression 
-VAS score 
 
2 (1-2) 
1 (1-2) 
2 (2-2) * 
2 (2-2) 
2 (1-2) 
62 (53-80) 
 
1 (1-2) 
1 (1-1.5) 
1 (1-2) 
1.5 (1-2) 
1 (1-2) 
77 (60-80) 
SSC-GIT 1.0 
-Reflux 
-Distension 
-Diarrhoea 
-Constipation 
-Abdominal pain 
- Social  
-Emotional 
 
55.6 (40.7-74.1) * 
50 (38.1-61.1) * 
55.5 (22.2-100) * 
55.5 (22.2-100) * 
66.7 (50-100) * 
81.7 (65-95) * 
55.6 (29.6-81.5) * 
 
92.6 (83.35-96.3) 
83.3 (72.2-94.35) 
100 (88.9-100) 
100 (77.7-100) 
100 (83.3-100) 
100 (100-100) 
100 (94.45-100) 
* p<0.05; Comparisons made using the Mann-Whitney test 
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4.3.3. Anthropometric measurements 
The weight, height and body mass index of the 2 patient groups were very similar. 
Mean BMI in symptomatic SSc patients was 22.9 (20.5-25.4) and in asymptomatic 
22.7 (20.15-24.9). This was lower than in the general UK population as measured in 
a study of 989 women (mean BMI 26) (133) but within the 25-75th percentiles. The 
rest of the anthropometric measurements, mid-arm circumference, mid-arm 
muscle circumference and triceps skinfold thickness were also not significantly 
different between the 2 groups. The values are expressed as percentiles for sex and 
age matched controls. Values below the 5th percentile are indicative of nutritional 
depletion and values between the 10-15th percentiles of minimal depletion (128). 
The medians and interquartile ranges can be seen in table 4.3. The median 
percentile for mid-arm circumference was the 25th percentile in both groups and 
the mid-arm muscle circumference percentile the 25th and 50th respectively for the 
Sx and ASx group. There were 6 Sx and 6 ASx patients for who the MAC was below 
the 15th centile and 7 Sx and 8 ASx patients that MAMC was below the 15th centile. 
The mean triceps skinfold thickness was overall at the 10th percentile for both 
groups. There was no statistically significant difference between the 2 groups for 
these measurements. The handgrip measurements were 47% and 50.5% of the 
value predicted in the symptomatic and asymptomatic patients respectively. More 
than 50% of patients reported difficulty performing the handgrip test, 12 of 23 Sx 
patients and 12 of 20 ASx patients suffered from digital ischaemia or hand 
contractures. 
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Table 4.3: Anthropometric measurements of the 2 patient groups 
 Symptomatic (n=23) Asymptomatic (n=20)  
 Median IQ range Median IQ range p value 
Weight 61 53-66 58.5 55-67 0.92 
Height 158 150-169 163 158.5-168 0.98 
BMI 22.9 20.5-25.4 22.7 20.15-24.9 0.8 
MAC cm 27.5 26.5-29.5 27.65 25.75-29 0.63 
MAC centile 25 10-50 25 10-37.5 0.52 
MAMC cm 23.1 21.3-24.95 23.15 20.58-24.7 0.67 
MAMC centile 25 10-50 50 10-75 0.63 
TSF mm 16 12.5-18 16 13.75-21.5 0.39 
TSF centile 10 5-25 10 5-25 0.63 
Handgrip  47 36-72 50.5 37.5-66.75 0.78 
  
Abbreviations: BMI – body mass index, MAC – mid-arm circumference, MAMC – 
mid-arm muscle circumference, TSF- triceps skinfold thickness   
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4.3.4. Malnutrition Universal Screening Tool 
The majority of patients, both Sx and ASx scored 0 on the MUST scoring. One ASx 
patient scored 2 secondary to BMI<18.5 and one Sx patient scored 1 secondary to 
BMI of 19. Another Sx patient scored 1 secondary to weight loss and lastly one Sx 
patient scored 2 for both low BMI and weight loss. 
 
4.3.5. Indirect calorimetry measurements 
The indirect calorimetry results are shown in table 4.4. Due to time restraint of the 
patient on the day of the tests, there was no data obtained from one of the 
asymptomatic patients. There was no significant difference in the resting energy 
expenditure (REE) between the 2 patient groups, both as the measured value and 
as a percentage of the predicted value for the age, sex and BMI of each patient.  Of 
the Sx patients 8 (44%) were hypometabolic (REE <90% predicted), 1 (6%) 
hypermetabolic (REE >110% predicted) and 9 (50%) normometabolic (REE 90-110% 
predicted); of the ASx patients 4 (25%) were hypometabolic, 1 (6%) hypermetabolic 
and 11 (69%) normometabolic. Typical traces of indirect calorimetry measurements 
from symptomatic and asymptomatic patients are shown in appendix 8.2. 
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4.3.6. Bioelectrical Impedance measurements 
The results obtained from bioelectrical impedance measurements are shown in 
tables 4.5 and 4.6 and figure 4.5. Bioelectrical impedance measurements were 
obtained from 18 Sx and 16 ASx patients. Impedance, resistance, reactance were all 
statistically significantly lower in the symptomatic compared to the asymptomatic 
patients. The phase angle, a potential marker of morbidity and mortality, was also 
lower in the symptomatic group (Sx: 8.35 [5.51-11.13] vs ASx: 16.39 [10.52-22.26], 
p=0.01. There was a negative correlation between the phase angle and ECM/BCM 
(r=-0.3, p=0.047), an index of early protein catabolism.  
The body composition measurements, specifically fat and fat free mass are shown 
both as percentages and also as fat and fat free mass index (mass/height2). These 
values have been shown to be significantly different in males and females 
(134;135). Similarly body water compositions are affected by sex, women generally 
having lower body water composition than men (136).  There were 3 male patients 
in the symptomatic group and for more accurate comparison between the 2 groups 
the values from the 3 male patients were excluded from the analysis, in order to 
avoid falsely significant differences.  
Symptomatic patients had higher percentage of fat free mass and lower percentage 
of fat mass than the asymptomatic patients but this difference was not statistically 
significant. The fat mass indices were not significantly different in the 2 groups. In 
contrast, the fat free mass indices were higher in the symptomatic group (figure 
4.5). Measurements of water spaces are presented in table 4.6. The male patients 
are again excluded from this analysis as it is well recognised that there are sex 
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differences in body water spaces (136). The TBW percentage was significantly 
higher in the symptomatic group compared to the asymptomatic group. The ICW 
percentage was lower and the ECW percentage was higher in the Sx patients. The 
TBW/FFM was higher in the Sx group 75.84 vs 72.26, p=0.04. This ratio is thought 
not to be influenced by gender and therefore analysis including the 3 male patients 
was also performed, Sx: 76.02 (73.47-78.56) vs ASx: 72.26 (69.73-74.78); p=0.034. 
ICW/FFM is possibly a better indicator of hydration and also not affected by gender, 
analysis including the 3 male patients showed Sx: 44.03 (41.51-46.59) vs ASx: 45.86 
(42.39-49.32); p=0.36. There was no significant difference in the Sx vs ASx patients 
in either analysis. These results suggest that the TBW is increased in the 
symptomatic group with an increase in ECW/ICW ratio.  
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Table 4.4: Indirect calorimetry measurements of the 2 patient groups 
 Symptomatic (n=23) Asymptomatic (n=19)  
 Mean 95% CI Mean 95% CI p value 
BMR 1301 1219-1383 1271 1220-1322 0.54 
REE 1221 1131-1311 1202 1098-1306 0.78 
REE %predicted 94.3 89.1-99.4 94.8 87.5-102.1 0.9 
Resp. Quotient 0.81 0.78-0.84 0.78 0.7-0.86 0.44 
     
Abbreviations: BMR – basal metabolic rate, REE – resting energy expenditure 
 
Table 4.5: Bioelectrical impedance measurements of the 2 patient groups 
 Symptomatic (n=18) Asymptomatic (n=16)  
 Mean 95% CI Mean 95% CI p value 
Impedance 608.4 540.3-676.6 862.5 759.1-965.9 <0.0001 
Phase angle 8.35 5.51-11.13 16.39 10.52-22.26 0.01 
Resistance 602 531.5-672.6 804.8 727.8-881.9 0.0002 
Reactance 78.85 63.84-93.86 269.4 159.1-379.7 0.0005 
 
  
123 
Table 4.6: Bioelectrical impedance measurements of body composition in the 2 
patient groups, excluding the 3 male patients from the symptomatic group. 
 Symptomatic (n=15) Asymptomatic (n=16)  
 Mean 95% CI Mean 95% CI p value 
FFM% 67.33 64.79-69.88 62.94 58.64-67.73 0.1 
FFMI 15.87 14.96-16.77 14.33 13.78-14.88 0.004 
FAT% 32.67 30.12-35.21 37.06 32.27-41.86 0.1 
FMI 7.76 6.9-8.61 8.89 6.91-10.87 0.28 
TBW% 51.11 48.68-54.15 45.34 41.83-48.84 0.013 
ECW% 41.42 38.99-43.86 36.38 31.69-41.07 0.055 
ICW% 58.57 56.13-61 63.61 58.92-68.31 0.055 
BCM (Kg) 23.39 21.81-24.96 22.15 21.18-23.11 0.15 
ECM (Kg) 17.99 16.76-19.21 16.92 15.62-18.22 0.21 
ECM/BCM 0.77 0.74-0.81 0.76 0.71-0.82 0.78 
TBW/FFM 75.84 73.39-78.29 72.26 69.73-74.78 0.038 
ICW/FFM 44.47 41.87-47.07 45.86 42.39-49.32 0.5 
 
Abbreviations: FFM- fat free mass, FFMI – fat free mass index, FMI – fat mass index, 
TBW – total body water, ECW – extra-cellular water, ICW – intra-cellular water, 
BCM – body cell mass, ECM – extra-cellular mass 
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Figure 4.5: A. Fat mass and fat free mass percentages in the symptomatic and 
asymptomatic patient groups. B. Fat and fat free mass indices in the 2 patient 
groups. 
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4.4. Discussion 
Several chronic inflammatory conditions are associated with changes in body 
composition and malnutrition. There is data suggesting that SSc patients are at a 
risk of malnutrition, especially those with GI symptoms (124). My study of 43 SSc 
patients, both with and without GI symptoms aimed to assess if there are 
significant differences in the 2 groups of patients by anthropometric 
measurements, indirect calorimetry and bioelectrical impedance measurements. 
This was an exploratory study collecting nutritional assessment data from SSc 
patients investigated for other aspects of gastrointestinal involvement. This study 
as an exploratory study was not powered to assess specific differences between the 
2 groups. The data presented, especially the bioelectrical impedance data, adds to 
the existing limited data on SSc patients and can be used to plan further studies. 
BMI is a commonly cited measurement but often not an accurate tool to assess 
malnutrition as shown in a number of studies (137;138). In this study BMIs in 
symptomatic and asymptomatic patients were similar (median <23) but lower 
compared to the general British population. In a large study that looked at self-
reported weight and perception of weight in the British population in 1999 and 
2007 it was shown that BMI increased over that period. The BMI of 1836 subjects 
studied in 2007 was 26.2, mean age 47.6. In the 989 women studied (mean age 
46.7) BMI was 26.05. Although our patient group mean age was higher, it is well 
recognised that BMI tends to increase with age. This difference in BMI compared to 
that of the general British population does suggest that there is a degree of reduced 
nutrition in SSc patients. This is further supported by the measured TSF values. 
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Although none of the measurements indicated severe depletion, the median TSF lay 
below the 15th centile in both groups suggestive of mild depletion. TSF relies on 
measuring skin thickness which may be difficult to assess and less accurate in a 
disease that affects skin thickness although this would be expected to be increased 
rather than decreased.  Lundberg et al had found increased mean TSF in their 
patients with SSc, of which 17/30 had dcSSc, compared to controls (123). The exact 
effect of increased skin thickness to TSF is not known. This is likely to be varied 
depending on the extent and severity of skin thickness and therefore it would be 
difficult to apply a correction factor for skinfold measurements in patients with 
dcSSc. Only eleven of 43 patients in this study had dcSSc, TSF measurements would 
not be expected to be affected in lcSSc as by definition the skin is affected below 
knees and elbows in lcSSc. 
Although handgrip strength is normally a good measure of protein malnutrition, in 
SSc patients this may not be applicable. The handgrip measurements obtained were 
low, but in the case of SSc patients this is most likely a reflection of impaired hand 
function secondary to digital vasculopathy or hand contractures rather than 
malnutrition.  
Surprisingly despite low BMI and anthropometric measurements there were only 4 
patients that scored 1 or 2 in the MUST score, thus putting them at medium or high 
risk of malnutrition. This is in contrast to a Canadian study of 586 SSc patients that 
showed that 11% and 17% of patients were at medium and high risk of malnutrition 
respectively (124).  A possible reason for the lower rates of malnutrition based on 
the MUST scores in this study is the small size of the patient groups.  According to 
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the Baron study, there was an association of MUST score with overall disease 
severity as indicated by the global physician’s assessment. My patient cohort was in 
the majority patients with relatively stable disease, including their GI disease and 
this may be another reason for the lower number of patients with MUST scores 1 or 
2.  Nonetheless MUST is a useful and easy to calculate nutritional score capable of 
predicting GP visits, hospital admissions, length of hospital stay and mortality (121) 
and it or another screening tool  should be calculated in SSc patients regularly both 
in the inpatient and outpatient setting.  
Indirect calorimetry is a relatively easy and accurate way of measuring REE. There 
have been numerous studies using indirect calorimetry in cancer patients, critically 
ill patients in intensive care and a number of other conditions but there is little 
evidence of indirect calorimetry being used in SSc patients. A recent study of 714 
cancer patients and 642 controls showed that a higher proportion of cancer 
patients were hypermetabolic compared to controls (139). This study used 
mREE/pREE (% predicted REE) to account for differences in height and weight as 
well as age and sex. Although SSc patients may be predisposed to malnutrition, this 
was not explained by differences in the metabolic rate. The indirect calorimetry 
measurements did not identify any difference in resting energy expenditure 
between the 2 SSc groups. Only 2 patients (1 Sx and 1 ASx) were hypermetabolic 
with the majority of patients being normometabolic. Although BMI was lower in SSc 
patients compared to British population the fact that MUST scores were largely 0 
suggest that any weight loss was not recent. There is anecdotal evidence that 
patients lose weight shortly after diagnosis and their weight then stabilises thus 
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explaining my findings. Another possible explanation is that this is still a small 
patient group and therefore small differences are less likely to become evident in 
this sample size. Predicted REE is calculated using the Harris-Benedict equation. 
This equation has been based on normal healthy population. A number of studies 
have shown that predictive equations are not as accurate as indirect calorimetry in 
patients who are critically ill (140), malnourished (141) or possibly patients with 
alterations in body composition (142) as found in my study. Therefore the 
conclusion of whether patients were normometabolic or hyper/hypometabolic may 
not be accurate. Nonetheless the measured REE was not different between the 
symptomatic and asymptomatic groups in my study.  
Another explanation is that the ensued malnutrition is secondary to malabsorption 
or energy deficiency rather than increased energy consumption. Marie et al in a 
recent study of 51 SSc patients showed that 43% had small intestinal bacterial 
overgrowth (SIBO) with associated GI symptoms (143). None of the patients in the 
asymptomatic group had SIBO, 3 symptomatic patients had antibiotics for bacterial 
overgrowth in the 3 months prior to the study but none on the day of the study. 
Krause et al showed that 50% of the patients they studied had lower energy intake 
than their energy requirements and that nutritional intervention had a significant 
effect on nutritional status (137). Although I did not assess the nutritional intake of 
the patients studied, the majority of patients had what they considered a normal 
diet; only one of the symptomatic patients and none of the asymptomatic were on 
nutritional supplements.  
129 
Bioelectrical impedance analysis measures the restriction of flow through the body 
of an electric current. The body offers 2 types of restriction of flow of the electric 
current, resistance and reactance. The resistance is primarily related to the amount 
of water present in the tissues and reactance is the resistive effect produced by cell 
membranes. In this study the Sx SSc patients had much lower impedance, 
secondary to both lower resistance and reactance, than the ASx patients. These 
differences may be the first, subtle changes in the body reflecting nutrition and 
hydration status. The relationship between resistance and reactance is measured as 
the phase angle and reflects different electrical properties of tissues and the 
relative contributions of fluid and cellular membranes which can be affected by 
various diseases. The phase angle has been described as a prognostic tool in various 
chronic diseases such as liver fibrosis and renal failure, motor neuron disease and 
also in malignancy such as lung, breast, pancreatic and colorectal cancers (144-148). 
Smaller phase angles suggest cell death. Sx SSc patients in this study did have a 
lower phase angle compared to ASx patients. In patients with advanced cancer, 
phase angle scores lower than 5.6 have been associated with shorter survival. In the 
Sx SSc patients in my study, although the phase angle scores were lower than those 
of the ASx patients, they were not as low as the above scores. Krause et al in their 
study of 124 SSc patients found poor nutritional status and lower phase angle 
values in patients with more active and severe disease. The overall phase angle 
values recorded in their study were much lower (mean 4.7). They also found that 
patients with malnutrition had a higher risk for SSc-related mortality and that phase 
angle was the best predictor for mortality (137). It is likely that other organ 
involvement, rather than just gastrointestinal involvement, contributes to the 
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phase angle values and therefore its prognostic potential. Although the groups of 
patients studied had largely similar pattern of other organ involvement, there were 
not enough patients to perform such subgroup analysis.  
Bioelectrical impedance is becoming increasingly utilised for assessment of body 
compartments. It has been used to assess both fat free mass and body fat mass but 
also body water compartments. Fat free mass and fat mass are more qualitative 
tools than BMI in the evaluation of nutritional status and they have been shown to 
be predictors of outcome (149;150). Reference intervals for FFMI and FMI for 
Caucasian European population were recently published (134). A study comparing 
patients at the time of hospital admission compared to controls showed a higher 
prevalence of low FFM and high FM (151). COPD patients who had low FFM had 
worse outcome post lung reduction surgery (152) and HIV patients with higher FFM 
had better physical functioning. RA patients often display reduced FFM, regardless 
of disease activity, together with stable or increased FM, in keeping with the 
concept of rheumatoid cachexia (153). In this study of SSc patients, the ASx patients 
had lower FFMI than Sx patients. This finding is unexpected in that the Sx patients 
would be more likely to develop malnutrition. For the analysis, the 3 male patients 
in the symptomatic group were excluded as there are significant gender differences 
in FFMI and I did not want to bias the results. Two of the 3 male patients had 
moderate to severe GI disease and therefore the difference between the 2 groups 
may not be as significant. As fat free mass consists of total body water, this 
difference may reflect more the difference in total body water especially as body 
cell mass was not different between the 2 groups. Krause et al compared SSc 
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patients with age and sex matched controls and did not find a difference in lean 
body mass and fat mass between the 2 groups. They did though find higher ECM 
and a higher ECM/BCM ratio in SSc patients than controls (137), thought to reflect 
increased fibrosis present in SSc patients. I did not find a difference in ECM/BCM 
ratio between the symptomatic and asymptomatic SSc patients but this would be 
explained by the fact that there was a similar ratio dcSSc:lcSSc in both groups of 
patients and the amount of fibrosis present is unlikely to differ significantly.  
Another important element of bioelectrical impedance is the calculation of body 
water compartments. Hydration disorders occur in both health and disease. In 
healthy people hydration affects cognitive function and exercise performance. In 
disease, over-hydration is frequently caused by heart, kidney or liver failure. In the 
SSc patients studied there was a significant difference in TBW between the Sx and 
ASx group. The percentages of ICW and ECW were also significantly different but 
not the ICW/FFM ratio. This has been suggested by Ritz et al to be a better indicator 
of cellular hydration and influenced less by gender and BMI (136). TBW/FFM was 
statistically higher in the Sx group, more so when the 3 male patients were included 
in the analysis. The fact that ICW/FFM ratio is not different in the 2 groups indicates 
that this difference in water spaces may not be secondary to differences in 
hydration. A possible explanation is that it is secondary to oedema, which would be 
indicated by the higher ECW%, although this would be subclinical as none of the 
patients had clinical oedema. Bioelectrical impedance seems to be a sensitive tool 
for evaluation of body water spaces as well as fat free and fat mass and is 
increasingly used in a number of chronic conditions (154). In a chronic disease such 
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as SSc which can affect multiple organs, it may prove to be a valuable tool in 
assessing not only nutritional status but hydration status also.  
At the time of the study design and data collection there was no data on 
bioelectrical impedance in SSc and only a couple of studies that had assessed 
nutrition, one by anthropometric assessments and dietary assessment (123) and 
one using bone mass density scan (155). Baron et al demonstrated increased risk of 
malnutrition in SSc patients as assessed with the MUST (124) and Krause et al 
recently showed for the first time that bioelectrical impedance is a useful 
nutritional tool in SSc patients with differences observed between SSc patients and 
healthy controls (137). Although Baron et al assessed the impact of GI symptoms on 
MUST scores and risk of malnutrition, Krause et al assessed consecutive SSc 
patients without specific reference to GI involvement. My study was an exploratory 
study of the use of bioelectrical impedance in SSc and on whether GI involvement 
causes changes in body composition as well as assessment of other nutritional 
assessment tools such as indirect calorimetry. The patients that I studied were all 
except one outpatients and with generally stable disease severity. This may explain 
the lower proportion of patients at risk of malnutrition based on the MUST score. 
Nonetheless the mean BMI, was lower than that of the British population. Although 
more commonly used markers of malnutrition such as BMI, which is part of MUST, 
were not different I showed that there are differences in body composition 
between patients with moderate to severe GI symptoms and those without. It is 
clear that further, larger studies on nutritional assessment and the effect of GI 
symptoms in development of malnutrition in SSc patients are needed. This study, as 
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an exploratory study proved that a detailed nutritional assessment based on 
anthropometric measurements and bioelectrical impedance can be easily 
undertaken without being very time consuming for the patients, involving invasive 
procedures or a need for significant resources. This kind of assessment could be 
undertaken in the outpatient setting. Indirect calorimetry is more time consuming, 
needs more equipment and in the outpatient setting is less useful and should 
probably be reserved for patients with more severe GI involvement and 
malnutrition as a tool for more accurate assessment of nutritional need. Through 
studying a larger number of patients with a variable extent of gastrointestinal 
involvement, both in terms of site involved and severity, as well as patients without 
gastrointestinal involvement we would be able to assess in the future the risk of 
malnutrition, the disease pattern associated with higher risk and early identifying 
features so as to try and prevent its occurrence. 
The findings of the studies undertaken as part of this thesis so far have helped 
define more the pathophysiological processes involved in gut involvement in SSc. I 
have also shown though how there are multiple processes involved  and the 
difficulty in identifying single causative factors for symptoms thus also making it 
challenging identifying therapeutic options. In a number of autoimmune and 
inflammatory conditions including systemic sclerosis animal models have been used 
to help both understanding disease processes and in testing new therapies. 
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CHAPTER 5:  
GASTROINTESTINAL MANIFESTATIONS IN A TRANSGENIC MOUSE 
MODEL OF SYSTEMIC SCLEROSIS 
 
  
Publication generated from this chapter can be found in Appendix 9 
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5.1. Introduction  
Animal models exist for a number of diseases and are widely used to understand 
disease processes in vivo. Animal models of systemic sclerosis have provided 
valuable insights into its pathogenenesis and have provided the means to test 
potentially useful therapeutic interventions.  The majority of models are murine, 
and can therefore benefit from the large number of inbred mutant mouse strains 
with detailed genetic, cellular and molecular information available for these strains. 
Vasculopathy, activation of the cellular immune system and fibrosis are key 
features of the pathogenesis of SSc found in the skin but also internal visceral 
organs, including the gastrointestinal tract. Although none of the animal models 
reproduce all the pathogenetic components, several of them show some of the 
typical abnormalities of SSc. The changes seen in the gastrointestinal tract differ in 
these animal models. Cellular infiltration and extracellular matrix (ECM) deposition 
are the most commonly seen features. Some of these animal models and 
specifically those with gastrointestinal tract involvement are briefly described 
below.  
University of California at Davis (UCD 200/206) chickens 
This avian model of SSc derives from male Leghorn chickens.  These chickens 
develop skin and systemic manifestations resembling human SSc. The chickens 
develop oedema and Raynaud’s like changes in their combs shortly after hatching. 
In a percentage of animals, the skin of the neck and back becomes oedematous and 
indurated and ischaemic lesions of the toes may also develop. Internal organs, 
including the oesophagus, heart, lungs, and kidneys, become involved in the disease 
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process between 3 and 6 weeks (156). Histopathologically the lesions resemble SSc.  
There is perivascular mononuclear cell infiltration in all layers of skin and 
subcutaneous tissue, signs of an obliterative vasculopathy and endothelial cell 
apoptosis with loss of functional capillaries and ECM deposition by fibroblasts 
which leads to fibrosis of the skin and the combs (157). Apart from 
histopathological findings, UCD-200 chickens develop autoantibodies, including 
antinuclear antibodies with a centromeric staining pattern, antiphospholipid 
antibodies and rheumatoid factor (156). In a study investigating involvement of 
internal organs in this model Nguyen et al showed that the oesophagus of UCD 200 
chickens, was the most affected internal organ, showing mononuclear cell 
infiltrations and increased deposition of collagen (158). UCD-206 chickens resemble 
the UCD-200 line but often have more severe disease manifestations.  
Mouse model of bleomycin-induced dermal fibrosis 
Bleomycin has strong anti-tumour effects but its use is limited by dose-dependent 
toxicity, mainly lung fibrosis but SSc-like skin fibrosis has also been reported.  Due 
to its profibrotic effects bleomycin administration has been used to study murine 
pulmonary fibrosis. Yamamoto et al established a model of skin fibrosis by daily 
subcutaneous injection of bleomycin for 4 weeks (159). In addition to fibrotic 
changes of the skin, lung fibrosis with thickened alveolar walls and cellular 
infiltrates also developed. The heart, kidneys and gastrointestinal tract were not 
involved. Bleomycin induced fibrosis can occur in various mouse strains but there 
are variations between strains in the severity and length of bleomycin 
administration required. Bleomycin induced skin fibrosis mimics inflammatory 
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changes that occur early in the disease process of SSc. It induces the production of 
reactive oxygen species, endothelial cell damage and expression of adhesion 
molecules attracting inflammatory cellular infiltrate (leukocytes, mast cells, 
macrophages) which leads to activation of fibroblasts. Furthermore there is 
sustained activation of TGF-β and other inflammatory and pro-fibrotic cytokines 
(159). The fibrosis though is only local without a systemic effect and also without 
typical vascular phenomena. The bleomycin-induced skin fibrosis model has been 
used to evaluate anti-inflammatory and anti-fibrotic therapies.  
Graft-versus-host disease (GVHD) model 
These murine models reflect immunologically driven fibrosis in the skin and other 
target organs and have some similarity with human GVHD, which in its chronic form 
can replicate some important features of systemic sclerosis. Human chronic GVHD 
occurs following haematopoetic cell transplantation. There are 2 types, cytotoxic 
and sclerodermatous GVHD, the latter resembles clinically diffuse SSc. These 
similarities lead to the development of a mouse model of SSc by transplanting 
haematopoetic cells from donor to recipient mice mismatched for minor 
histocompatibility antigens (160). Approximately 2 weeks after transplantation, T 
cells, monocytes, mast cells, and other leukocytes infiltrate affected tissues and 
stimulate resident fibroblasts to release large amounts of ECM proteins (161). TGF-
β has been shown to play a critical role in this process (162). Three weeks after 
bone marrow transplantation, sclerodermatous GVHD mice develop pulmonary and 
dermal fibrosis with loss of dermal fat and atrophy of appendages (160). Ruzek et al 
developed a modified GVHD model by using RAG-2KO mice genetically deficient in 
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mature T and B cells as recipients for transfer of donor B10.D2 spleen cells to 
induce the GVH SSc disease (163). This model demonstrates the fibrotic effects of 
dermal thickening of extremities and progressive fibrosis of internal organs as well 
as vasoconstriction and morphologic changes in smooth muscle cells surrounding 
vessels and evidence of early immune responses. There was also intestinal 
involvement in this model, affecting mainly the large intestine where accumulation 
of connective tissue is observed in the lamina propria and submucosa (163).  
Type 1 and type 2 tight skin (Tsk-1 and Tsk-2) mouse strains 
Tsk-1 is a spontaneous dominant mutation that occurred in the inbred B10.D2 
(58N/Sn) strain. Homozygous animals die in utero whereas heterozygous animals 
develop SSc like features with skin fibrosis as well as visceral changes such as heart 
enlargement and lung abnormalities, namely distended lungs and emphysema like 
changes (164). Fibrosis in Tsk-1 mice arises from increased ECM production by 
activated fibroblasts, although the exact mechanisms remain unclear. Cellular 
immunity (in view of production of autoantibodies in the Tsk-1 mouse), 
inflammatory cells and the fibrillin-1 gene have all been implicated. The second 
tight skin mutation is an autosomal dominant mutation resulting from 
administration of the mutagenic agent ethylnitrosourea (165). Again only 
heterozygous animals survive. Tsk-2 mice develop fibrosis of the skin and internal 
organs. They also display inflammatory cell infiltrates in the affected tissue and 
autoantibodies such as anti-Scl-70, anti-centromere and anti dsDNA. The internal 
organ changes seen in these 2 models do not fully mirror the changes seen in SSc, 
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for example they develop emphysematous rather than fibrotic changes in the lungs. 
Intestinal involvement has not been reported in these mouse models. 
Transgenic and knockout mouse models 
Improved genetic techniques have allowed the development of specific transgenic 
and knockout animals that enabled further characterisation of the signalling 
pathways, cytokines and inflammatory mediators involved in the disease process. 
Examples of such mouse models are the caveolin knock-out mice and mice with 
mutations involving the platelet-derived growth factor receptors and TGF-β 
signalling. Some of these mouse models have demonstrated gastrointestinal 
involvement. 
Caveolin knock-out mice 
Caveolin is a plasma membrane-associated protein responsible for caveolae 
formation, flask-shaped membrane invaginations. Caveolins modulate receptor 
complexes and signal transduction. Radiation induced lung fibrosis has previously 
been found to be associated with down-regulation of caveolin-1 in alveolar 
epithelium. This was confirmed in more recent studies and caveolin-1 knockout 
mice were found to induce a systemic fibrotic disease affecting the lungs and other 
organs (166). Alveolar septae are thickened due to hypercellularity and increased 
deposition of ECM. In addition to lung fibrosis, caveolin knockout mice develop skin 
fibrosis with a marked increase in collagen deposition.  These mice also display 
vascular changes with altered vessel tone and permeability as well as pulmonary 
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hypertension on histological analysis (167). In the intestine caveolin knockout mice 
show abnormalities in pacing and contractile activity of the small intestine (168). 
Platelet derived growth factor (PDGF) receptor mutations 
PDGF signalling regulates the development of mesenchymal cell types including 
proliferation, survival, migration, and control of differentiation. PDGF receptor 
alpha (PDGFRα) signalling serves critical functions during embryo development. 
Aberrant PDGFR signalling has been implicated in diverse fibrotic conditions (169) 
where fibroblasts proliferate and deposit excessive connective tissue matrix, 
leading to progressive scarring and organ dysfunction. The overactivation of 
PDGFRα signalling has been investigated in knockin mouse lines with mutations of 
PDGFRα. These mice developed tight skin that adhered strongly to underlying 
muscle. Connective tissue fibrosis was noted in heart muscle, around bronchioles, 
in skeletal muscle and in the kidneys as well as the gastrointestinal tract (170). 
TBRICA; Cre-ER mice 
Overactivity of TGF-β leads to extracellular matrix overproduction and promotes 
myofibroblast differentiation. It is thought to play a key role in the development of 
systemic sclerosis. Bou Gharios et al had previously identified a largely fibroblast 
specific, transcriptional enhancer far upstream of the transcription start site of the 
pro-a2(I) collagen gene (171). Sonnylal et al using a Cre/loxP system in which 
tamoxifen-inducible recombinase was activated after birth, generated transgenic 
mice in which TGF-β signalling was disrupted after birth (172). The TBRICA; Cre-ER 
mice when injected with tamoxifen which activated TGF-β signalling developed 
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marked skin fibrosis and thickening of the walls of the small arteries of the lungs 
and kidneys, key pathological features of SSc. They also showed increased collagen 
accumulation and abnormalities in extracellular matrix deposition. These mice 
though did not show fibrotic lesions of the lungs or other internal organs (172).  
TβRIIΔk mice 
Denton et al generated another transgenic mouse strain with fibroblast specific 
TGF-β signalling activation (173;174). They used the same promoter of the pro-a2(I) 
collagen gene to express a kinase deficient type II TGF-β receptor (TβRIIΔk) in 
fibroblasts. Despite TβRIIΔk having previously been characterised as a dominant 
negative inhibitor of TGF-β signalling, adult mice expressing this construct 
demonstrated TGF-β overactivity and developed skin fibrosis. A proportion of 
animals also developed significant lung fibrosis paralleling the human disease (173). 
Further experiments from the same group examined the effect of experimental 
injury to alveolar epithelial cells and showed that even minor epithelial injury 
induced significant lung fibrosis (175). More recently Derrett-Smith et al showed 
diminished aortic ring contractility and relaxation in this mouse model compared to 
wild-type controls and associated aortic adventitial fibrosis and smooth muscle 
attenuation in the thoracic aorta as well as cardiac fibrosis (176). This mouse model 
was used in the experiments described in this chapter. 
The development of novel animal models of SSc is an ongoing process, and, 
particularly, the repertory of genetic mouse models is expanding (177). 
Nonetheless, no animal model so far exhibits all aspects of the disease process. The 
GI tract has not been the focus in these animal models but is affected in some of 
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them mainly characterised by fibrosis. As the TβRIIΔk mice show skin and 
pulmonary fibrosis as well as a structural vasculopathy it was felt that vascular and 
fibrotic changes may also occur in the gastrointestinal tract of these mice. The aim 
of this study was to assess histologically and physiologically the gastrointestinal 
tract and specifically the lower GI tract of the transgenic TβRIIΔk-fib mouse strain to 
see if any of the key features of SSc seen replicated in other organs are also evident 
in the lower GI tract. 
 
5.2. Methods 
5.2.1. Animals 
5.2.1.1. Generation of genetically modified mouse model TβRIIΔk-fib 
The transgenic (TG) TβRIIΔk-fib strain was generated and characterized by Professor 
Christopher Denton at University College London and University of Texas, and has 
been described previously (173;174). In brief, a fibroblast-specific expression 
cassette was devised in which there was expression of the target cDNA but also co-
expression of a marker gene. The fibroblast-specific expression cassette was 
subcloned from the upstream region of the proα2(I)collagen gene. This 
incorporates a fragment between -19.5 and -13.5kb upstream of the transcription 
start site that, when linked to an endogenous minimal promoter drives gene 
expression at high levels in fibroblasts, but not in other type I collagen producing 
cells. Reporter genes linked to this promoter-enhancer show high level fibroblast-
specific expression in embryonic development and postnatally. The mouse strain 
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TβRIIΔk-fib was generated by subcloning the cDNA encoding the extracellular and 
transmembrane portion of the human type II TGFβ receptor into the Sal1 site of the 
pCD3 expression vector. A bacterial β-galactosidase marker gene (LacZ) was co-
expressed from a dicistronic transgene mRNA product via an encephalomyocarditis 
virus internal ribosome entry site sequence (IRES) (178). Neonatal pups were 
genotyped by PCR analysis of genomic DNA extracted from tail-biopsy specimens, 
by using primers specific for the β-galactosidase reporter gene (5'-
CGGATAAACGGAACTGGAAA- 3' and 5'-TAATCACGACTCGCTGTATC-3') (Sigma- 
Genosys, Haverhill, UK). Littermate wild-type (WT) C57/B6 mice were used as 
control animals.  
5.2.1.2. Animal housing 
The mice examined were both male and female transgenic mice and littermate 
wild-type controls. Animals were housed in a clean conventional colony, with access 
to food and water ad libitum. Strict adherence to institutional guidelines was 
practiced, and full local ethics committee and Home Office approval were obtained 
prior to all animal procedures.   
 
5.2.2. Histological Analysis 
5.2.2.1 Sample collection 
Animals were sacrificed by cervical dislocation following narcosis with carbon 
dioxide. The stomach and the small and large intestine were dissected en bloc and 
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immersed in 10% formal saline containing 4% formaldehyde (CellPath, UK) for 
histology.  
5.2.2.2. Tissue processing and preparation 
For formalin-fixed paraffin-embedded (FFPE) specimens, gut tissue was fixed 
overnight in 10% formal saline containing 4% formaldehyde (CellPath, UK). Fixed 
tissues were processed and dehydrated overnight, and embedded in molten 
paraffin wax. For routine histology and immunohistochemistry, 3μm sections were 
cut using a Leica UK microtome, and mounted onto polylysine coated microscope 
slides (VWR, UK).  
5.2.2.3. Routine histology 
Prior to staining, sections of stomach, small and large intestine were de-waxed in 
xylene (Genta Medical, UK), and passed through graded alcohols to water. 
Gastrointestinal tract architecture was determined by staining with haematoxylin 
and eosin (H&E) as per standard protocols. Non fibrillar collagen deposition was 
detected by sequential staining with Weigert’s iron haematoxylin followed by 
picrosirius red. Following staining, sections were dehydrated with alcohol, cleared 
in xylene, and mounted with a permanent mount (DPX).  Unless stated, reagents 
were purchased from Raymond Lamb Ltd, UK. 
5.2.2.4. Immunohistochemistry 
Immunohistochemical analysis was performed on FFPE gastrointestinal sections. 
Sections were pre-treated with methanol and 0.5% hydrogen peroxide (VWR, UK) 
for 10 minutes to quench endogenous peroxidase activity, followed by antigen 
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retrieval in citrate buffer 10mM (pH 6) by microwave for 5-20 minutes. Samples 
were washed x 3 between steps with phosphate buffered saline (PBS; Oxoid, UK). 
Endogenous biotin activity was blocked using an avidin/biotin blocking kit (Vector 
Laboratories, US) according to the manufacturer’s instructions. Primary antibodies 
used were: 0.7µg/ml mouse monoclonal anti α-smooth muscle actin (α-SMA; 
Sigma-Aldrich, St. Louis, MO), 0.66µg/ml of the proliferation marker rat anti-Ki67 
Tec-3 (; Dako, Denmark), and 100µg/ml of rabbit phospho-SMAD2/3 (pSMAD2/3) 
(Santa Cruz Biotechnology, Santa Cruz, CA) a marker of TGF-β pathway activation. 
For neural staining 10µg/ml of protein gene product (PGP) 9.5, a general neural 
tissue marker and 2µg/ml of anti-S-100 (a glial cell marker) were used. A mouse-on-
mouse immunodetection kit was used with the mouse monoclonal primary 
antibodies, in order to reduce non-specific binding. After washing with PBS, 
sections were sequentially incubated for 30 minutes with a 1/200 dilution of a 
biotinylated secondary antibody, followed by Vectastain avidin biotin complex 
(ABC) - peroxidase conjugate, (or Vectastain ABC - alkaline phosphatase for α-SMA). 
Sections were developed using chromogen DAB (3,3’ diaminobenzidine 
tetrachloride). α-SMA was developed using  alkaline phosphatase substrate  with 
levamisole solution to block endogenous alkaline phosphatase activity. Finally, 
sections were briefly counterstained with Meyer’s haematoxylin, and prepared for 
permanent mounting. Unless stated, reagents were purchased from Vector, USA.   
All histology and immunohistochemistry sections were viewed and photographed 
using a Zeiss Axioscope light microscope (Carl Zeiss, Germany) with Axiovision 
software. Sections were photographed at x100 and x200 magnifications.  
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The images of large and small bowel stained with Ki-67 and pSMAD2/3 antibodies 
were further analysed for quantification of positively stained cells. At x200 
magnification, positively stained cells (brown) and negatively stained cells were 
counted in up to 10 crypts and results given as a proportion of all cells counted. 
Thickness of muscularis propria (both longitudinal and circular muscle) was 
assessed in tissue stained with α-SMA. The muscularis propria was measured in 
representative sections of large intestine at x100 magnification using the Axiovision 
software.  
Representative small and large bowel sections stained with picrosirius red were 
photographed at x25 magnification thus allowing the whole bowel section to be 
photographed in one field and the extent of collagen deposition seen was 
quantified using the NIS Elements BR 2.30 system (Nikon, Japan). The colour 
wavelengths of the image were transformed into digital readings, allowing for 
quantification of the various colour wavelengths with pixels as the unit of measure. 
The colour spectra were analyzed and those corresponding to collagen (red 
wavelengths) were quantified as percentage of the whole tissue.  Comparison was 
made between transgenic mice and wild-type controls. Results are given as mean 
percentage of tissue +/- standard deviation. 
5.2.3. Isometric tension measurement in isolated large intestine 
Transgenic mice (6.5-7.5 month old) and sex and age matched wild-type littermate 
controls were sacrificed by cervical dislocation following narcosis with carbon 
dioxide. The distal large intestine was dissected and immersed in 10% formal saline 
containing 4% formaldehyde (CellPath, UK) for histology. The proximal large 
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intestine was dissected and immersed in fresh Krebs buffer (119 mmol/L NaCl, 4.7 
mmol/L KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 11 mmol/L glucose, 25 
mmol/L NaHCO3, 2.5 mmol/L CaCl2).  Large intestine, specifically the caecum, was 
washed in aerated fresh Krebs buffer, and the loose connective tissue removed. It 
was then cut longitudinally in 2-3 mm wide rings and the rings cut along the 
mesenteric border to form strips of tissue 2-3 mm x 7-10 mm long. These strips 
were tied at each end with thread and mounted on the transducers in 7 ml organ 
baths containing Krebs buffer at 37°C, continuously oxygenated with 95% O2/5% 
CO2. Isometric tension was measured with force-displacement transducers (Grass 
Instruments, Quincy, MA), and digitized using a multichannel recording system 
(Grass Instruments, Quincy, MA) with MP100 acquisition unit and AcqKnowledge 
software (Biopac Systems, Goleta, CA). A resting tension of 500-550 mg was applied 
to the strips, which were then allowed to equilibrate for 60 minutes. In this period, 
tissues were washed out with Krebs buffer, and the applied tension readjusted at 
15-minute intervals (179;180).  
After the equilibration period, the intestinal strips were contracted with cumulative 
doses of potassium chloride (KCl) (30 mmol/L and 80 mmol/L) until a stable 
contraction plateau was reached. Contractile responses were measured by 
recording changes in tension (milligrams). After washout, the tissues were allowed 
to re-equilibrate for 30 minutes, and contractile dose-response curves were 
constructed using cumulative doses of carbachol (10-9 to 10-4 mol/L) and 5-
hydroxytryptamine (5-HT; 10-9 to 10-4 mol/L) (181) with washout and equilibration 
after each dose response curve. As a negative control 1 strip was pre-treated for 20 
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minutes with 10µM atropine before contractile responses to carbachol were 
measured. The gut contractile response of 6 mice (3 transgenic and 3 wild-type) 
was examined on 2 experiments (3 mice, mix of wild-type and transgenic) 
performed on consecutive days. The scale of contractile responses was different in 
the 2 experiments and therefore if the results were expressed in milligrams it would 
not be possible to combine the 2 experiments. Therefore the maximum contractile 
response was established for each experiment and the rest of the contractile 
responses are expressed as percentage of the maximal contraction. Data are 
expressed as mean ± SEM.  
 
5.2.4. Statistics 
Student t-test was used to compare quantitative values obtained between 
transgenic and wild-type animals described above. A value of p<0.05 was 
considered significant. 
 
5.3. Results 
5.3.1. Animals                                                                                                                                                                                                                                                                                             
The mice examined were both male and female transgenic mice and equal number 
sex and age matched littermate wild-type controls. Initially 2 age groups of mice 
were sacrificed, 3 transgenic and 3 wild-type controls aged 11-13 months and 
another 6 (3 transgenic and 3 wild-type) aged 5.5-6.5 months. Fibrosis may develop 
in gut tissue with age and therefore 2 age groups of mice were examined. Colonic 
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tissue from another 3 transgenic and 3 wild-type mice (6.5-7.5 months old) was 
used for the isobaric tension measurements of large bowel and other histological 
analysis.  
 
5.3.2. Histological analysis 
5.3.2.1. Routine histology 
The gastrointestinal tract architecture was examined by H&E staining. Figure 5.1 
shows large intestinal mucosa with the anatomical layers identified. Figure 5.2 
shows representative examples of H&E staining from large intestine, small intestine 
and stomach. There was no difference in the gastrointestinal tract architecture 
between the transgenic TβRIIΔk-fib strain and wild-type mice and between the 2 
age groups. Picrosirius red staining was used to assess collagen deposition. 
Representative examples are shown in figure 5.3. The amount of collagen was 
estimated as percentage of tissue stained red with picrosirius red for small and 
large intestine, results given as percentage of tissue. Collagen deposition was higher 
in the large intestine (% of tissue stained red: WT: 6.4 ± 1 vs TG: 9.2 ± 0.9; p=0.059) 
and the small intestine (WT: 4.6 ± 2 vs TG: 6.17 ± 1.5; p= 0.23) of the transgenic 
mice compared to the wild-type controls although this did not reach statistical 
significance. 
5.3.2.2. Immunohistochemistry 
Smooth muscle cells were stained with α-SMA antibody. There was no obvious 
smooth muscle atrophy observed in the mouse GIT of transgenic TβRIIΔk-fib strain 
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or wild-type control mice. Although previously smooth muscle attenuation has 
been reported in the aorta of this transgenic mouse model, there was no obvious 
difference in smooth muscle thickness in small and large intestine between 
transgenic and wild-type mice. Representative examples of α-SMA staining are 
shown in figure 5.4.  
Cellular proliferation was assessed using the proliferation marker Ki-67, a nuclear 
protein associated with the cell cycle and expressed from late G1 through to M 
phase (182). There was no difference in the number of positively stained cells 
between the transgenic mice and wild-type controls both in the small (WT: 67.8 ± 
15.2 vs TG: 80.8 ± 3.2; p=0.68) and large intestine (WT: 43.9 ± 9.8 vs TG: 41.5 ± 10.2; 
p=0.63). TGF-β pathway activation was assessed through staining for pSMAD2/3. 
No difference in positively stained cells was seen between transgenic and wild-type 
mice in the small (WT: 41.7 ± 18 vs TG: 42 ±17.9; p=0.97) or large (WT: 34.2 ± 15.6 
vs TG: 39.3 ± 16.5; p=0.51) intestine. Representative examples of Ki-67 and 
pSMAD2/3 staining are shown in figures 5.5 and 5.6.  
 
5.3.3. Isometric tension measurement in isolated large intestine 
In systemic sclerosis, gastrointestinal involvement has been attributed to 
dysmotility and smooth muscle atrophy and fibrosis. In order to investigate 
whether gut dysmotility occurs in the TβRIIΔk-fib mouse strain I examined 
responses of strips of proximal large intestine in isolated organ bath experiments. 
Colon smooth muscle contraction was induced with potassium chloride (KCl) which 
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directly causes smooth muscle cell contraction and then with carbachol a known 
cholinergic agonist.  Contractile responses to KCl were significantly reduced in 
transgenic mice at 80mM concentration (WT: 53.5 ± 14.2 vs TG: 13.5 ± 12.8; 
p=0.022) but not at the lowest 30mM concentration (WT: 48.9 ± 30.5 vs TG: 33.5 ± 
29.6; p=0.56) (figure 5.7and 5.8A). Contractile responses to carbachol were reduced 
in transgenic mice compared to wild-type controls. The difference was significant in 
the higher carbachol concentrations 10-5 (WT: 90.4 ± 8.7 vs TG: 50.6 ± 17.8; 
p=0.025) and 10-4 (WT: 64.6 ± 7.2 vs TG: 31.97 ± 13.9; p=0.023) (figure 5.7 and 
5.8B). The addition of atropine to the organ bath after the initial contractions to KCl 
abolished any contractile response to carbachol in both experiments. 5-HT has been 
shown to be an intestinal neurotransmitter and therefore response to 5-HT was 
also investigated. No significant contractile response was observed following 5-HT 
addition in either wild-type or transgenic mice.  
In order to further investigate the reduced contractile response of colon smooth 
muscle observed in transgenic TβRIIΔk-fib strain mice, the remaining colon was 
used as described above for histology and immunohistochemistry. H&E and 
picrosirius red staining was performed as described earlier for the 2 age groups of 
mice. No difference was seen between transgenic and wild-type mice in large 
intestinal architecture and there was no evidence of increased inflammatory cells. 
There was higher collagen deposition in the colon of transgenic mice compared to 
wild-type controls as estimated by the percentage of tissue staining red on 
picrosirius red staining (% of tissue stained red: WT: 3.95 ± 1.2 vs TG: 9.7 ± 3.5; 
p=0.05). Immunohistochemical staining with α-SMA did not reveal any difference in 
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smooth muscle cell staining between transgenic and wild-type mice. There was no 
difference in the percentage of positively stained cells for Ki-67 (WT: 47.3 ± 11.9 vs 
TG 42 ± 13.9; p=0.64) and pSMAD2/3 (WT 26.3 ± 16.2 vs TG 26.7 ± 4.5; p=0.97) 
between the transgenic and wild-type mice. There was no obvious difference in the 
neural cells stained between the transgenic and wild-type mice to explain the 
difference in contractile responses (figure 5.9).  
In summary, there was no major architectural differences in mucosa and smooth 
muscle of the intestinal tract between wild-type and transgenic mice. There was 
evidence of increased fibrotic connective tissue in the large intestine of the 
transgenic mice. The function of the large bowel as demonstrated in the isobaric 
tension experiments was altered in transgenic mice with reduced contractile 
responses seen in the transgenic mice. 
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Figure 5.1: Haematoxylin and eosin staining of 2 different segments of large 
intestine in wild-type and transgenic mice (magnification x100). The different layers 
of the intestine are depicted. 
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Figure 5.2: Haematoxylin and eosin staining of representative sections of large 
intestine, small intestine and stomach in wild-type and transgenic mice 
(magnification x100). 
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Figure 5.3: Picrosirius red staining of representative sections of large intestine, 
small intestine and stomach in wild-type and transgenic TβRIIΔk-fib strain mice 
(magnification x100). 
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Figure 5.4: alpha-smooth muscle actin (SMA) staining of representative sections of 
large intestine, small intestine and stomach in wild-type and transgenic mice 
(magnification x100). 
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Figure 5.5: Ki-67 staining of representative sections of large intestine and small 
intestine in wild-type and transgenic mice (magnification x100). 
 
Wild-type                                           Transgenic 
   
 
 
  
 
 
  
Small intestine 
Large intestine 
158 
Figure 5.6: phospho SMAD2/3 staining of representative sections of large intestine 
and small intestine in wild-type and transgenic mice (magnification x100). 
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Figure 5.7: Traces of colonic strips’ contractile responses in 3 transgenic and 3 wild-
type mice. Responses to KCl and high doses of carbachol are shown. 
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Figure 5.8: Summary data of colonic contractile responses to A) KCl and B) 
carbachol in wild-type and transgenic mice. Results are expressed as % of maximal 
contraction (+/- standard error of mean). 
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Figure 5.9: Protein gene product (PGP) 9.5 staining of large intestinal mucosa in 
wild-type (a and b) and transgenic mice (c and d), magnification x100 (a and c) and 
x200 (b and d). 
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5.4. Discussion 
The transgenic TβRIIΔk-fib mouse strain is a mouse model of SSc in which the 
primary defect is fibroblast-specific perturbation of TGF-β signalling. This mouse 
model replicates some of the hallmark features of SSc. These transgenic mice have 
been shown previously to have abnormal wound healing with failure of wound 
contraction and scar formation. They develop skin fibrosis and sporadic lung fibrosis 
(173;174). They have also been shown to develop exaggerated lung fibrosis after 
bleomycin treatment (175). In more recent experiments Derrett-Smith et al 
described in this strain diminished aortic ring contractility and relaxation and 
associated aortic adventitial fibrosis as well as cardiac fibrosis (176). The aim of this 
study was to investigate if there are histological or functional features of colonic 
involvement in this mouse model.  
Although oesophageal involvement is more common than colonic involvement in 
SSc patients, the upper GI tract has been more extensively investigated and 
therefore there is overall better understanding of the pathophysiological processes 
occurring in the oesophagus. Different processes may operate in different parts of 
the GI tract and therefore I chose to concentrate on the lower GI tract in order to 
potentially enhance our understanding of the pathophysiology of colonic 
involvement. 
Although other models of systemic sclerosis such as the GVHD mouse model and 
PDGF knock-in mouse model have been shown to develop gastrointestinal 
involvement, this has not been the focus of experiments previously except in the 
UCD chickens  (157). In a study to investigate the initial disease phase, the 
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oesophagus of UCD chickens which was the most affected internal organ, showed 
endothelial cell apoptosis followed by mononuclear cell infiltrations and increased 
deposition of collagen (158). The intestine was not found to be affected in the UCD 
chickens.  
Gastrointestinal dysmotility is common in systemic sclerosis but the underlying 
pathogenesis remains only partially understood. Histological studies of the gastric 
wall in systemic sclerosis patients have shown prominent fibrosis and severe 
ultrastructural alterations of smooth muscle cells and nerve fibres (183) and a 
similar picture has been described in the rectum (13). These studies were based on 
full thickness or deep biopsies which are not easily obtained. An animal model 
exhibiting intestinal involvement could significantly enhance our understanding of 
the disease process as well as the effect of treatments. 
Our results showed that the gastrointestinal tract of this transgenic TβRIIΔk-fib 
mouse strain was structurally normal on light microscopy but there is increased 
collagen deposition observed in mainly the submucosa and the muscularis mucosa. 
The fibrosis observed in this transgenic mouse strain is likely to be related to 
altered TGF-β bioactivity as has been observed in lung tissue in these mice. A role of 
TGF-β has been shown in other experimental models of intestinal fibrosis such as 
the TNBS colitis mouse model. In the TNBS colitis model acute and then chronic 
inflammation precede the development of fibrosis. In the intestine of the TβRIIΔk-
fib mouse model there was no evidence of increased inflammation. This is 
consistent with the findings in lung tissue although injury with bleomycin has been 
shown to induce inflammation to both skin and lung tissue in these mice. No 
164 
intestinal injury was induced in these experiments. Another reason for the absence 
of inflammation may be that this occurs earlier in the disease process and the mice 
examined were all at least 5-6 months old. An inflammatory response at an earlier 
time will be investigated in future studies. 
Transgenic TβRIIΔk-fib strain mice were shown to have reduced colonic contractility 
to both direct non-receptor mediated muscle stimulation with KCl and to carbachol, 
a cholinergic agonist which causes contraction via direct activation of muscarinic 
receptors. As contractions to both these agents are through direct activation of the 
smooth muscle the most likely cause for the reduced contractions in transgenic 
mice is either smooth muscle atrophy or fibrosis of the smooth muscle. No 
contractions were induced in transgenic or wild-type mice with 5-HT. 5-HT is found 
in only about 1% of enteric neurons in the mouse but is an enteric neurotransmitter 
which has been shown to increase colonic motor migrating complexes and induce 
colonic contractions.  As 5-HT was added to the organ bath after the KCl and 
carbachol it is possible that the tissue’s contractile response had diminished. 
Alternatively the contractions induced by 5-HT may be much finer compared to the 
actions of KCl and carbachol which act directly onto the smooth muscle. A third 
explanation is that there is an underlying neuropathic process which prevented the 
effect of this neurotransmitter.  
Dysmotility is one of the key features of gut involvement in systemic sclerosis. 
Although the pathogenesis of this remains uncertain neuropathy and smooth 
muscle atrophy have both been demonstrated (37;53;60;86). Fibrosis and collagen 
deposition can disrupt neural pathways causing neuropathy. There was no evidence 
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of degeneration of neural tissue histologically in the transgenic TβRIIΔk-fib strain 
mice but as mentioned above, changes may only be demonstrable on electron 
microscopy.  One histological study showed structurally normal enteric neurons but 
morphological abnormalities in the axon terminals and degeneration of 
unmyelinated fibres in rectal tissue (13) and Manetti et al found similar features in 
gastric tissue (183). Other causes for neuropathy are neurotransmitter depletion 
that has been previously demonstrated in SSc (112) and autoantibodies. Howe et al 
found myenteric neuronal antibodies in patients with SSc (25). Goldblatt et al in a 
later study showed that functional antibodies from SSc patients inhibited M3-
muscarinic receptor mediated enteric cholinergic neurotransmission in mouse 
colon (27). Although there was no difference in the number of myenteric and 
submucosal plexi neurons a neuropathic cause for the observed reduced colonic 
contractility cannot be excluded.  
This transgenic mouse model develops skin, lung and adventitial fibrosis which can 
be spontaneous in a proportion of mice but is more pronounced after tissue injury. 
There was increased colonic but not small bowel fibrosis seen in a proportion of the 
transgenic TβRIIΔk-fib strain mice. This is spontaneous fibrosis as there was no 
intestinal injury induced. To investigate further the intestinal involvement in this 
mouse model the effect of tissue injury to the development of fibrosis will be 
investigated in future studies. Although fibrosis may be a late development, at least 
in human intestinal involvement it is also the point where intestinal dysfunction 
becomes irreversible. It is possible therefore, that anti-fibrotic agents may have an 
effect on gut dysfunction. So far no drugs are effective in preventing or reversing 
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gut involvement and any treatment is aimed at symptom control. The TβRIIΔk-fib 
mouse strain may in the future be a useful tool in testing the effect of such 
treatments in gut involvement. 
In conclusion, I have shown that this transgenic mouse model previously shown to 
develop skin, lung and cardiac fibrosis also develops colonic fibrosis with associated 
effect in colonic tissue contractility. Although fibrosis is not the only 
pathophysiological process underlying gut involvement in systemic sclerosis, this 
mouse model may offer further insight in pathologic processes leading to the 
development of gut fibrosis as well as providing a potential experimental platform 
for exploring therapies targeting gastrointestinal manifestations of SSc. 
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CHAPTER 6:  
DISCUSSION AND CONCLUSIONS 
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The aim of this thesis was to conduct experiments in order to assess the primary 
pathologies affecting the gastrointestinal tract in systemic sclerosis (SSc), 
specifically pathologies affecting the mucosa, vasculature, smooth muscle and 
enteric nervous system in systemic sclerosis. To do this, the intention was to use 
the best currently available validated techniques. 
 
In the first instance I wanted to establish the prevalence of GI symptoms in UK 
patients with SSc attending a tertiary care rheumatology outpatient department 
(Chapter 2). I used a contemporary disease specific questionnaire about 
gastrointestinal symptoms created by Khanna et al (68) and validated it in a UK 
patient cohort. I showed that gastrointestinal symptoms are common and they 
have a significant effect on patients’ quality of life. The questionnaire used was the 
only available GI questionnaire specifically for SSc patients at the time, but had not 
been validated against objective measures of gut involvement. Ideally GI 
involvement should be diagnosed based on findings on investigations such as 
oesophageal manometry, endoscopy or imaging but as these are often invasive 
procedures, development of symptoms is often used as a marker to signify GI 
involvement.  
This is both one of the aims of this study, but also one of the limitations: a 
subjective symptom questionnaire is not an accurate measure of disease. It may 
both underestimate (due to asymptomatic or more stoical patients that may not 
report symptoms)  and over-estimate (due to GI symptoms being secondary to non-
SSc related GI disease or side effects of drugs) GI involvement both in extent and 
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severity. Patients’ notes were reviewed for evidence of GI investigations and 
documented GI involvement. A lot of patients have not had any invasive 
gastroenterological investigations and for those that had, these were often 
performed at patients’ local hospitals and therefore unfortunately the findings 
were not always available. Another limitation of this questionnaire is that although 
it covers a wide range of symptoms it does not cover anorectal symptoms. A unique 
feature of this questionnaire is that it enquires about symptom frequency, and 
gastrointestinal disease burden is derived by that, rather than by symptom severity 
which is more commonly assessed in disease assessment and quality of life 
questionnaires. The benefit of using symptom frequency is that frequency (in this 
case, number of days in a week) is a more objective measure than severity. 
Furthermore this questionnaire addresses a multitude of symptoms thus providing 
information about the range of gastrointestinal sites (apart from the anorectum) 
that may be affected in SSc. 
A second version of this questionnaire has included questions on anorectal 
symptoms and is also shorter and easier to complete but at the same time keeping 
the wide range of symptoms being assessed. Validation of this second version of 
this questionnaire in a UK population needs to be undertaken and is planned in 
future studies. This questionnaire should also be validated against objective 
evidence of GI involvement. Questionnaires are often used as indicators of disease 
activity for other organ involvement, such as pulmonary involvement in SSc. The 
use of a GI questionnaire such as the one used in this thesis or its second version 
may have a role as part of routine assessment of GI involvement in SSc patients 
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both on diagnosis and in subsequent visits both to assess progression of disease 
and response to treatment: this needs to be addressed in future long-term 
prospective studies. 
In order to establish any association between GI involvement and other SSc 
characteristics patients’ notes were reviewed. Gastrointestinal involvement was 
mainly based on the presence of symptoms with the limitations of this approach as 
previously discussed and although no specific associations were found this is based 
on possibly inaccurate assessment of GI involvement. Furthermore, the definition 
of severe GI involvement based on higher frequency of GI symptoms (3 or more 
days/week on the questionnaire used) is an arbitrary cut off that evolved from 
Khanna et al’s original description of their survey instrument. The implications of 
my findings are that in future studies, GI involvement as well as severity, should be 
proven by a GI history allied to endoscopic, physiological or radiological studies. 
Specific autoantibody profile associated with GI involvement needs to be further 
assessed with extensive autoantibody profiling of patients including myenteric 
autoantibodies: it may be that certain aspects of GI involvement, such as 
dysmotility or vascular changes or sites affected are associated with certain 
autoantibody profile or other disease characteristics. With the increasing 
recognition of GI involvement as well as the greater availability of GI investigations, 
such involvement may need to become better characterised as routine in the 
future. 
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More than 50 percent of SSc patients suffer from anorectal symptoms including 
faecal incontinence. This is often under-reported by the patients but also possibly 
due to lack of effective treatment options not specifically inquired about by 
physicians. Studies to date have mainly shown that patients with SSc have low anal 
sphincter resting pressure and imaging of the anal sphincters has classically shown 
internal anal sphincter (IAS) atrophy. I studied patients with and without faecal 
incontinence performing more extensive anorectal assessment than previously 
published, and importantly also studied GI asymptomatic individuals (Chapter 3). A 
key finding was that endoanal ultrasonography revealed IAS atrophy not only in the 
SSc patients with faecal incontinence but also in the SSc patients without such 
symptoms. Furthermore the resting pressure in these asymptomatic SSc patients 
was not necessarily increased compared to those patients with faecal incontinence. 
A new finding in this study and I would contend a key factor in symptom 
development is evidence of neuropathy most likely affecting the myenteric plexi. 
This is shown not only by absent rectoanal inhibitory reflex (RAIR, an intrinsic 
enteric mediated reflex) but also attenuated anal sensation. Anorectal sensation 
can be measured by mucosal electrosensation but also by sensation to rectal 
distension. Such rectal distension was not undertaken in this cohort, as I felt it was 
invalid in a disease that causes fibrosis and it could confound the interpretability of 
the results. Sensitivity to electrical stimulation is not affected by this process and 
furthermore allows study of both rectal and anal sensitivity.  
The RAIR has previously been shown to be absent or impaired in patients with SSc 
and this was confirmed in this study. I speculated that one possible confounding 
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factor to the loss of this reflex is the lower resting pressure already observed in the 
SSc patients with faecal incontinence, which could impair the ability to demonstrate 
a RAIR. A further key result therefore was the observation that the absence of RAIR 
did not correlate with the resting pressure or the degree of IAS atrophy. 
Furthermore it was the latency period component of the RAIR which was longer in 
Sx SSc patients, suggesting a delay in synaptic transmission. Another method of 
assessing neuropathy is pudendal nerve terminal latency measurements The 
pudendal nerve is a mixed nerve providing efferent and afferent pathways to the 
EAS, perineal musculature and mucosa of the anal canal amongst other structures. 
In keeping with current best practice, I chose not to use pudendal nerve terminal 
latency measurements as this method has been shown to be inconsistent, with 
normal latencies recorded even in a damaged nerve as long as some fast fibres 
remain intact. The test has a low sensitivity and specificity and it is very operator 
dependent.  
Neuropathy seems to be a key factor in symptom development. One implication of 
my results is that neuropathy and its pathogenesis needs to be investigated further 
in the future, especially the significance of autoantibodies as well as therapeutic 
interventions for its treatment such as sacral nerve stimulation and posterior tibial 
nerve stimulation.  
The structure of the anal sphincters was assessed by endoanal ultrasound (EAUS). 
An alternative method would have been endoanal MRI. This is much more time 
consuming and can be more uncomfortable for the patients in addition to being 
more expensive. More importantly the internal sphincter is very well seen on EAUS 
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and thickness and atrophy accurately assessed. Atrophy and thinning of the EAS 
may be more difficult to assess on EAUS but there is still good correlation with MRI 
which is more sensitive (184;185). Muscle integrity of both the internal and external 
sphincter is also very accurately assessed by EAUS. As it is mainly the IAS which is 
affected in SSc I felt that EAUS was the best method to assess the sphincter 
complex in these patients.  
One limitation of this study was the choice of the control group. I made the decision 
to use patients with faecal incontinence as I felt that if there are features distinct to 
SSc patients for the development of incontinence such a control group would be 
better able to demonstrate that. The main cause of incontinence in that control 
group was obstetric injury which may lead to more complex pathophysiological 
processes than mere sphincter tear, such as occult nerve injury.  
I excluded patients with diabetes from this study in order to avoid this confounding 
factor as diabetic neuropathy could lead to a similar clinical picture. Studying 
patients with diabetes and anorectal symptoms and comparing them with patients 
with SSc could provide further information in the pathophysiology of anorectal 
symptoms in SSc as the underlying pathophysiological processes of diabetic 
vasculopathy and neuropathy may be similar to those seen in systemic sclerosis. 
 
In the 4th chapter I described the effect of gut symptoms on nutritional status of 
SSc patients. Severe gastrointestinal involvement can lead to malnutrition and 
ultimately even the need for parenteral nutrition. Hence there is a need for 
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accurate nutritional assessment and identification of patients at risk of developing 
malnutrition. This was an exploratory study using nutritional assessments such as 
bioelectrical impedance and indirect calorimetry. There are very few previous 
nutritional studies in SSc patients and my aim was to try and establish if there are 
any differences between SSc patients with and without gut symptoms. The findings 
of this study could then be used to plan future studies. Even with the small number 
of patients studied I did find some significant differences between the groups in 
bioelectrical impedance findings. These differences were found in the impedance 
measurements as well as body composition such as fat free mass and total body 
water. The clinical significance of these findings is not known but early changes in 
body composition may identify patients that are at risk of developing significant 
malnutrition. The other significant difference found between SSc patients with and 
without gut symptoms is a higher phase angle in the patients without gut 
symptoms. Phase angle has been shown in other patient groups to be a prognostic 
indicator. In order for the importance of these findings to be assessed further a 
prospective longitudinal study of a larger number of patients should be planned in 
the future. This study assessed a number of nutritional assessments and I showed 
that a thorough and comprehensive nutritional assessment can be performed in a 
short period of time in the outpatient setting. The weight, height and therefore BMI 
as well as calculation of the MUST score can be easily undertaken. Anthropometric 
assessments are probably less useful in SSc patients as measurement of triceps 
skinfold thickness and handgrip can be altered by the cutaneous manifestations of 
SSc. Indirect calorimetry involves expensive equipment, operator expertise and is 
time consuming but bioelectrical impedance can be assessed easily. Therefore 
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assessing BMI, MUST score and bioelectrical impedance in a prospective and 
longitudinal study is planned for the future. 
There are a number of limitations of this initial, observational, study. This study, 
being exploratory, was not powered to show specific differences and therefore 
these results need to be reproduced in a larger study. The second limitation of this 
study was that I did not use a control group. In future studies a healthy age and sex 
matched control group should be included.  
 
Studies investigating patients with and without gastrointestinal involvement with 
physiological, radiological and endoscopic assessments have provided a wealth of 
information regarding the pathophysiology of gastrointestinal disease in SSc. This 
has been supplemented by histological findings from surgical specimens as well as 
post-mortem examinations. Nonetheless there were still unanswered questions. I 
showed that neuropathy is a key feature in the aetiopathogenesis of 
gastrointestinal involvement and more specifically in the development of anorectal 
symptoms. Gastrointestinal involvement leads to differences in body composition 
and there may be early evidence of nutritional deficiencies. 
Other aspects of SSc such as skin involvement, vasculopathy and pulmonary 
hypertension have been investigated through the use of animal models. These 
animal models, especially more recently transgenic and knock-out mouse models, 
have provided much more detailed understanding of the fibrotic and inflammatory 
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processes and the relative contributions of specific ligands, receptors and their 
signalling pathways.  
In chapter 5 I investigated the gastrointestinal tract of a transgenic mouse strain 
with fibroblast specific TGF-β signalling activation gene to express a kinase deficient 
type II TGF-β receptor (TβRIIΔk) in fibroblasts. The TβRIIΔk transgenic mice develop 
skin fibrosis with a proportion of animals developing significant lung fibrosis and 
also diminished aortic ring contractility and cardiac fibrosis. Fibrosis is believed to 
be a late stage of the disease process and once it has developed changes are not 
reversible. In this thesis I have shown the first evidence of an animal model of gut 
fibrosis in SSc. I have demonstrated that this transgenic mouse strain develops 
fibrosis in the large intestine and this is associated with dysmotility. The major 
limitation of this study is the small number of mice examined but this is 
unavoidable with transgenic mice in view of the expense associated with the 
generation, breeding and maintenance of the mice. Another limitation is the 
quantification of fibrosis done by quantifying the amount of staining in sections of 
the GI tract. This semi-quantitative method has been used in a number of studies 
assessing collagen deposition in the gastrointestinal tract. Further evaluation of 
fibrosis will need to be performed in future studies. This should include performing 
a Sircol assay and studying mice of different ages in order to investigate at what 
time point gut fibrosis develops in this mouse model. It is possible that a degree of 
fibrosis develops even in control mice with increasing age which would explain the 
slight differences in fibrosis noted between younger and older mice. The colonic 
dysmotility observed in this mouse strain is likely secondary to increased fibrosis as 
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no other structural or immunohistochemical differences were demonstrated 
between the transgenic and wild-type mice. More specifically there was no 
evidence of difference in neural staining although this does not exclude neuropathy 
which could be secondary to circulating autoantibodies or neural changes only 
visible on electron microscopy. Nonetheless this is a fibrotic mouse strain as 
demonstrated in skin, lung, aorta and heart and now also in intestinal tissue. The 
importance of this finding is that although a number of mouse models have shown 
fibrosis in skin and lung there are only a couple of other mouse models that 
demonstrate fibrosis in the gut. Further studies with larger number of mice and 
further histological examination, including electron microscopy and physiological 
studies investigating other neurotransmitters should be planned in the future to 
further characterise gut involvement in this mouse strain. Development of a mouse 
model of SSc that demonstrates gut involvement will allow further research into the 
mechanisms of gut fibrosis and its treatment. 
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Appendix 2: SF-36 questionnaire 
 
Name:      Hospital No: 
 
 
 
SF-36 HEALTH SURVEY 
 
 
INSTRUCTIONS:  This survey asks for your views about your health.  This information will 
help keep track of how you feel and how well you are able to do your usual activities. Answer 
every question by marking the answer as indicated. If you are unsure about how to answer a 
question, please give the best answer you can. 
 
1. In general, would you say your health is:  
(circle one number only) 
Excellent 1 
Very good 2 
Good 3 
Fair 4 
Poor 5 
 
 
2. Compared to one week ago, how would you rate your health in general now? 
(circle one number only) 
Much better now than one week ago 1 
Somewhat better now than one week ago 2 
About the same as one week ago 3 
Somewhat worse now than one week ago 4 
Much worse now than one week ago 5 
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3. The following questions are about activities you might do during a typical day.  Does 
your health now limit you in these activities?  If so, how much? 
(circle one number on each line) 
 
ACTIVITIES 
Yes, 
Limited 
A Lot 
Yes, 
Limited 
A Little 
No, Not 
Limited 
At All 
Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports 
1 2 3 
Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf 
1 2 3 
Lifting or carrying groceries 1 2 3 
Climbing several flights of stairs 1 2 3 
Climbing one flight of stairs 1 2 3 
Bending, kneeling, or stooping 1 2 3 
Walking more than a mile 1 2 3 
Walking half a mile 1 2 3 
Walking one hundred yards 1 2 3 
Bathing or dressing yourself 1 2 3 
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4. During the past week, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? 
(circle one number on each line) 
 YES NO 
Cut down on the amount of time you spent on work or 
other activities 
1 
 
2 
Accomplished less than you would like 1 2 
Were limited in the kind of work or other activities 1 2 
Had difficulty performing the work or other activities (for 
example, it took extra effort) 
1 2 
 
 
5. During the past week, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed 
or anxious)? 
 (circle one number on each line) 
 YES NO 
Cut down on the amount of time you spent on work or other activities 1 2 
Accomplished less than you would like 1 2 
Didn't do work or other activities as carefully as usual 1 2 
 
 
6. During the past week, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups? 
 (circle one number only) 
Not at all ................................................................................................................................. 1 
Slightly .................................................................................................................................... 2 
Moderately .............................................................................................................................. 3 
Quite a bit ............................................................................................................................... 4 
Extremely................................................................................................................................ 5 
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7. How much bodily pain have you had during the past week? 
 (circle one number only) 
None ....................................................................................................................................... 1 
Very mild ................................................................................................................................. 2 
Mild ......................................................................................................................................... 3 
Moderate ................................................................................................................................ 4 
Severe .................................................................................................................................... 5 
Very severe ............................................................................................................................ 6 
 
 
8. During the past week, how much did pain interfere with your normal work (including both 
work outside the home and housework)? 
 (circle one) 
Not at all ................................................................................................................................. 1 
A little bit ................................................................................................................................. 2 
Moderately .............................................................................................................................. 3 
Quite a bit ............................................................................................................................... 4 
Extremely................................................................................................................................ 5 
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9. These questions are about how you feel and how things have been with you during the 
past week.  For each question, please give the one answer that comes closest to the way 
you have been feeling.  How much of the time during the past week. 
 (circle one number on each line) 
 
 All of 
the 
Time 
Most of 
the 
Time 
A Good 
Bit of 
the Time 
Some 
of the 
Time 
A Little 
of the 
Time 
None 
of the 
Time 
Did you feel full of life? 1 2 3 4 5 6 
Have you been a very nervous 
person? 
1 2 3 4 5 6 
Have you felt so down in the dumps 
that nothing could cheer you up? 
1 2 3 4 5 6 
Have you felt calm and peaceful? 1 2 3 4 5 6 
Did you have a lot of energy? 1 2 3 4 5 6 
Have you felt downhearted and low? 1 2 3 4 5 6 
Did you feel worn out? 1 2 3 4 5 6 
Have you been a happy person? 1 2 3 4 5 6 
Did you feel tired? 1 2 3 4 5 6 
 
10. During the past week, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
 (circle one) 
All of the time  .................................................................................................................................... 1 
Most of the time ......................................................................................................................... 2 
Some of the time ............................................................................................................................... 3 
A little of the time  .............................................................................................................................. 4 
None of the time ................................................................................................................................ 5 
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11. How TRUE or FALSE is each of the following statements for you? 
 (circle one number on each line) 
 Definitely 
True 
Mostly 
True 
Don't 
Know 
Mostly 
False 
Definitely 
False 
I seem to get ill a little easier than 
other people 
1 2 3 4 5 
I am as healthy as anybody I know 1 2 3 4 5 
I expect my health to get worse 1 2 3 4 5 
My health is excellent 1 2 3 4 5 
 
Thank you 
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Appendix 3: EuroQol questionnaire 
 
 
EuroQoL 
 
Patient number……… 
Patient initials………Date  ………………….. 
 
By placing a tick in one box in each group below, please indicate which statements best describe your 
own health state today. 
 
Mobility 
I have no problems in walking about                                                                       
I have some problems in walking about                                                     
I am confined to bed                                                                                                     
 
Self-Care 
I have no problems with self-care                                                               
I have some problems washing or dressing myself    
I am unable to wash or dress myself     
 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities                                     
I have some problems with performing my usual activities                               
I am unable to perform my usual activities                                                              
 
Pain/Discomfort 
I have no pain or discomfort                                                                                         
I have moderate pain or discomfort      
I have extreme pain or discomfort      
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Anxiety/Depression 
I am not anxious or depressed                                                                               
I am moderately anxious or depressed                                                               
I am extremely anxious or depressed                                                                 
 
 
Linear analogue scale 
Indicate for today, where  
 
100 is the best state you can imagine 
0 is the worst state you can imagine 
 
Draw mark on the scale 
 
 
 
 l………………..l………………..l………………..l………………..l………………..l 
 
               0                      20                   40                    60                    80                    100 
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Appendix 4: Wexner constipation score 
 
Name:Hospital No: 
Wexner Constipation Score 
Please answer the following questions that relate to the emptying of your 
bowels. Circle the most appropriate number that applies to you. 
 
1). Typically how often do you empty your bowels?       Score 
    1-2 Times per 1-2 days                                                        0 
    2 times per week                                                                  1 
    Once per week                                                                      2 
    Less than once per week                                                     3 
    Less than once per month                                                   4 
 
2). How often do you have to strain to empty your bowels? 
    Never                                                                                     0 
    Rarely                                                                                    1 
    Sometimes                                                                           2 
    Usually                                                                                  3 
    Always                                                                                  4 
 
3). How often do you feel you have not fully evacuated your rectum when you   
      empty your bowels? 
  Never(always feel empty)                                                    0 
  Rarely                                                                                      1 
  Sometimes                                                                              2 
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  Usually                                                                                     3 
  Always (never feel empty)                                                   4 
 
4). How often do you suffer with abdominal pains due to your bowel evacuation  
      problem? 
   Never                                                                                       0 
   Rarely                                                                                       1 
   Sometimes                                                                              2 
   Usually                                                                                     3 
  Always                                                                                      4 
 
5). Typically how long do you spend in the lavatory per attempt? 
Less than 5 Mins                                                                      0 
5 – 10Minutes                                                                          1 
10 – 20 Mins                                                                             2 
20 – 30 Mins                                                                            3 
More than 30Mins                                                                 4 
 
6). Which of the following do you need, to help with the emptying of your bowel? 
No help                                                                                    0 
Laxatives                                                                                  1 
Digital assistance, suppositories, or enema                      2 
 
7). Typically how often do you attempt to empty your bowels WITHOUT a result    
      in a 24hr period? 
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Never                                                                                     0 
1-3                                                                                          1 
3-6                                                                                          2 
6-9                                                                                          3 
More than 9                                                                         4 
 
8).How long have you had these bowel symptoms? 
0 Years                                                                                   0 
1-5 Years                                                                               1 
5-10 Years                                                                            2 
10-20 Years                                                                          3 
More than 20 Years                                                           4 
 
Thank you 
------------------------------------------------------------------------------------------------- 
To be completed by Unit 
 
Total score ……………………… 
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Appendix 5: Wexner faecal incontinence score 
 
Name:Hospital No: 
Wexner Faecal Incontinence Scoring System 
 
Please note that all questions below refer to your bowels and not to your bladder. 
 
                             
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you 
 
 
To be completed by Unit 
Total                                          ……………………….. 
Please circle the numbers below which best describe your 
symptoms.  
 
 
220 
Appendix 6: Copy of consent form 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
 
Title of project:  Quantifying anorectal function and malnutrition in systemic sclerosis (SSc)  
 
 
Name of Principal investigator:  Dr Anton Emmanuel 
Please initial box 
 
1
. 
I confirm that I have read and understood the information sheet dated 04/02/08 
(version 02) for the above study and have had the opportunity to ask questions. 
 
 
   
2
.
  
I confirm that I have had sufficient time to consider whether or not I want to be 
included in the study  
 
 
   
3
. 
I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
Unit Director:Dr Anton Emmanuel BSc, MD, FRCP 
Unit Consultants:Mr Richard Cohen MD, FRCS 
Dr Laurence Lovat BSc, PhD, FRCP 
Mr Austin O’Bichere MD, FRCS 
GI Physiologist:Dr Amanda Roy BSc, PhD 
Physiology Unit 
Podium Level  2 
University College Hospital 
235 Euston Road 
London  NW1 2BU 
 
Tel: 0845 155 5000 ext 73209 
Fax: 020 7380 9239 
 
el:  08451 555 000 extension 73200 
Fax: 0207 380 9239 
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4
. 
I understand that sections of any of my medical notes may be looked at by 
responsible individuals or from regulatory authorities where it is relevant to my 
taking part in research.  I give permission for these individuals to have access to my 
records. 
 
   
 
5
. 
 
I agree to take part in the above study. 
 
 
 
 
Continued on next page/ 
(1 form for Patient, 1 to be kept as part of the study documentation, 1 to be kept with 
hospital notes) 
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CONSENT FORM 
 
Title of project: Quantifying anorectal function and malnutrition in systemic sclerosis (SSc)  
 
Name of Principal investigator:  Dr Anton Emmanuel 
 
 
 
________________________________________________________________ 
Name of patientDateSignature 
 
 
________________________         _____________________ ______________________ 
Name of Person taking consentDateSignature 
(if different from researcher) 
 
_______________________  ____________________ ______________________ 
Researcher (to be contacted DateSignature 
if there are any problems)  
 
Unit Director:Dr Anton Emmanuel BSc, MD, FRCP 
Unit Consultants:Mr Richard Cohen MD, FRCS 
Dr Laurence Lovat BSc, PhD, FRCP 
Mr Austin O’Bichere MD, FRCS 
GI Physiologist:Dr Amanda Roy BSc, PhD 
Physiology Unit 
Podium Level  2 
University College Hospital 
235 Euston Road 
London  NW1 2BU 
 
Tel: 0845 155 5000 ext 73209 
Fax: 020 7380 9239 
 
Tel:  08451 555 000 extension 73200 
F x: 0207 380 9239 
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Comments or concerns during the study  
 
If you have any comments or concerns you may discuss these with the 
investigator.   If you wish to go further and complain about any aspect of the way 
you have been approached or treated during the course of the study, you should 
write or get in touch with the Complaints Manager, UCL hospitals.  Please quote 
the UCLH project number at the top this consent form. 
 
 
(1 form for Patient, 1 to be kept as part of the study documentation, 1 to be kept with 
hospital notes). 
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Appendix 7: Copy of patient information leaflet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantifying anorectal function and malnutrition in systemic sclerosis (SSc) 
 
 
 
 
 
  
Unit Director:Dr Anton Emmanuel BSc, MD, FRCP 
Unit Consultants:Mr Richard Cohen MD, FRCS 
Dr Laurence Lovat BSc, PhD, FRCP 
Mr Austin O’Bichere MD, FRCS 
GI Physiologist:Dr Amanda Roy BSc, PhD 
Physiology Unit 
Podium Level  2 
University College Hospital 
235 Euston Road 
London  NW1 2BU 
 
Tel: 0845 155 5000 ext 73200 
Fax: 020 7380 9239 
 
Tel:  08451 555 000 extension 73200 
Fax: 0207 380 9239 
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PATIENT INFORMATION LEAFLET 
 
 
Introduction 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether or not you wish to take part.    
 
What is the purpose of the study? 
The purpose of the study is to investigate gut function and nutritional status in 
patients with Systemic Sclerosis (SSc). Both patients with gastrointestinal symptoms 
and asymptomatic patients will be asked to take part. The results of this study will 
help us understand further why patients with SSc develop gastrointestinal symptoms 
and enable us to tailor their treatment. Assessing both symptomatic and 
asymptomatic patients will also help us identify any specific features associated with 
gastrointestinal and nutritional problems. 
 
Why have I been chosen? 
You have Systemic Sclerosis and may have gut symptoms associated with this. We 
want to assess patients like you so that we can understand better why patients with 
SSc develop gut problems. The more patients we have to study SSc will allow us to 
get more accurate results and this will lead to a more accurate understanding. Other 
patients (approximately …..) with SSc are also included in the study.  
 
Do I have to take part? 
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It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form.  If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of continuing care you receive. 
 
What is involved in the study? 
The study will involve two sets of investigations (anorectal assessment and 
nutritional assessment) which we will be performed on the same day.  
 
Anorectal assessment will involve: 
 
1) Answering 3 questionnaires assessing lower gut symptoms and the effect of SSc 
on your quality of life (Wexner constipation score, St Mark’s faecal incontinence 
score and SF-36). On average they take about 10 minutes to complete. 
 
2) Anorectal assessment: anorectal physiology and endoanal ultrasound 
Anorectal physiology tests take approximately 30-40 minutes to perform. During 
ano-rectal physiology the strength, sensitivity, and integrity of reflexes of the back 
passage and pelvic floor muscles will be tested and also the compliance (elasticity) 
of the bowel wall. Testing for strength is done by inserting a small catheter, “the size 
of a straw”, no further than 7cm into the back passage to measure pressures on 
squeezing and resting. Testing compliance will be done by inflating a small 
inflatable balloon inserted in the back passage. At the same time we will also test 
sensation and reflexes. Sensation will also be tested by a small electrically 
stimulating catheter.  
 
The endo-anal ultrasound scan will involve a small probe the size of your index 
finger being placed no further than 7 cm into the back passage. On ultrasound the 
muscles will be looked at for tears and quality. The actual scan should not take more 
than 5 minutes. None of these tests have been reported as being painful although 
some patients have reported that they can be uncomfortable a times.  
The results from the questionnaires, endo-anal ultrasound and the anorectal 
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physiology will allow for better understanding of the effect of SSc on lower gut 
function. 
 
3) Nutritional assessment 
This assessment takes approximately 45 minutes. You will be asked to fast for 4 
hours (except water) and to avoid caffeinated drinks and alcohol the day before. The 
weight and height, arm circumference and skinfold thickness of the back of your arm 
will be measured. The latter will be measured by gently pinching the skin at the back 
of your arm and measuring it with a calliper. Your hand-grip strength will also be 
measured. In the second part of the assessment you will be asked to rest for 30 
minutes and then two small electrode pads will be applied on your foot and hand and 
whilst you’re lying completely relaxed a measurement will be taken. Following this 
and whilst still lying down you face will be covered by a plastic ‘bubble’ connected 
by a plastic tube to a computer, this is quite spacious and you will only be asked to 
stay relaxed and breath normally for 15 minutes. This test gives us an estimation of 
how much energy you need during the day. 
 
What are known risks of the study or the side effects of any treatment received? 
Anorectal physiology, endo-anal ultrasound and the nutritional assessment are safe 
procedures. There are no risks associated with any of these procedures.  
 
What are the possible benefits of taking part? 
Your referring doctor is involved in the study and will have full access to the 
investigation results and these may inform further treatment plan. However it may be 
that this study will have no direct benefit to you, but we hope the information we 
gather from this study will benefit patients with SSc in the future. 
 
What happens to the data collected about me? 
We will create a database for this study. The data will be annoymised such that your 
name, hospital number date of birth and address will be fully removed and you will 
be given a unique trial identification number. The list of identification numbers will 
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be held on a password protected secure computer separate from the database 
controlled by trial principal investigator (Dr Anton Emmanuel). We will store basic 
information such as your age, as well as results of your endo-anal ultrasound, 
anorectal physiology, nutritional assessment and data from questionnaires. The 
database will be stored on a password protected computer drive held by UCL who 
will collect, store, handle and process the data. Only the trial principal investigators 
(Dr Anton Emmanuel, Prof Alastair Forbes) and study co-ordinator (Dr Nora Thoua) 
will have access to the database and will be responsible for the safety and security of 
the data. With your permission we may use your data for future studies, although 
again it will be anonymised when handled as explained above. For this reason we 
expect to keep the database for 3 years. 
 
What will happen to the results of the research study?  
The information regarding your studies will be held in the department of GI 
physiology, UCH and will be kept safely in this department. Dr Anton Emmanuel is 
the principal investigator and will ensure the safety and security of your information. 
All information which is collected about you during the course of the research will 
be kept strictly confidential.  Any information about you which leaves the hospital 
will have your name and address, date of birth and all identifiable information 
(including patient/hospital/NHS number) removed so that you cannot be recognised 
from it. 
 
Will my GP be informed?  
Studies not being conducted by your GP require us to inform them regarding your 
participation in our study, but only if you agree for us to do so.  
 
What happens when the research study stops? 
Once we have completed our study, we will examine the data we have collected and 
publish our results in journals for other doctors to read and thus benefit other women 
in the future, with similar problems to yours. 
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What will happen if the findings affect me? 
 A report of the findings of your investigations will be sent to your referring doctor 
in the usual manner; who will decide on the treatment you need. This study does not 
affect your results or treatment. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns of this 
study, the normal National Health Service complaints mechanisms should be 
available to you. 
 
What will happen to the results of the research study? What will happen to the 
results of the research study? 
We will publish the results so that as many of our findings as possible will be made 
available to the medical and scientific community. You will not be personally 
identified in any publication. The timing of any publication will depend mostly on 
the speed with which we collect data but we hope will take no more than a year. 
Your doctor at UCH will be able to tell you about the results when they are 
published so you can get a copy if you wish. 
 
Who is organising and funding the research? 
This study is being organised by the doctors at the bottom of this information sheet 
in collaboration with Prof. Chris Denton and Dr Geraldine Brough at Royal Free 
Hospital. Funding for this study is provided by the Scleroderma Society and Royal 
Free and University College Hospitals. The doctors are not paid for including you in 
this study. 
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Withdrawal from the project 
Your participation in the trial is entirely voluntary.  You are free to decline to enter 
or to withdraw from the study at any time, without having to give a reason.  If you 
choose not to enter the trial, or to withdraw once entered, this will in no way affect 
your future medical care.  All information regarding your medical records will be 
treated as strictly confidential and will only be used for medical purposes.  Your 
medical records may be inspected by competent authorities and properly authorised 
persons, but if any information is released this will be done in a coded form so that 
confidentiality is strictly maintained.  Participation in this study will in no way affect 
your legal rights. 
 
Who has reviewed the study? 
This study has been reviewed by the UCL/UCLH Research Ethics Committee. 
 
Contact for further information  
Dr Nora Thoua, Gastroenterology Research Registrar, University College Hospital 
London,  
Tel: 0845 155 5000  Ext: 73208   
Email: nora.thoua@uclh.nhs.uk 
 
Dr. Anton Emmanuel, Senior lecturer in Neurogastroenterology and Consultant 
Gastroenterologist, University College Hospital London,  
Tel: 0845 155 5000 Ext: 73208 
 
Professor Alastair Forbes, Professor of Gastroenterology and Nutrition, University 
College Hospital London, 
Tel: 0845 155 5000 ext  
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Appendix 8:  
8.1. Photograph of NT demonstrating the indirect calorimetry assessment set up. 
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8.2. Indirect calorimetry traces from A) a symptomatic patient and B) an 
asymptomatic patient. 
 
A) Symptomatic patient 
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B) Asymptomatic patient 
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Appendix 9: Copies of publications arising from this thesis 
 
 
 
